

# ShareHope

SHAREHOPE MEDICINE CO., LTD.

Stock Code: 8403

# 114

annual report

## Building Asia's Leading Healthcare Ecosystem

Missioncare / Since 1975

### Missioncare Healthcare

Asia's Leading Healthcare Ecosystem

12 Major Business Units



50+

Years of Heritage



18

Cities & Counties Served



1,233

Service Locations Nationwide



敏盛綜合醫院  
Min-Sheng General Hospital

HVD

哈佛健診



躍獅連鎖藥局

PHI

精準健康

智醫康寓

HEALTHY RESIDENCE



MYTREX

敏成



TECHGROUP

方鼎I股份有限公司

Published on April 29, 2026

Annual Report Website: <https://mops.twse.com.tw/>

Company Website: <https://www.share-hope.com/>

# SHAREHOPE MEDICINE CO ., LTD.

## 2025 Annual Report

### 1. Name, title, contact number, and email address of the company spokesperson and acting spokesperson

1. Company spokesperson

Name: Liu Yilian

Title: Deputy Chief Dean

Telephone: (02)3322-1589 E xt 210

E-mail: spokesperson@share-hope.com

2. Company spokesperson

Name: Li Peichen

Title: Assistant Manager

Telephone: (02)3322-1589 E xt 210

E-mail: jinlee@share-hope.com

### 2. Address and telephone number of the head office, branch office, and factory

1. General Administration Office

Address: 4th Floor, No. 107, Minsheng Rd ., Taoyuan District , Taoyuan City Tel: ( 03 ) 346-9595

### 3. Name, address, website and telephone number of the stock transfer agency

Name: Qunyi Jinding Securities Co., Ltd. Stock Agency Department

Address: B2, No. 97, Section 2, Dunhua South Road, Da'an District , Taipei City

Website: <https://agency.capital.com.tw>

Tel: (02) 2702-3999

### 4. Name, firm name, address, website and phone number of the accountant who certified the financial report for the most recent year

Accountant's Name: Kou Huizhi, Guo Xinyi CPA

Firm Name: A&H CPA LLP

Address: 68F , No. 7, Section 5, Xinyi Road, Xinyi District, Taipei City

Website: <https://home.kpmg/tw/>

Tel: ( 02 ) 8101-6666

### 5. Name of the trading venue where overseas securities are listed for trading and methods for inquiring about the information of such overseas securities

This company does not apply

### 6. Company website : <http://www.share-hope.com>

# Directory

1. Report to Shareholders .....	1
1.1 Business results for 2025.....	1
1.2 Overview of the 2026 Business Plan.....	3
1.3 Impact of external competition, regulatory environment and overall business environment.....	6
2. Corporate Governance Report .....	8
2.1. Information on directors , supervisors , general manager, deputy general manager, assistant manager, and heads of departments and branches.....	8
2.2 Corporate Governance Operation.....	38
2.3 Information on public fees for accountants.....	131
2.4 Information on change of accountant.....	131
2.5 The company's chairman, general manager, or manager in charge of financial or accounting affairs who has worked for the firm to which the certifying CPA belongs or its affiliated companies within the past year. ....	131
2.6 Changes in equity transfers and equity pledges by directors, supervisors, managers, and shareholders holding more than 10% of the shares in the most recent year and up to the date of publication of the annual report.....	131
2.7 Information on whether the top ten shareholders in terms of shareholding ratio are related persons or spouses or relatives within the second degree of kinship. ....	134
2.8 The number of shares held by the company, its directors, supervisors, managers and enterprises directly or indirectly controlled by the company in the same invested enterprise, and the calculation of the comprehensive shareholding ratio .....	136
3. Participation and Fund Raising .....	138
3.1 Capital and Shares.....	138
3.2 Corporate bond handling status .....	144
3.3 Special shares handling situation.....	144
3.4 Overseas depository receipts.....	144
3.5 Employee stock option certificates .....	144
3.6 Issuance of new shares in the event of a merger or acquisition or transfer of shares of another company .....	144
3.7 Fund utilization plan and implementation status .....	144
4. Operation Overview.....	145
4.1 Business Content.....	145
4.2 Market and Production and Sales Overview .....	164
4.3 Information about employees .....	173
4.4 Environmental Protection Expenditure Information .....	176
4.5 Labor-Capital Relations.....	178

4.6 Information and communication security management .....	185
4.7 Intellectual Property Management .....	188
4.8 Important Contracts.....	191
5. Review and Analysis of Financial Status and Financial Performance and Risk Issues .....	194
5.1 Financial Status.....	194
5.2 Operating Results .....	195
5.3 Cash Flow .....	196
5.4 Impact of major capital expenditures on financial operations in the most recent year .....	197
5.5 Recent investment policies, major reasons for profit or loss, improvement plans, and investment plans for the coming year.....	197
5.6 Risks .....	199
5.7 Other important matters .....	201
6. Special matters to be recorded .....	202
6.1 Relevant information of related enterprises in the most recent year: .....	202
6.2 Status of private placement of securities in the most recent year and up to the publication date of the annual report.....	207
6.3 Other necessary supplementary explanations: .....	207
7. Article 36, Paragraph 3 , Item 2 of the Securities Exchange Act have occurred in the most recent year and up to the date of publication of the annual report .....	208

# 1. Report to Shareholders

## 1.1 Business results for 2025

### (1) Results of business plan implementation

Our consolidated revenue for fiscal year 2025 was NT \$ 4,357,867,000 , and net profit after tax was NT \$ 141,727,000 , with earnings per share of NT\$1.03 . Revenue increased compared to the previous year, and profit, excluding the gains from the disposal of real estate transactions in fiscal year 2024, also increased compared to the previous year.

based on the 2025 operating results, businesses with insufficient synergy have been gradually consolidated and improved. The operating performance of all subsidiaries and investments has been improving and continues to strengthen. The subsidiary Mincheng Health (Leap Lion) is expected to achieve breakthrough development this year, and the company will fully support it.

The operating results are summarized as follows:

#### ➤ Consolidated Financial Statements ( Unit: Thousand Yuan )

	2024	2023
operating income	4,357,867	4,325,831
operating costs	3,648,854	3,611,427
Operating profit	709,013	714,404
operating expenses	628,199	750,297
Other income and expenses, net	90,041	214,382
operating profit	170,855	178,489
Operating income/Income and expenditure	(20,705)	(4,579)
Net profit before tax	150,150	173,910
income tax expense	38,253	51,512
Net profit for this period	111,897	122,398
Net profit for this period is attributable to:		
parent company owner	141,727	200,097
non-controlling interest	(29,830)	(77,699)

#### ➤ Summary of individual financial statements

	2025	2024
Net profit for the year (thousand yuan)	141,727	200,097
Earnings per share: basic (yuan)	1.03	1.45
Diluted earnings per share (yuan)	1.03	1.45

( Note ) 2025's EPS is retrospectively adjusted.

## (2) Financial income and expenditure and profitability analysis

### 1. Financial income and expenditure

Unit: NT\$ thousand

project	2025	illustrate
Cash and cash equivalents at the beginning of the year	1,459,635	
Net cash inflow from operating activities	364,125	
Net cash outflow from investing activities	(121,066)	This is mainly due to the effective management of operating expenses this year , which increased net cash inflow from operating activities .
Net cash outflow from financing activities	(359,877)	The main reasons for the increase were the acquisition of real estate and financial assets and the increase in margin deposits; and the disposal of investment real estate.
Effect of exchange rate changes on cash and cash equivalents	(4,131)	The main purposes are repayment of loans, repayment of lease principal, and distribution of cash dividends.
Cash and cash equivalents at year end	1,338,686	

### 2. Profitability Analysis

project	2025	2024
Return on assets (%)	2.15	2.25
Return on equity (%)	2.86	3.08
Operating profit to paid-in capital ratio (%)	12.41	13.62
Ratio of pre-tax net profit to paid-in capital	10.91	13.27
Net profit rate (%)	2.57	2.83
after tax (RMB)	1.03	1.45

### (3) Research and development status

Our company provides medical logistics services, with its main focus on business and channel expansion. It is not a manufacturing company and does not have a research and development department.

Mincheng, a subsidiary of the Company, upholds the spirit of technological innovation, strengthens its core meltblown technology, applies it to products in the people's livelihood, industry, and medical and biotech industries, and develops related processes and products. We continue to invest in R&D resources, whether it is equipment, funds, or the recruitment of R&D talents with a master's degree or above. Our main goal is to accelerate the development of new products and processes and shorten the R&D schedule from both hardware and software strengths. The R&D team is also constantly trying to develop products in new application areas required by different industries, including feasibility assessment of new polymer materials in meltblown processes, and the gradual development of special non-woven fabric composite processes.

## 1.2 Overview of the 2026 Business Plan

### (1) Business Policy

Pharmaceutical distribution business :

- Joint Procurement Platform for Pharmaceuticals : Includes pharmaceuticals, medical supplies, home care products, etc.
- Pharmaceutical and medical supplies warehousing and logistics management.
- Professional information and consulting services for pharmaceuticals and medical supplies.
- Distribution and agency of pharmaceuticals, health foods and cosmeceuticals.

Specialist service business :

- Medical equipment leasing: including the sale, purchase and leasing of medical equipment, engineering and surgical instruments, information hardware and software and other specific equipment.
- Subsequent services for leased medical equipment: including maintenance ( original or aftermarket ) , repair and related maintenance consultation, and assistance in handling second-hand equipment.
- Project leasing: We tailor-make our products and services to meet the needs of our customers and provide them with complete and appropriate leasing projects.
- Professional consulting: Provide evaluation related to the establishment, procurement and updating of medical equipment, software and hardware consulting related to the establishment of medical institutions, establishment and cooperation consulting of large medical equipment; floor planning, engineering design and cooperation consulting of medical specialties.
- Specialized management: Cooperate with medical specialists in medical institutions to provide high-end medical equipment for specialized management, combine medical expertise with the equipment supply chain, provide more advanced and professional medical services to the medical public, and assist with suggestions on space and engineering design planning.

Health Management Career:

- Medical and health checkup management consulting and entrusted operation services.
- Medical testing laboratory management consulting and outsourced operation services.
- Integrated marketing of medical testing instruments, reagents, and consumables.
- Healthcare staff planning and dispatch services.
- Planning and setup of medical clinics.
- Workplace health management consulting services.
- Acquisition and management of hospital operating rights.

Our company will continue to carefully plan the development direction of various health management-related services in accordance with market demand and changes in the regulatory environment, so as to improve the overall service quality and operational efficiency.

Dialysis Services

- Provide logistical support to the dialysis center, including equipment rental, supply of medicines and medical supplies.

## Smart Medical City Division

- "Smart Healthcare Residence" is a mixed-use apartment hotel located in the Taoyuan City Station area, close to the train station and major transportation arteries. It provides convenient connections and mobility, as well as comprehensive living amenities, for business travelers, medical check-ups, and short- and long-term travelers. It is committed to creating a "healthy living circle" as its core service, allowing every guest to enjoy a wonderful and healthy stay.
- In addition to collaborating with businesses in the Taoyuan area to provide catering services for residents of the Smart Healthcare Residence, the catering business is also actively developing "Min Sheng Healthy Kitchen" to provide meals for hospital patients and staff, striving to promote healthy, balanced and diverse dietary choices.

## (2) Expected sales volume and basis

### 1. Medical supply services

The Pharmaceutical Distribution Department has long been engaged in the supply platform of pharmaceuticals and medical supplies, possessing excellent supply chain management and procurement cost advantages, which forms sufficient conditions for integrated procurement. Furthermore, it can strive for preferential conditions through collective bargaining to reduce the procurement costs of pharmaceuticals and medical supplies.

With continued investment in Leap Health Co., Ltd., Leap Health has successively established multiple pharmacies and the Good Neighbor e-commerce platform throughout Taiwan, and has targeted the chronic prescription and over-the-counter drug market. In recent years, due to the widespread chronic diseases, the number of long-term prescriptions and out-of-pocket drugs in Taiwan's medical market has been increasing year by year, driving the gradual growth of Taiwan's pharmacy market.

### 2. Specialized service business

The equipment leasing business and medical institution service management have continued to grow steadily and dynamically as the company's overall business has expanded.

In addition, the Specialty Services Department will focus more on the cooperative operation of medical specialties, and implement a mutually beneficial development model that combines specialty operations with equipment leasing and medical management. It will cooperate with the development and layout of the group's various business units, continue to deepen the depth and breadth of its business, and explore new growth momentum.

### 3. Health management services

Following the impact of the pandemic, the public has placed greater emphasis on health management and preventive medicine. The number of people undergoing mandatory physical examinations and personal health checkups, as well as related revenue, have shown a stable growth trend within health management departments. Furthermore, due to changes in the domestic labor market structure and adjustments in the operational strategies of some competitors, the demand for health checkups for foreign migrant workers has also increased. In

2025 , the company will continue to expand its health checkup service team, while simultaneously strengthening cost control and operational process management, and developing and implementing paperless operational processes to improve service quality and customer satisfaction, thereby contributing to customer relationship management and brand image building. In addition to continuing to expand business to achieve annual budget targets, the company will also gradually plan the layout of health checkup service locations in accordance with its medium- and long-term strategic direction.

With changes in the medical environment and adjustments to health insurance policies, some medical institutions are increasingly adopting a single-supplier service model for their medical testing laboratories to improve operational efficiency, thereby gaining benefits such as professional technical support, resource integration, and cost control. Health management departments, leveraging their existing medical testing technical experience and management systems, and combining equipment leasing planning with integration with external reagent suppliers, possess a competitive advantage in undertaking related business.

In addition, in response to the policy of including "Next Generation Sequencing (NGS)" in the National Health Insurance reimbursement and the regulatory adjustments made by health authorities to the testing items developed by laboratories, our company has established a complete evaluation and application process to assist in the evaluation and selection of appropriate testing institutions to provide necessary testing services in accordance with clinical diagnostic and treatment needs.

In terms of health management and healthcare human resources support, the company integrates the group's healthcare human resources to provide occupational safety and health management services, including on-site healthcare personnel, workplace health management planning and remote care, and conducts data analysis and human resource management through information systems to support customers' health management needs and medical professional human resource dispatch and management services.

#### 4. Dialysis Division

In conjunction with the company's business units, we continue to expand logistical support for each dialysis center , including equipment rental, and the supply of medicines and medical supplies.

#### 5. Smart Medical City Division

The Smart Healthcare Residence currently features 192 guest rooms, surrounded by thriving commercial facilities to meet travelers' shopping, entertainment, and daily needs. It incorporates a modern smart room system and self-service to cater to diverse traveler requirements. In addition to providing high-quality accommodation, it is committed to creating a healthy and holistic space. Through environmental planning and atmosphere design, it aims to ensure every guest experiences a balanced stay, both physically and mentally .

Adhering to the concept of health, the catering business provides diversified and nutritionally balanced catering services, seamlessly integrating high-quality catering into the accommodation experience, and enhancing the home-like feel and service depth of apartment hotels.

### (3) Future company development strategy

The company's four major development guidelines for 2026 are:

1. Expand and consolidate core business .
2. Develop new businesses .
3. Build a specialized brand .
4. Shape a culture of discipline .

## **1.3 Impact of external competition, regulatory environment and overall business environment**

With the popularization of preventive medicine concepts, the market demand for health checkups continues to attract attention. Market estimates suggest that the domestic health checkup market has a considerable economic scale. In recent years, regulatory authorities have placed greater emphasis on workplace safety, worker health, and occupational medicine. Relevant regulations, such as the Occupational Safety and Health Act and its supporting management measures, have been revised to provide clearer standards for the quality management of worker medical examinations and workplace medical services.

Relevant regulatory adjustments may impact the operational models of labor health check-up services and medical staff dispatch services, and will also require businesses to continuously improve internal management performance, operational efficiency, and cost control capabilities to maintain service quality and customer relationship management. The company will prudently adjust its operating strategies in accordance with market and regulatory changes, and gradually promote standardized and large-scale service models.

In terms of pharmaceutical supply services, due to the impact of the National Health Insurance (NHI) budget policy , medical institutions and NHI pharmacies face multiple pressures , including limited growth in NHI revenue , point-based accounting , and cost reduction . They must therefore resort to joint procurement to lower operating costs . Consequently, a new business model is emerging that involves obtaining pharmaceutical outsourcing and procurement authorization from medical institutions , while continuously vertically integrating and managing the supply chain to effectively expand sales channels and achieve horizontal integration synergies.

Sheng Hung's investment in Yue Shih Pharmacy and Yue Shih Health has led to the establishment of a chain of pharmacies across Taiwan in recent years , now numbering nearly 100 , making it an important base for cultivating community healthcare services . Among them, the franchised pharmacies in Taoyuan leverage the resources of the Min Sheng Medical System to expand medication assessment services for long-term care institutions and provide home care medical services. This allows patients with chronic disease certificates and those requiring health consultations to receive comprehensive and professional services conveniently within their communities, which also contributes to the expansion of the pharmaceutical distribution business and garners support and feedback from end consumers.

In terms of equipment leasing, in response to the sluggish environment and the post-epidemic medical and capital utilization needs , equipment leasing owners have

requested to reduce rents and interest rates or extend the use period, and the company's profits have been relatively reduced; in addition to the coordinated medical and engineering services and medical service management and engineering suggestions as the added value of equipment leasing, the company also responds to market demand and strives for greater profits. The direction is to merge agents or obtain the agency rights of important medical equipment and special materials, and provide cooperative institutions with the establishment of an instrument-centered medical specialty cooperative management service model, and conduct upstream and downstream integration in terms of product sales, leasing, management, maintenance and resale of second-hand equipment, and consider the layout of AI smart medical care, in order to develop more comprehensive and professional medical leasing and specialty services.

In the dialysis business, we actively integrate the dialysis business of the system hospitals and external parties, continuously improve the functions of the department within the system medical ecosystem, and combine the inherent advantages of medical services, pharmaceuticals, health materials, equipment rental, etc. in the system medical ecosystem to provide comprehensive logistical support for dialysis centers.

This year, the company will focus on developing the medical business ecosystem and strive for sustainable growth. At the same time, it will focus on six major axes as operational development priorities, namely: e- medical services , physical pharmacy channels , expansion of medical service locations, expansion into the upstream field of medical materials, and operation and management of smart medical and health examination businesses . It is expected that with the active introduction of innovative models and the synergy of the group's resource integration, the full-year operation will have the opportunity to reach a new peak.

**Chairman Hung-jen Yang**



## 2. Corporate Governance Report

### 2.1. Information on directors , supervisors , general manager, deputy general manager, assistant manager, and heads of departments and branches

#### (1) Information of directors and supervisors

April 20 , 2026

Professional title (Note1)	Nationality or place of registration	Name	gender age (Note2)	choose(At once)appoint date	term of office	first election date (Note 3)	When elected hold shares		now Number of shares held		Spouse and minor children currently hold shares		Hold shares in someone else's name		Main academic qualifications (Note 4)	Currently holding positions in the company and other companies	Other managers, directors or supervisors who are related by spouse or within the second degree of affinity			Remarks (Note 5)
							Number of shares	shareholding ratio	Number of shares	shareholding ratio	Number of shares	shareholding ratio	Number of shares	shareholding ratio			job title	Name	relation	
Chairman	China Republic of China	Minsheng Medical Control Co., Ltd. Limited Company		2024.06.24	3 years	2003.09.10	36,298,290	28.80%	39,637,732	28.80%	-	-	-	-	1. Department of Medicine, National Taiwan University 2. Master of Public Health, Harvard University, USA 3. Peter. Drucker School of Management MBA Program 4. John. Master of Health Sciences, Johns Hopkins 5. Visiting Scholar at Stanford University 6. PhD, Institute of Sports Science, National Taiwan Sport University 7. CEO of Minsheng Medical System 8. Director of Beijing Smile Angel Children's Hospital 9. Director of Minsheng General Hospital	1. CEO of Min Sheng Healthcare System 2. Chairman of Minsheng Medical Holdings Co., Ltd. 3. Chairman of the Board of Directors of Sangu (Stock) Company 4. Chairman of Precision Health (stock) company 5. Chairman of Hengxin Investment Co., Ltd. 6. Chairman of Yue Shi Health (Stock) Co., Ltd. 7. Chairman of Born Management Consulting Co., Ltd. 8. Chairman of Mincheng Health Technology Co., Ltd. 9. Chairman of Anzhun Technology (Stock) Co., Ltd.	none	none	none	He also serves as the CEO. In order to strengthen the independence of the board of directors, the company has added one independent

Professional title (Note1)	Nationality or place of registration	Name	gender (Note2)	choose(At once)appoint date	term of office	first election date (Note 3)	When elected hold shares		now Number of shares held		Spouse and minor children currently hold shares		Hold shares in someone else's name		Main academic qualifications (Note 4)	Currently holding positions in the company and other companies	Other managers, directors or supervisors who are related by spouse or within the second degree of affinity			Remarks (Note 5)
							Number of shares	shareholding ratio	Number of shares	shareholding ratio	Number of shares	shareholding ratio	Number of shares	shareholding ratio			job title	Name	relation	
	China Republic of China	Representative Yang Hongren	male 51-60	2024.06.24	3 years	2003.09.10	924,480	0.74%	1,029,687	0.74%	-	-	-	-		10. Chairman of Shengyun Pharmaceutical Co., Ltd. 11. Chairman of a medical electronics digital transformation (stock) company 12. Chairman of Bisheng Construction (Stock) Co., Ltd. 13. Director of Shengshi Digital Health (Stock) Co., Ltd. 14. Director of the United Medical Foundation 15. Director of Universal Biotechnology Multimedia (Stock) Co., Ltd. 16. Director of Yida International Hospital Management Consulting Co., Ltd. 17. Director of Minsheng Asset Management Co., Ltd. 18. Director of Fangding Information Technology Co., Ltd. 19. Director of Hehehe Healthy Living (Stock) Co., Ltd. 20. Supervisor of Shengyu Health Technology (Stock) Co., Ltd. 21. Supervisor of China Development and Medical Venture Capital (Stock) Co., Ltd. 22. Supervisor of Yuede Enterprise (Stock) Co., Ltd. 23. Supervisor of Bozhi Cultural and Creative (Stock) Co., Ltd.	director	Yang Chen Caibi	Mother and Child	ent director in 2013 to enhance the board's functions and strengthen its supervisory function.
Vice Chairman	China Republic of China	Minsheng Medical Control Co., Ltd. Limited Company		2024.06.24	3 years	2003.09.10	36,298,290	28.80%	39,637,732	28.80%	-	-	-	-	1. Department of Economics, National Taiwan University 2. Master of Business Administration from the University of Texas at Dallas 3. Foreign banks are responsible for the overall business in the Taiwan market. 4. Serves as a professional senior manager in several listed electronics companies in Taiwan.		none	none	none	-
	China Republic of China	Representative Xu Shengxin	male 61-70	2024.06.24	3 years	2003.09.10 (Note 6)	-	-	-	-	-	-	-	-	5. CEO of BioLue Medical Technology Co., Ltd. 6. Director of Mincheng Health Technology Co., Ltd. 7. Director of Yue Shi Health (Stock) Co., Ltd.		none	none	none	

Professional title (Note1)	Nationality or place of registration	Name	gender (Note2)	choose(At once)appoint date	term of office	first election date (Note 3)	When elected hold shares		now Number of shares held		Spouse and minor children currently hold shares		Hold shares in someone else's name		Main academic qualifications (Note 4)	Currently holding positions in the company and other companies	Other managers, directors or supervisors who are related by spouse or within the second degree of affinity			Remarks (Note 5)
							Number of shares	shareholding ratio	Number of shares	shareholding ratio	Number of shares	shareholding ratio	Number of shares	shareholding ratio			job title	Name	relation	
director	China Republic of China	Minsheng Medical Control Co., Ltd. Limited Company		2024.06.24	3 years	2010.09.01	36,298,290	28.80%	39,637,732	28.80%	-	-	-	-	1. Yuan Ze Management Institute EMBA 2. Department of Medical Technology, Taipei Medical College 3. Senior Vice President of Min Sheng General Hospital 4. Executive Vice President of Min-Sheng General Hospital and General Manager of Shengyun Pharmaceutical Co., Ltd.	1. Chairman of Zhongyuan Medical Management (Stock) Company 2. Vice Chairman of Shengyun Pharmaceutical Co., Ltd. 3. Director of Mincheng Health Technology Co., Ltd. 4. Director of the United Medical Foundation 5. Director of Harvard Health (Stock) 6. Director of Fangding Information Technology Co., Ltd. 7. Director of Precision Health (stock) Co., Ltd. 8. Director of Hehehe Healthy Living (Stock) Co., Ltd. 9. Supervisor of Yue Shi Health (Stock) Co., Ltd.	none	none	none	-
	China Republic of China	Representative Liu Qingwen	male 61-70	2024.06.24	3 years	2010.09.01 (Note 7)	56,847	0.05%	62,075	0.05%	-	-	-	-			none	none	none	
director	China Republic of China	Minsheng Medical Control Co., Ltd. Limited Company		2024.06.24	3 years	2009.08.01	36,298,290	28.80%	39,637,732	28.80%	-	-	-	-	1. PhD, School of Management, University of Cambridge, UK 2. Master of Economics, National Taiwan University 3. Bachelor of Economics, National Taipei University (College of Law and Business, National Chung Hsing University)	1. President of the Taiwan Economic Research Society and Director of the Sustainable Development Policy Research Center 2. Member of the 11th and 12th National Financial Stabilization Fund Management Committee, Executive Yuan 3. Adjunct Associate Professor, Institute of Biotechnology, National Taiwan University 4. Researcher at the Taiwan Institute of Economic Research, Director of the Intellectual Property Evaluation Service Center, Director of the Biotechnology Industry Research Center, and Director of the Seventh Research Institute. 5. Supervisor of the 4th to 7th sessions and Standing Director of the 8th session of the China Intangible Assets and Enterprise Appraisal Association, and Chairman of the AI and ESG Committee. 6. First and second chairpersons, standing directors, and convener of the sustainability group of the Taiwan Bionic Technology Development Association	none	none	none	
	China Republic of China	Representative Sun Zhili	female 51-60	2024.06.24	3 years	2009.08.01 (Note 8)	-	-	-	-	-	-	-	-			none	none	none	
director	China Republic of China	Minsheng Medical Control Co., Ltd. Limited Company		2024.06.24	3 years	2023.06.30	36,298,290	28.80%	39,637,732	28.80%	-	-	-	-	1. Doctor of Medicine, Institute of Clinical Medicine, National Taiwan University 2. Bachelor of Medicine, National Taiwan University	1. Chief Director of Hospital Division 2. Director of the Roche Foundation, a medical foundation 3. Honorary Professor, National Taiwan University College of Medicine	none	none	none	-

Professional title (Note1)	Nationality or place of registration	Name	gender age (Note2)	choose(At once)appoint date	term of office	first election date (Note 3)	When elected hold shares		now Number of shares held		Spouse and minor children currently hold shares		Hold shares in someone else's name		Main academic qualifications (Note 4)	Currently holding positions in the company and other companies	Other managers, directors or supervisors who are related by spouse or within the second degree of affinity			Remarks (Note 5)
							Number of shares	shareholding ratio	Number of shares	shareholding ratio	Number of shares	shareholding ratio	Number of shares	shareholding ratio			job title	Name	relation	
	China Republic of China	Representative Chen Wenzhong	male 61 - 70	2024.06.24	3 years	2023.06.30	-	-	-	-	-	-	-	3. Professor of Internal Medicine and Emergency Medicine, National Taiwan University College of Medicine 4. Director of the Cardiovascular Center, National Taiwan University Hospital 5. Director of Cardiology Department, National Taiwan University Hospital 6. Director of the Department of Emergency Medicine, National Taiwan University Medical School 7. Director of the Department of Emergency Medicine, National Taiwan University Hospital 8. Director of Taoyuan Hospital, Ministry of Health and Welfare, Executive Yuan 9. Director of Hsinchu Hospital, Ministry of Health and Welfare, Executive Yuan 10. Director of Luodong Boai Hospital	4. Chief Director of Minsheng General Hospital	none	none	none	-	
director	China Republic of China	Rongyang Management Consultants Limited Company		2024.06.24	3 years	2018.06.27	133,928	0.11%	146,249	0.11%	-	-	-	1. Master of Public Administration, University of Southern California (USC) 2. Deputy CEO of Min Sheng Healthcare System 3. President of Longtan Minsheng Hospital and President of Dayuan Minsheng Hospital 4. Executive Vice President of Min Sheng General Hospital 5. Chairman of Asia Pacific Health (Stock) Co., Ltd. 6. The Fifth Regional Hospital Association of the Republic of China 7. Deputy Captain of the Taoyuan County Patrol Brigade	1. Chairman of Rongyang Management Consulting Co., Ltd. 2. Chairman and General Manager of Minsheng Asset Management Co., Ltd. Vice Chairman of Bisheng Construction (Stock) Co., Ltd. 4. Director of Mincheng Health Technology Co., Ltd. 5. Supervisor of Precision Health (stock) Co., Ltd. 6. General Manager of the Smart Healthcare City Business Unit	none	none	none	-	
	China Republic of China	Representative Zhang Changrong	male 51-60	2024.06.24	3 years	2003.09.10	-	-	-	-	-	-	-		6. General Manager of the Smart Healthcare City Business Unit	none	none	none		
director	China Republic of China	Yang Chen Caibi	female 81-90	2024.06.24	3 years	2003.09.10 (Note 9)	1,416,771	1.12%	1,547,113	1.12%	1,324	0 %	-	1. Department of Physics, Normal University 2. Teaching assistant and lecturer at Taipei Medical College 3. President of Xinsheng Medical School 4. Chairman of Jiuyu Co., Ltd. 5. Chairman of Minsheng Asset Management Co., Ltd.	1. Chairman of Jiabei Industrial Co., Ltd. 2. Chairman of Yang Zheng Investment Co., Ltd. 3. Director of Ariel Aesthetics Co., Ltd. 4. Director of Yue De Enterprise Co., Ltd.	Chairman	Yang Hongren	Mother and Child	-	

Professional title (Note1)	Nationality or place of registration	Name	gender (Note2)	choose(At once)appoint date	term of office	first election date (Note 3)	When elected hold shares		now Number of shares held		Spouse and minor children currently hold shares		Hold shares in someone else's name		Main academic qualifications (Note 4)	Currently holding positions in the company and other companies	Other managers, directors or supervisors who are related by spouse or within the second degree of affinity			Remarks (Note 5)
							Number of shares	shareholding ratio	Number of shares	shareholding ratio	Number of shares	shareholding ratio	Number of shares	shareholding ratio			job title	Name	relation	
Independent Director	China Republic of China	Wu Genzai	male 61-70	2024.06.24	3 years	2018.6.27	-	-	-	-	-	-	-	-	1. Department of Accounting, National Taiwan University 2. Auditor and audit team leader of Deloitte Touche Tohmatsu CPA Ltd. 3. CFO and Director of Management Department in Manufacturing Industry 4. Partner Accountant of Chengxin United Accounting Firm 5. Special lecturer at the Small and Medium Enterprises Division of the Ministry of Economic Affairs and the Business Management Consulting Company 6. Passed the 1991 Higher Accountant Examination	1. Partner Accountant of Zhanyu United Certified Public Accountants 2. Director of Zhan Yu Development Industrial Co., Ltd.	none	none	none	-
Independent Director	China Republic of China	Li Shuxing	male 61-70	2024.06.24	3 years	2019.6.27	-	-	-	-	-	-	-	-	1. PhD in Accounting, New York University 2. Bachelor of Business Administration, National Chengchi University 3. Dean of School of Management, Tunghai University 4. Acting Dean of the School of Management, Tunghai University 5. Vice President for Finance, National Taiwan University 6. Dean of College of Management, National Taiwan University 7. Dean of the Department of Accounting, National Taiwan University 8. Editor-in-chief of Asia-Pacific Journal of Accounting and Economics 9. Editor-in-Chief of NTU Management Series 10. AACSB Visiting Committee Member 11. Member of AACSB Asia Pacific Advisory Committee 12. Chairman of the Chinese Accounting Education Association	1. Dean of the College of Management, Chang Gung University / Professor of the Department of Digital Finance 2. Independent Director of Fubon Financial Holdings Co., Ltd. 3. Independent Director of Kanglian Biomedical Technology Co., Ltd. 4. Independent Director of Alphabet Inc.	none	none	none	-

Professional title (Note1)	Nationality or place of registration	Name	gender (Note2)	choose(At once)appoint date	term of office	first election date (Note 3)	When elected hold shares		now Number of shares held		Spouse and minor children currently hold shares		Hold shares in someone else's name		Main academic qualifications (Note 4)	Currently holding positions in the company and other companies	Other managers, directors or supervisors who are related by spouse or within the second degree of affinity			Remarks (Note 5)
							Number of shares	shareholding ratio	Number of shares	shareholding ratio	Number of shares	shareholding ratio	Number of shares	shareholding ratio			job title	Name	relation	
Independent Director	China Republic of China	Chen Houming	male 61-70	2024.06.24	3 years	2021.07.30	-	-	-	-	-	-	-	-	1. PhD, Graduate School of Business, National Taiwan University 2. Master of Applied Statistics, University of Iowa, USA 3. Master of Management Science, Tamkang University 4. Chairman of the Chinese Negotiation Management Society 5. Member of the National Development Fund Management Committee, Executive Yuan 6. Convener of Management Department of the Ministry of Science and Technology, Executive Yuan 7. President of the Business Development Research Institute 8. Dean of the College of Social Sciences and Management, Director of the Institute of Business Administration, and Director and Director of the Department of Business Administration, National Chung Hsing University 9. Professor of International Business Department, National Chi Nan University 10. Associate Researcher, Chinese Institute for Economic Research	1. Professor Emeritus, Department of International Business and Graduate Institute, National Taiwan University 2. Chairman of the Chinese Business Management Education Development Association 3. Honorary Chairman of the Taiwan Marketing Science Association 4. Independent Directors of Xinbang Electronics Co., Ltd. 5. Independent Director of Fuchiao Industrial Co., Ltd. 6. Independent Directors of Creative Electronics (Stock) Co., Ltd.	none	none	none	-
Independent Director	China Republic of China	Yao Xiubi	female 4 1-50	2024.06.24	1 year	2023.06.30	-	-	-	-	-	-	-	-	1. Master of Business Administration, University of Missouri-Columbia 2. Tunghai University Super EPOST 3. Department of Finance, National Chung Cheng University 4. Ginko International Co., LTD Acting Spokesperson 5. Director of the Chairman's Office of Yongsheng Optical Co., Ltd.	1. Assistant Manager of Strategic Investment Department, Yong Sheng Optics (Stock) Co., Ltd. 2. Director of the Taichung City Jin Ke Cultural and Educational Foundation 3. Director of Yujiasheng (Stock) Co., Ltd. 4. Supervisor of Shangjingcheng (Stock) Company 5. Director of Xiamen Weimeng Environmental Protection Materials Co., Ltd.	none	none	none	-

Note 1 : Corporate shareholders should list their names and representatives separately (if the representative is a corporate shareholder, the name of the corporate shareholder should be indicated), and should fill in Table 1 below.

Note 2 : Actual age should be listed and expressed in interval format.

Note 3 : Enter the date when you first served as a director or supervisor of the company. If there was any interruption, please provide an explanation.

Note 4 : Experience related to the current position, such as having worked at an auditing and certification accounting firm or related company during the aforementioned period, should specify the job title and responsibilities held.

Note 5 : If the company's chairman and general manager or equivalent (top manager) are the same person, spouses, or first-degree relatives, the reasons, rationale, necessity, and corresponding measures (such as increasing the number of independent directors and ensuring that more than half of the directors do not concurrently serve as employees or managers) should be explained.

Note 6 : Mr. Hsu Sheng-hsin was not a director during the period from September 2018 to October 2019 .

Note 7 : Mr. Liu Qingwen was not a director during the period from August 2010 to June 2017 and from November 2019 to July 2011.

Note 8 : Ms. Sun Zhili served as an independent director from August 1992 to June 2018; she did not serve as a director from July 2018 to August 2018.

Note 9 : Ms. Yang Chen Caibi served as a supervisor from March 2010 to July 2010; she did not serve as a director from August 2015 to October 2016.

## Major shareholder of a legal person shareholder

April 20 , 2026

Name of legal person shareholder (Note 1)	Major shareholder of a legal person shareholder (Note 2)
Minsheng Medical Control Co., Ltd.	Min Sheng Asset Management Co., Ltd. 13.95% , Yang Zheng Investment Co., Ltd. 11.88% , Taoyuan Yi Ren Charity Foundation 11.33% , Ruian Pharmaceutical Co., Ltd. 5.40% , Hsin Tung Biotechnology Co., Ltd. 3.31% , Fu Lin Investment Co., Ltd. 2.99% , Yang Chen Cai Bi 2.36% , Yung Shin Pharmaceutical Industrial Co., Ltd. 2.17% , Sheng Li Management Consulting Co., Ltd. 1.79% , Yang Yi Zhen 1.60%.
Rong Yang Management Consultants Limited	Chang Chang-jung ( 99.96%), Yang Yi-chen (0.04%)

Note 1: If the director or supervisor is a legal person shareholder representative, the name of the legal person shareholder should be filled in.

Note 2 : Fill in the name of the major shareholder of the legal person shareholder ( whose shareholding ratio is the top ten ) and their shareholding ratio. If the major shareholder is a legal person, the following Table 2 should be filled in.

Note 3 : For corporate shareholders who are not corporate organizations, the names of shareholders and shareholding ratios that should be disclosed above are the names of investors or donors ( please refer to the Judicial Yuan announcement for inquiries ) and their investment or donation ratios. If the donor is deceased, the word "deceased" shall be noted.

## If the major shareholder is a legal person, the major shareholder

April 20, 2026

Name of legal person (Note 1)	Major shareholder of a legal person (Note 2)
Yang Zheng Investment Co., Ltd.	Minsheng Medical Control Co., Ltd. 14.70% , Yangzheng Investment Co. , Ltd. 8.47% , Yangchen Caibi 7.71% , Ruian Pharmaceutical Factory Co. , Ltd. 5.29% , Yang Minsheng 4.77% , Yang Hongren 3.77% , Mincheng Health Technology Co. , Ltd. 3.37% , Xindong Biotechnology Co. , Ltd. 3.27% , Fulin Investment Co. , Ltd. 2.93% , Yongxin Pharmaceutical Industry Co. , Ltd. 2.13% .
Minsheng Asset Management Co., Ltd.	Yang Minsheng 58.58% , Yang Chencaibi 31.18% , Yang Yizhen 5.12% , Yang Yishan 5.12% .
Taoyuan City Foundation Yiren Charity Foundation	Min Sheng General Hospital 32.83% , Yang Min Sheng 18.24% , MiG International (Stock) 7.3% , Liu Qingwen 5.47% , Qianyi Xingye Co., Ltd. 4.38%, Lin Zongxi 2.04% , Zhao Guoqing 1.82% , Yang Wenren 1.82% , Huang Ming'an 1.82% , Chen Wenzhong 1.82% ( donation ratio in 2025) .
Ruian Pharmaceutical Co., Ltd.	Jianqiao Xinyuan Pharmaceutical Biotechnology Co. , Ltd. 94.57%
Xindong Biotech Co., Ltd.	Yu-Yuan Corporation 14.06% , Taiwan Venture Capital Corporation 11.88% , Yung - Yu Industrial Corporation 10.94% , National Development Fund Management Committee of Executive Yuan 6.54% , Ching - Shen - Tang Investment Corporation 0.63% , Hsu Sheng - Hsiung 0.09% , Ting - Chi Industrial Corporation 0.08% .
Fulin Investment Co., Ltd.	Fulin Engineering ( Stock ) Co., Ltd. 17.95% , Sun Xinhui 14.54% , Sun Minling 6.59% , Sun Guanyu 20.95% .
Yongxin Pharmaceutical Industry Co., Ltd.	Yung Shin International Investment Holdings ( Stock ) Co., Ltd. is 100% owned .
Shengli Management Consultants Co., Ltd.	Yang Yizhen 50% , Yang Yishan 50% .

Note 1: If the major shareholder in Table 1 above is a legal person, the name of the legal person should be filled in.

Note 2: Fill in the name of the legal person's major shareholder (whose shareholding ratio is the top ten) and their shareholding ratio .

Note 3: If the legal person shareholder is not a company organization, the shareholder name and shareholding ratio that should be disclosed above are the names of investors or donors (refer to the Judicial Yuan announcement for inquiries) and their Contribution or donation ratio. If the donor is deceased, please add "deceased" .

(2) The professional knowledge and independence of directors or supervisors:

1. Disclosure of professional qualifications of directors and supervisors and independence of independent directors :

condition Name	Professional qualifications and experience ( Note 1)	Independence situation (Note 2)	Number of independent directors of other publicly listed companies
Representative of Minsheng Medical Control Co., Ltd. Chairman Yang Hongren	Major: Department of Medicine, National Taiwan University; Possesses medical professional work experience and the operational judgment, international market perspective, and decision-making ability required by our company. Experience: Director of Kangning Hospital / Director of Beijing Yanran Angel Children's Hospital / Chief Physician at Minsheng General Hospital.	Yang Hongren is the representative of the company's corporate directors, and also serves as the company's chairman and CEO, as well as a director of its subsidiaries . He is also one of the company's top ten individual shareholders (0.73%), but is not an independent director. The remaining conditions meet the independence requirements listed in Article 3 , Paragraph 1 of the "Regulations Governing the Establishment and Compliance of Independent Directors of Publicly Offered Companies" promulgated by the Financial Supervisory Commission . She is the mother of Director Yang Chen Caibi, and they are related by blood within two degrees of kinship .	0
Representative of Minsheng Medical Control Co., Ltd. Xu Shengxin, Vice Chairman	Major: Department of Economics, National Taiwan University; with work experience in investment marketing management and operations management, and possessing the business and industry knowledge and crisis management capabilities required by the company. Experience: Responsible for overall Taiwan market business at a foreign bank / He serves as a professional senior manager in several listed electronics companies in Taiwan.	Hsu Sheng-hsin is the representative of the company's corporate directors and a director of its subsidiaries, but not an independent director. All other aspects meet the independence requirements listed in Article 3 , Paragraph 1 of the "Regulations Governing the Establishment and Compliance of Independent Directors of Publicly Listed Companies" promulgated by the Financial Supervisory Commission .	0
Representative of Minsheng Medical Control Co., Ltd. Liu Qingwen Director	Specialization: EMBA from Yuan Ze University; with work experience in medical institution management and operations management, as well as the industry knowledge, accounting and financial analysis skills required by this company. Experience: Vice President of Medical Affairs, Min Sheng General Hospital / Chairman, Sheng Hong Pharmaceutical Co., Ltd.	Director Liu Qingwen is the representative of the Company's corporate directors and serves as the Company's General Manager and a director of its subsidiaries . He is not an independent director. The remaining conditions meet the independence requirements listed in Article 3 , Paragraph 1 of the "Measures for the Establishment and Compliance of Independent Directors of Publicly Listed Companies" promulgated by the Financial Supervisory Commission .	0
Representative of Minsheng Medical Control Co., Ltd. Sun Zhili Director	Professional background: PhD from Cambridge School of Management, University of Cambridge; possesses professional experience required for academic and business operations, as well as business and industry knowledge required by the company. Experience: President of the Taiwan Economic Research Society and Director of the Sustainable Development Policy Research Center; Member of the 11th and 12th National Financial Stabilization Fund Management Committee, Executive Yuan; Adjunct Associate Professor, Institute of Biotechnology, National Taiwan University	Sun Zhili is the representative of the Company's corporate directors and is not an independent director. The remaining conditions meet the independence requirements listed in Article 3 , Paragraph 1 of the "Regulations Governing the Establishment and Compliance of Independent Directors of Publicly Listed Companies" promulgated by the Financial Supervisory Commission .	0

condition Name	Professional qualifications and experience ( Note 1)	Independence situation (Note 2)	Number of independent directors of other publicly listed companies
Representative of Minsheng Medical Control Co., Ltd. Director	Major: Department of Medicine, National Taiwan University; Possesses medical professional work experience and the industry knowledge, crisis management ability, and decision-making ability required by the company. Experience: MD, Graduate Institute of Clinical Medicine, National Taiwan University / MD, Department of Medicine, National Taiwan University / Professor, Department of Internal Medicine and Emergency Medicine, College of Medicine, National Taiwan University / Director, Cardiology Center, National Taiwan University Hospital / Department of Cardiology, National Taiwan University Hospital / Department of Emergency Medicine, College of Medicine, National Taiwan University / Director, Department of Emergency Medicine, National Taiwan University Hospital	Director Chen Wenzhong is the representative of the company's corporate directors and is not an independent director. The remaining conditions meet the independence requirements listed in Article 3 , Paragraph 1 of the "Regulations Governing the Establishment and Compliance of Independent Directors of Publicly Listed Companies" promulgated by the Financial Supervisory Commission.	0
Representative of Rongyang Management Consultants Co., Ltd. Director	Professional background: Master of Public Administration, University of Southern California (USC); Experience in healthcare institution management and asset management, and leadership skills required by our company: Executive Vice President of Min Sheng Ching Kuo General Hospital / Deputy CEO of Asia Pacific Healthcare Co., Ltd. / 5th & 6th Board Member of the Republic of China Regional Hospital Association / Deputy Captain of Taoyuan County Patrol Brigade	Chang Chang-jung is the representative of the company's corporate directors and is not an independent director. All other conditions meet the independence requirements listed in Article 3 , Paragraph 1 of the "Regulations Governing the Establishment and Compliance of Independent Directors of Publicly Listed Companies" promulgated by the Financial Supervisory Commission .	0
Director Yang Chen Caibi	Major: Physics Department of Normal University; possesses professional experience in academics, investment management, and the business required by this company. Experience: Teaching Assistant and Lecturer at Taipei Medical College / Principal of Shin Kong Medical School / Chairman of Jiu Yu Co., Ltd. / Chairman of Min Sheng Asset Management Co., Ltd.	Director Yang Chen Caibi currently serves as an individual director and is also one of the top ten individual shareholders of the Company (1.12%) . However, she also meets the independence requirements of the regulatory authorities. For the two years prior to her election and during her term of office, she met the independence requirements listed in Article 3 of the "Regulations Governing the Establishment and Compliance of Independent Directors of Publicly Listed Companies" promulgated by the Financial Supervisory Commission . During her tenure as a director, she has been granted the right to participate fully in decision-making and express opinions in accordance with Article 14-3 of the Securities and Exchange Act, and has independently exercised her relevant powers accordingly. She is the mother of Chairman Yang Hongren, and they are related by blood within the second degree of kinship.	0

condition Name	Professional qualifications and experience ( Note 1)	Independence situation (Note 2)	Number of independent directors of other publicly listed companies
Wu Genzai Independent Director	<ol style="list-style-type: none"> <li>Major: Department of Accounting, National Taiwan University (passed the 1991 Certified Public Accountant Examination); possesses work experience in accounting, finance, and business operations required by this company.</li> <li>Experience: Auditor/Audit Team Leader at Deloitte Touche Tohmatsu, Finance Director and Management Director at the Manufacturing Industry, Partner Accountant at Cheng Hsin Certified Public Accountants, Special Lecturer at the Small and Medium Enterprise Administration, Ministry of Economic Affairs, and Management Consulting Company.</li> <li>Independent Director Wu has extensive experience in accounting practice. Through his expertise, he can provide insightful guidance on various aspects of data review and offer appropriate suggestions.</li> </ol>	<p>None of the four independent directors listed on the left fall under any of the circumstances described in Article 30 of the Company Act , were not elected as government entities, legal persons, or their representatives in accordance with Article 27 of the Company Act, and do not have a spousal or second-degree kinship relationship with other directors. Furthermore, none of the following circumstances existed in the two years prior to their election :</p> <ol style="list-style-type: none"> <li>An employee of the company or its affiliates.</li> <li>Directors or supervisors of the company or its related enterprises ( except for independent directors appointed by the company and its parent company, subsidiaries or subsidiaries of the same parent company in accordance with this law or local laws) .</li> <li>The individual, their spouse, minor children, or other persons holding more than 1% of the company's total issued shares or being among the top ten shareholders.</li> <li>The spouse, relatives within the second degree of kinship or direct blood relatives within the third degree of kinship of the manager in item 1 or the persons listed in items 2 and 3 .</li> <li>Directors, supervisors, or employees of corporate shareholders who directly hold 5% or more of the total issued shares of the company, are among the top five shareholders, or whose representatives are appointed as directors or supervisors of the company in accordance with Article 27, Paragraph 1 or Paragraph 2 of the Company Act ( except for independent directors appointed by the company and its parent company, subsidiaries, or subsidiaries of the same parent company in accordance with this Act or local laws) .</li> <li>The directorships or voting shares of the Company and other companies are controlled by the same person who is a director, supervisor or employee of the other company ( except for independent directors appointed by the Company and its parent company, subsidiary or subsidiary of the same parent company in accordance with this law or local laws) .</li> <li>The chairman, general manager or equivalent person of the company and another company or organization are the same person or spouse, and are directors (board members), supervisors (supervisors) or employees of the other company or organization ( except for independent directors appointed by the company and its parent company, subsidiary or subsidiary of the same parent company in accordance with this law or local laws) .</li> <li>Serve as a director (councilor), supervisor (supervisor),</li> </ol>	0
Li Shuxing Independent Director	<ol style="list-style-type: none"> <li>Professional background: PhD in Accounting from New York University; Lecturer at a public or private college or university with relevant academic background required for the company's business; Possesses professional experience in business, finance, accounting, and the company's business.</li> <li>Experience: Vice President of Finance/Dean of the College of Management/Head of the Department of Accounting, National Taiwan University; Acting Dean of the College of Management/Chair Professor of the Department of Accounting, Tunghai University; President of the Chinese Accounting Education Association</li> <li>Independent Director Li possesses accounting expertise and has many years of experience as an independent director in other industries; he can share the company's diversified business experience and provide management decision-making advice in areas such as industry integration analysis and risk management.</li> </ol>	<ol style="list-style-type: none"> <li>The directorships or voting shares of the Company and other companies are controlled by the same person who is a director, supervisor or employee of the other company ( except for independent directors appointed by the Company and its parent company, subsidiary or subsidiary of the same parent company in accordance with this law or local laws) .</li> <li>The chairman, general manager or equivalent person of the company and another company or organization are the same person or spouse, and are directors (board members), supervisors (supervisors) or employees of the other company or organization ( except for independent directors appointed by the company and its parent company, subsidiary or subsidiary of the same parent company in accordance with this law or local laws) .</li> <li>Serve as a director (councilor), supervisor (supervisor),</li> </ol>	3
Chen Houming Independent Director	<ol style="list-style-type: none"> <li>Professional background: PhD in Marketing, Graduate Institute of Business Administration, National Taiwan University; Lecturer at public or private colleges and universities with relevant majors required for the company's business; Professional experience in business and the company's business.</li> <li>Experience: Director of the Institute for Business Development, National Chung Hsing University; Dean of the College of Social Sciences and Management.</li> <li>Independent Director Chen possesses management expertise and experience as an independent director in other industries, enabling him to provide diverse advice on operations and management in a timely manner and offer clear guidance in practical operations.</li> </ol>	<ol style="list-style-type: none"> <li>The directorships or voting shares of the Company and other companies are controlled by the same person who is a director, supervisor or employee of the other company ( except for independent directors appointed by the Company and its parent company, subsidiary or subsidiary of the same parent company in accordance with this law or local laws) .</li> <li>The chairman, general manager or equivalent person of the company and another company or organization are the same person or spouse, and are directors (board members), supervisors (supervisors) or employees of the other company or organization ( except for independent directors appointed by the company and its parent company, subsidiary or subsidiary of the same parent company in accordance with this law or local laws) .</li> <li>Serve as a director (councilor), supervisor (supervisor),</li> </ol>	3

condition Name	Professional qualifications and experience ( Note 1)	Independence situation (Note 2)	Number of independent directors of other publicly listed companies
Yao Xiubi Independent Director	<ol style="list-style-type: none"> <li>1. Specialty: Master of Business Administration from the University of Missouri-Columbia; possesses professional experience in applying financial statement analysis, evaluating industry mergers and acquisitions , and the business of this company.</li> <li>2. Experience: Executive spokesperson for Tunghai University's Super EPOST program / Department of Finance, National Chung Cheng University / Ginko International Co., LTD / Director of the Chairman's Office, Yung Sheng Optical Co., Ltd.</li> <li>3. Independent Director Yao possesses management expertise and experience as a director in other industries. He can provide suggestions on the company's diversified business operations and offer management decision-making advice in analyzing financial statements and evaluating mergers and acquisitions.</li> </ol>	<p>manager or shareholder holding 5% or more of the shares of a specific company or institution that has financial or business dealings with the company, as listed in (1) to (4) below.</p> <ol style="list-style-type: none"> <li>(1) Holding more than 20% but not more than 50% of the total number of issued shares of the company.</li> <li>(2) The other company and its directors, supervisors and shareholders holding more than 10% of the total shares collectively hold more than 30% of the total issued shares of the company, and there has been a record of financial or business dealings between the two parties. The shares held by the aforementioned persons include those held by their spouses, minor children and those held in the name of others.</li> <li>(3) More than 30% of the company's operating revenue comes from other companies and their group companies.</li> <li>(4) More than 50% of the quantity or total purchase amount of the company's main product raw materials (referring to those accounting for more than 30% of the total purchase amount and being essential raw materials for manufacturing products) or main commodities (referring to those accounting for more than 30% of the total operating revenue) come from other companies and their group companies.</li> </ol> <p>9. Professionals, sole proprietors, partners, directors (supervisors), supervisors (managers), managers, and their spouses who have provided auditing services or received cumulative remuneration exceeding NT\$500,000 in the past two years for business, legal, financial, accounting, or related services to companies or related enterprises. However, members of the Salary and Compensation Committee, the Public Tenders Review Committee, or the Special Mergers and Acquisitions Committee, who exercise their powers in accordance with this Act or relevant laws and regulations of the Enterprise Mergers and Acquisitions Act, are not included in this restriction.</p>	0

Note 1: Upon investigation, all directors of the Company have not committed any of the violations specified in Article 30 of the Company Law .

## 2. Diversity and independence of the board of directors:

The Company has established the "Director Election Rules", which state that the election of directors (including independent directors) of the Company should take into account the overall configuration, the composition of members should take into account diversity, and formulate appropriate diversity guidelines based on its own operations, operating patterns and development needs, which should include but not be limited to the following two aspects :

1. Basic conditions and values: gender, age, nationality and culture, etc.
2. Professional knowledge and skills: professional background (such as law, accounting, industry, finance, marketing or technology), professional skills and industry experience, etc.

The Company's current Board of Directors consists of 11 directors, including 4 independent directors, with extensive experience and expertise in the fields of medicine, finance, business and management. At the same time, in accordance with the board diversity policy, the company also attaches great importance to gender equality in the composition of the board of directors. When electing directors in 2023, a female director was added, making the current board of directors include three female directors. When the shareholders' meeting re-elected the current board of directors in 2024, three female directors were maintained, with a ratio of 27.3%, which was in compliance with the relevant laws and regulations at the time of the election. However, the company has 11 board seats, but less than one-third of them are female directors, which is due to the characteristics of the industry. The Company intends to seek talent recommendations from various channels such as industry and academia when the Board of Directors is re-elected upon expiration of its term, in order to improve corporate governance effectiveness and implement a policy of diversity in board members.

The current board of directors of our company has elected 11 directors, of which 4 are independent directors, accounting for 36.3 % . During the election, the company evaluated them and issued an independent director qualification checklist. When taking office, the independent directors signed an independent director declaration, confirming that none of the independent directors are subject to the provisions of Article 26-3, Paragraphs 3 and 4 of the Securities and Exchange Act , and exercised their independence. In addition, except for Director Yang Chen Caibi and Director Yang Hongren, who are mother and son, the other directors of this board of directors are not spouses or relatives within the second degree of kinship.

Diversity of board members:

Diversified core projects	Basic composition								Industry Experience				Professional capabilities			
	Country of Citizenship	gender	concurrently serves as the company staff	age				Independent Director Term of Office	Medical profession	Medical institution management	educate	Investment Management	law	Accounting and Finance	Marketing Management	Information Technology
41 to 50				51 to 60	61 to 70	71 above	Within 3 sessions									
Yang Hongren	Republic of China	male	V		V				V	V	V	V		V	V	
Xu Shengxin	Republic of China	male				V			V	V		V		V	V	
Liu Qingwen	Republic of China	male	V			V			V	V		V		V	V	
Sun Zhili	Republic of China	female			V						V	V		V	V	
Chen Wenzhong	Republic of China	male	V			V			V	V	V	V		V	V	
Zhang Changrong	Republic of China	male	V		V					V				V	V	
Yang Chen Caibi	Republic of China	female					V			V	V	V				
Wu Genzai	Republic of China	male				V		V						V		
Li Shuxing	Republic of China	male				V		V			V	V		V	V	
Chen Houming	Republic of China	male				V		V			V	V		V	V	
Yao Xiubi	Republic of China	female		V				V			V			V	V	

The overall capabilities of the board members are:

Diversified core projects	gender	Operational judgment ability	Accounting and financial analysis skills	Business management capabilities	Crisis handling ability	Industry knowledge	International Market Outlook	Leadership	Decision-making ability
Name of Director									
Yang Hongren	male	V	V	V	V	V	V	V	V
Xu Shengxin	male	V	V	V	V	V	V	V	V
Liu Qingwen	male	V	V	V	V	V	V	V	V
Sun Zhili	female	V	V	V	V	V	V	V	V
Chen Wenzhong	male	V	V	V	V	V	V	V	V
Zhang Changrong	male	V	V	V	V	V	V	V	V
Yang Chen Caibi	female	V	V			V			V
Wu Genzai	male	V	V	V	V	V		V	V
Li Shuxing	male	V	V	V	V	V	V	V	V
Chen Houming	male	V	V	V	V	V	V	V	V
Yao Xiubi	female	V	V	V	V	V	V	V	V

(3) General Manager, Deputy General Managers, Assistant Managers and Heads of Departments and Branches

April 20 , 2026

job title	Country of Citizenship	Name	Date of appointment	Shareholding		Spouse and minor children Shareholding		Using someone else's name Shareholding		Major Educational Background	Currently holding other positions in other companies	Managers who are spouses or have a relationship within the second degree of kinship			Remark
				Number of shares	Shareholding ratio	Number of shares	Shareholding ratio	Number of shares	Shareholding ratio			Number of shares	Shareholding ratio	job title	
Chief Executive Officer	Republic of China	Yang Hongren ( Note 1)	2020/01/ 31	1,029,687	0.74%	0	0	0	0	1. Department of Medicine, National Taiwan University 2. Master of Public Health, Harvard University, USA 3. Peter. Drucker School of Management MBA 4. John. Master of Health Sciences, Johns Hopkins 5. PhD, Institute of Sports Science, National Taiwan Sport University 6. Visiting Scholar at Stanford University 7. CEO of Minsheng Medical System 8. Director of Beijing Smile Angel Children's Hospital 9. Physician in charge of Minsheng General Hospital	1. CEO of Min Sheng Healthcare System 2. Chairman of Minsheng Medical Holdings Co., Ltd. 3. Chairman of the Board of Directors of Sangu (Stock) Company 4. Chairman of Precision Health (stock) company 5. Chairman of Hengxin Investment Co., Ltd. 6. Chairman of Yue Shi Health (Stock) Co., Ltd. 7. Chairman of Born Management Consulting Co., Ltd. 8. Chairman of Mincheng Health Technology Co., Ltd. 9. Chairman of Anzhun Technology (Stock) Co., Ltd. 10. Chairman of Shengyun Pharmaceutical Co., Ltd. 11. Chairman of a medical electronics digital transformation (stock) company 12. Chairman of Bisheng Construction ( Stock ) Co., Ltd. 13. Director of Shengshi Digital Health (Stock) Co., Ltd. 14. Director of the United Medical Foundation 15. Director of Universal Biotechnology Multimedia (Stock) Co., Ltd. 16. Director of Yida International Hospital Management Consulting Co., Ltd. 17. Director of Minsheng Asset Management Co., Ltd. 18. Director of Fangding Information Technology Co., Ltd. 19. Director of Hehehe Healthy Living ( Stock ) Co. , Ltd. 20. Supervisor of Shengyu Health Technology (Stock) Co., Ltd. 21. Supervisor of China Development and Medical Venture Capital (Stock) Co., Ltd. 22. Supervisor of Yuede Enterprise (Stock) Co., Ltd. 23. Supervisor of Bozhi Cultural and Creative (Stock) Co., Ltd.	Dong thing	Yang List color Bi	mother son	Chairman and CEO

job title	Country of Citizenship	Name	Date of appointment	Shareholding		Spouse and minor children Shareholding		Using someone else's name Shareholding		Major Educational Background	Currently holding other positions in other companies	Managers who are spouses or have a relationship within the second degree of kinship			Remark
				Number of shares	Shareholding ratio	Number of shares	Shareholding ratio	Number of shares	Shareholding ratio			Number of shares	Shareholding ratio	job title	
President	Republic of China	Liu Qingwen	2005/6/1	62,075	0.05 %	0	0	0	0	<ul style="list-style-type: none"> <li>1. Department of Medical Technology, Taipei Medical College</li> <li>2. Yuan Ze Management School EMBA</li> <li>3. Senior Vice President of Min Sheng General Hospital</li> <li>4. Executive Vice President of Min-Sheng General Hospital</li> <li>General Manager of Shengyun Pharmaceutical Co., Ltd.</li> </ul>	<ul style="list-style-type: none"> <li>1. Chairman of Zhongyuan Medical Management (Stock) Company</li> <li>2. Vice Chairman of Shengyun Pharmaceutical Co., Ltd.</li> <li>3. Director of Mincheng Health Technology Co., Ltd.</li> <li>4. Director of the United Medical Foundation</li> <li>5. Director of Harvard Health (Stock)</li> <li>6. Director of Fangding Information Technology Co., Ltd.</li> <li>7. Director of Precision Health (stock ) Co., Ltd.</li> <li>8. Director of Hehehe Healthy Living ( Stock ) Co. , Ltd.</li> <li>9. Supervisor of Yue Shi Health (Stock) Co., Ltd.</li> </ul>	none	none	none	
Deputy General Manager	Republic of China	Wu Mingxun	2008/1/1	287,106	0.20%	36,212	0.03%	0	0	<ul style="list-style-type: none"> <li>1. Master of Life Sciences, National Chung Hsing University</li> <li>2. Master of Management, Yuan Ze University</li> <li>3. Deputy Director of the Quality Control Center at Min Sheng General Hospital</li> <li>4. Adjunct Lecturer at Yuanpei University of Science and Technology</li> <li>5. Ministry of Education-appointed lecturers</li> <li>6. Expert committee members and inspection committee members of accredited medical institutions for labor physical and health examinations.</li> <li>7. Laboratory biosafety experts and scholars</li> <li>8. Accreditation and review committee members for precision medicine molecular testing laboratories</li> <li>9. Clinical Medical Personnel Training Program Review Committee</li> <li>10. Supervisors, Directors, and Standing Directors of the 9th to 15th National Federation of Medical Laboratory Technicians of the Republic of China</li> <li>11. Supervisor, Director, and Standing Director of the 11th to 13th Sessions of the Taiwan Society of Medical Laboratory Science</li> </ul>	<ul style="list-style-type: none"> <li>1. General Manager of Zhongyuan Medical Management (Stock) Company</li> <li>2. Head of Medical Technology Department, Min Sheng General Hospital</li> </ul>	none	none	none	

job title	Country of Citizenship	Name	Date of appointment	Shareholding		Spouse and minor children Shareholding		Using someone else's name Shareholding		Major Educational Background	Currently holding other positions in other companies	Managers who are spouses or have a relationship within the second degree of kinship			Remark
				Number of shares	Shareholding ratio	Number of shares	Shareholding ratio	Number of shares	Shareholding ratio			job title	Name	relation	
Deputy General Manager	Republic of China	Kovison	2023/06/01	196	0 %	0	0	0	0	1. Department of Pharmacy, Taipei Medical College 2. Graduate Institute of Pharmacy, Kaohsiung Medical University 3. Yuan Ze University Graduate Institute of Management 4. Head of Pharmacy Department, Min Sheng General Hospital 5. Senior Manager of the Pharmaceutical Distribution Department, Shenghong Pharmaceutical Co., Ltd.	Super Biotech ( stock ) supervisor	none	none	none	
(Business Unit) President	Republic of China	Zhang Changrong (Note 2)	2026/03/13	0	0 %	0	0	0	0	1. Master of Public Administration, University of Southern California (USC ) 2. Deputy CEO of Min Sheng Healthcare System 3. President of Longtan Minsheng Hospital and President of Dayuan Minsheng Hospital 4. Executive Vice President of Min Sheng General Hospital 5. Chairman of Asia Pacific Health (Stock) Co., Ltd. 6. Members of the 5th and 6th Councils of the Regional Hospital Association of the Republic of China 7. Deputy Captain of the Taoyuan County Patrol Brigade	1. Chairman of Rongyang Management Consulting Co., Ltd. 2. Chairman and General Manager of Minsheng Asset Management Co., Ltd. 3. Vice Chairman of Bisheng Construction (Stock) Co., Ltd. 4. Director of Mincheng Health Technology Co., Ltd. 5. Supervisor of Precision Health (stock ) Co., Ltd.				
Deputy General Manager	Republic of China	Chen Pengxuan	2019/08/16	160	0%	0	0	0	0	1. Graduated from the Institute of Medical Management, Chang Gung University 2. Senior Vice President, Intelligent Medical Technology (Stock) Company 3. General Manager of Maclon (Stock) Co., Ltd. 4. Deputy Executive Director of Long-Term Care Business Unit, Shenghong Pharmaceutical Co., Ltd. 5. Executive Director of Min Sheng Healthcare System 6. Min Sheng Healthcare System / Nursing Supervisor	1. Vice Chairman of Yue Shi Health (Stock) Co., Ltd. 2. Chairman of Fangding Information Technology Co., Ltd. 3. General Manager of Mincheng Health Technology Co., Ltd.	none	none	none	
Deputy General Manager	Republic of China	Cai Yufang	2019/09/01	0	0	0	0	0	0	1. Master of Business Administration for Senior Executives, National Central University 2. Department of Law, Soochow University 3. Head of Administration, Shenghong Pharmaceutical Co., Ltd. 4. Minsheng Medical Holdings Co., Ltd. / Legal Specialist Specialist , Ford Lio Ho Motor Co., Ltd. 6. State-owned Assets Bureau/Legal Specialist , Ministry of Finance	1. Executive Vice President of Precision Health (Stock) Co., Ltd. 2. Supervisor of Zhongyuan Medical Management (Stock) Company	none	none	none	

job title	Country of Citizenship	Name	Date of appointment	Shareholding		Spouse and minor children Shareholding		Using someone else's name Shareholding		Major Educational Background	Currently holding other positions in other companies	Managers who are spouses or have a relationship within the second degree of kinship			Remark
				Number of shares	Shareholding ratio	Number of shares	Shareholding ratio	Number of shares	Shareholding ratio			Number of shares	Shareholding ratio	job title	
Deputy General Manager	Republic of China	He Weiguang (Note 3)	2020/08/01	0	0	0	0	0	0	<ol style="list-style-type: none"> <li>1. Bachelor of Science in Computer Science and Engineering, National Chiao Tung University</li> <li>2. Master of Science, Graduate Institute of Computer Science and Engineering, National Taiwan University</li> <li>3. Director of the Digital Service Innovation Research Institute, Institute for Information Industry (IUI)</li> <li>4. Manager of Information Department/Director of Marketing Division, TTV Corporation</li> <li>5. Project Leader, Industrial Development Bureau, Ministry of Economic Affairs, Smart Innovation Service Promotion Project</li> <li>6. Project Leader of the Internet of Things Intelligent Manufacturing Base Project, Industrial Development Bureau, Ministry of Economic Affairs</li> <li>7. Project Leader, Department of Commerce, Ministry of Economic Affairs, Online Community Innovative Service Development Program</li> <li>8. Co-host of the Demonstration Information Application Development Project for Digital Television/Telecommunications Value-Added Services, Department of Technology, Ministry of Economic Affairs</li> </ol>	<ol style="list-style-type: none"> <li>1. Executive Director of Medical Electronics Digital Transformation (Stock) Company</li> <li>2. Director of Universal Biotechnology Multimedia (Stock) Co., Ltd.</li> <li>3. Director of Yue Shi Health (Stock) Co., Ltd.</li> <li>4. Director of Shengshi Digital Health (Stock) Co., Ltd.</li> </ol>	none	none	none	
Deputy General Manager	Republic of China	Zhong Yiting	2024/11/01	0	0	0	0	0	0	<ol style="list-style-type: none"> <li>1. Institute of Gerontology and Health Care, Chang Gung University of Science and Technology</li> <li>2. Yuan Ze University Graduate Institute of Management</li> <li>3. Department of Nursing and Department of Medical Administration, Yuanpei University of Science and Technology</li> <li>4. Associate Dean of Harvard Healthcare</li> <li>5. Deputy Director and Director of the Nursing Department, Min Sheng General Hospital</li> <li>6. Director of Nursing Department, Beijing Aiyuhua Women and Children's Hospital</li> <li>7. Director of Nursing Department, Beijing Mingde Hospital</li> <li>8. Deputy Director of the President's Office, Beijing Yanran Angel Children's Hospital</li> <li>9. Director of the Administrative Department of Longtan Minsheng Hospital</li> </ol>	1. CEO of Harvard Healthcare	none	none	none	

job title	Country of Citizenship	Name	Date of appointment	Shareholding		Spouse and minor children Shareholding		Using someone else's name Shareholding		Major Educational Background	Currently holding other positions in other companies	Managers who are spouses or have a relationship within the second degree of kinship			Remark	
				Number of shares	Shareholding ratio	Number of shares	Shareholding ratio	Number of shares	Shareholding ratio			job title	Name	relation		
										10. Head of Quality Control Team, Asia Pacific Health (Stock) Co., Ltd. 11. Surgical Case Manager, Medical Affairs Secretary Team Leader, and Director's Office Specialist at Min Sheng General Hospital 12. Head of the Drug Procurement and Warehouse Team at Shenghong Pharmaceutical (Stock) Co., Ltd. 13. Disease triage specialist and anesthesia nurse at Dayuan Min-Sheng Hospital 14. Senior Specialist, Chairman's Office, Shenghong Pharmaceutical (Stock) Co., Ltd. 15. Yue Shi Health (Pharmacy) Company (Pharmacy) Project Vice President 16. Part-time lecturer at Xinsheng Medical College 17. Ministry of Education-appointed lecturer						
Chief Financial Officer	Republic of China	Lin Fangyu (Note 4)	2025/10/17	0	0	0	0	0	0	1. Department of Accounting, Tunghai University 2. Chief Financial Officer of YueShi Health (Stock) Co., Ltd. 3. Chief Financial Officer and Spokesperson of Minsheng Health Technology Co., Ltd. 4. Accounting Manager, Head of Finance Department, and Acting Spokesperson of Zongge Precision Co., Ltd. 5. Audit Specialist, Audit Manager, and Accounting Manager at Shenghong Pharmaceutical (Stock) Co., Ltd. 6. Audit Team Leader, Fanxuan System Technology Co., Ltd. 7. Project Manager, Underwriting Department, Fubon Securities Co., Ltd.	none					
Accounting supervisor	Republic of China	Huang Yamei	2018/05/01	13,298	0.02%	0	0	0	0	1. Department of Accounting, Ming Chuan University 2. Deputy Audit Team Leader, Ernst & Young 3. Accounting Supervisor and Finance Supervisor of Hekang Biotechnology Co., Ltd. 4. Audit Manager of Hekang Biotechnology Co., Ltd. 5. Accounting Manager of Minsheng Medical Control Co., Ltd. 6. Accounting Manager of Shenghong Pharmaceutical Co., Ltd.	Director of Zhongyuan Medical Management (Stock) Company	none	none	none		

job title	Country of Citizenship	Name	Date of appointment	Shareholding		Spouse and minor children Shareholding		Using someone else's name Shareholding		Major Educational Background	Currently holding other positions in other companies	Managers who are spouses or have a relationship within the second degree of kinship			Remark
				Number of shares	Shareholding ratio	Number of shares	Shareholding ratio	Number of shares	Shareholding ratio			job title	Name	relation	
Audit supervisor	Republic of China	Ye Peiyu	2022/03/25	0	0	0	0	0	0	1. Graduate of the Institute of Finance and Banking, National Central University 2. Liande Electronics Co., Ltd. / Deputy Audit Manager 3. Juyan Hutong International Co., Ltd. / Deputy Audit Manager 4. Senior Audit Manager, Jingcai Technology Co., Ltd.	none	none	none	none	

Note 1: The Company has 11 directors. Four directors also serve as employees, of which three hold positions at the vice president level or above, and one holds a general senior management position. More than half of the directors do not serve as employees.

As the chairman also serves as the CEO, in order to strengthen the independence of the board of directors, the company added one independent director and one director in 2023 to enhance the functions of the board and strengthen its supervisory role.

Note 2: Zhang Changrong (Business Unit) took office as General Manager on March 13, 2026.

Note 3: Deputy General Manager He Weiguang resigned on March 17, 2026.

Note 4: Lin Fangyu took office as Chief Financial Officer on 17. October, 2025.

#### (4) Remuneration paid to directors, supervisors, general manager and deputy general manager in the most recent year

##### 1. Remuneration of directors (including independent directors):

Unit: NT\$1,000; % ; 1,000 shares

job title	Name	Directors' remuneration								Total amount of A, B, C and D and their proportion in net profit after tax		Part-time employees receive relevant remuneration								A, B, C, D, E, F and G, etc. Total amount of seven items and their proportion in net profit after tax		Receive remuneration from a subsidiary or parent company
		Remuneration (A)		Retirement pension (B)		Directors' Remuneration (C)		Business execution expenses (D)				Salaries, bonuses and special expenses, etc. (E)		Retirement pension (F)		Employee remuneration (G) (Note)						
		Book male manager	All companies in the financial report	Book male manager	All companies in the financial report	Book male manager	All companies in the financial report	Book male manager	All companies in the financial report	Book male manager	All companies in the financial report	Book male manager	All companies in the financial report	Book male manager	All companies in the financial report	Book male manager	All companies in the financial report	Cash Amount	Stock Amount	Cash Amount	Stock Amount	
Chairman	of Minsheng Medical Control Co., Ltd .: Yang Hongren	3,000	3,000	0	0	1,187	1,210	451	555	4,638 3.27%	4,765 3.36%	13,859	14,144	264	281	2,930	0	2,930	0	21,691 15.30%	22,120 15.61%	650
director	of Minsheng Medical Control Co., Ltd .: Xu Shengxin																					
director	of Minsheng Medical Control Co., Ltd .: Liu Qingwen																					
director	of Minsheng Medical Control Co., Ltd .: Sun Zhili																					
director	of Minsheng Medical Control Co., Ltd .: Chen Wenzhong																					
director	Rongyang Management Consulting Co., Ltd .: Zhang Changrong																					
director	Yang Chen Caibi																					
Independent Director	Li Shuxing	1,200	1,200	0	0	703	703	516	516	2,419 1.71%	2,419 1.71%	0	0	0	0	0	0	0	0	2,419 1.71%	2,419 1.71%	0
Independent Director	Wu Genzai																					
Independent Director	Chen Houming																					
Independent Director	Yao Xiubi																					

1. Please describe the policy, system, standards, and structure for the payment of remuneration to independent directors, and explain the relationship between the amount of remuneration and factors such as the responsibilities, risks, and time invested in the work:  
Independent directors' remuneration is based on a fixed monthly travel allowance, attendance fees for meetings (board of directors, remuneration committee, audit committee, nomination committee, etc. ), and a distribution of director's compensation. Meeting attendance fees are paid according to market rates. The remuneration for independent directors performing their duties is based on their individual industry experience and professional contributions to the company's operating performance and operations. In addition, a performance evaluation is conducted annually according to company regulations, and the weighted data from each evaluation item is used to calculate the director's remuneration distribution. Evaluation items include, but are not limited to, the director's status, concurrent management roles, meeting attendance rate, term of office, joint guarantees for financing, and self-evaluation of board performance, among other factors, to calculate the remuneration ratio.
2. In addition to the information disclosed in the table above, the remuneration received by the company's directors for services provided to all companies listed in the financial statements in the most recent year (such as acting as consultants to non-employees) is: **None** .

Note : The company's 2025 annual director remuneration has not yet been approved by the shareholders' meeting and is only expressed in terms of the estimated amount of the proposed distribution.

2. Directors' remuneration range:

Remuneration scale

The remuneration bracket for each director of the Company	Name of Director			
	Total remuneration for the first four items (A+B+C+D)		Total remuneration for the first seven items (A+B+C+D+E+F+G)	
	The Company	All companies in the financial report	The Company	Parent company and all its invested businesses
lower than 1,000,000 yuan	Xu Shengxin, Liu Qingwen, Sun Zhili, Chen Wenzhong, Zhang Changrong, Yang Chen Caibi, Wu Genzai, Li Shuxing, Chen Houming Yao Xiubi, Rongyang Management Consulting Co., Ltd.	Hsu Sheng-hsin, Liu Ching-wen, Sun Chih-li, Chen Wen-chung, Chang Chang-jung, Yang Chen Tsai-pi, Wu Genzai, Li Shuxing, Chen Houming Yao Xiubi, Rongyang Management Consulting Co., Ltd.	Xu Shengxin, Sun Zhili, Yang Chen Caibi, Wu Genzai, Li Shuxing, Chen Houming Yao Xiubi	Xu Shengxin, Sun Zhili, Yang Chen Caibi, Wu Genzai, Li Shuxing, Chen Houming Yao Xiubi
1,000,000 Yuan (inclusive) ~ 2,000,000 yuan (not including)	none	none	Chang Chang-jung and Rong Yang Management Consultants have Limited Company	Chang Chang-jung and Rong Yang Management Consultants have Limited Company
2,000,000 yuan (inclusive) ~ 3,500,000 yuan (not included)	Yang Hongren	Yang Hongren	Chen Wenzhong	Chen Wenzhong
3,500,000 yuan (inclusive) ~ 5,000,000 yuan (exclusive)	Minsheng Medical Holdings Co., Ltd.	Minsheng Medical Holdings Co., Ltd.	Liu Qingwen,	Liu Qingwen
5,000,000 yuan (inclusive) ~ 10,000,000 yuan (not included)	none	none	none	none
10,000,000 yuan (inclusive) ~ 15,000,000 yuan (not included)	none	none	Yang Hongren	Yang Hongren
15,000,000 yuan (inclusive) ~ 30,000,000 yuan (exclusive)	none	none	Minsheng Medical Holdings Co., Ltd.	Minsheng Medical Holdings Co., Ltd.
30,000,000 yuan (inclusive) ~ 50,000,000 yuan (exclusive)	none	none	none	none
50,000,000 yuan (inclusive) ~ 100,000,000 yuan (exclusive)	none	none	none	none
More than 100,000,000 yuan	none	none	none	none
total	13	13	13	13

3. Remuneration of the General Manager and Deputy General Manager: (Summarize and disclose names by level)

Unit: NT\$ thousand; %

job title	Name	Salary(A)		Retirement pension (B)		Bonus and Special expenses, etc. (C)		employee remuneration (D) (Note)				Total amount of A, B, C and D and their proportion in net profit after tax (%)		remuneration from a subsidiary or parent company
		The Company	Financial Reports All company	The Company	All financial reports company	The Company	Financial Reports All company	The Company		All financial reports company		The Company	Financial Report Report to the internal office There is a company	
								Cash Amount	Stock Amount	Cash Amount	Stock Amount			
CEO	Yang Hongren	19,845	22,282	759	821	2,635	3,240	4,396	0	4,396	0	27,635 (19.50%)	30,739 (21.69%)	850
President	Liu Qingwen													
Deputy General Manager	Wu Mingxun													
Deputy General Manager	Kovison													
Deputy General Manager	Chen Pengxuan													
Deputy General Manager	He Weiguang													
Deputy General Manager	Cai Yufang													
Deputy General Manager	Zhong Yiting													
Chief Financial Officer	Lin Fangyu													

Note: The company's employee remuneration for 2024 has not yet been approved by the shareholders' meeting and is only expressed as an estimated amount of the proposed distribution .

4. Remuneration range for general manager and deputy general manager:

The remuneration range for each general manager and deputy general manager of the company	Name of General Manager and Deputy General Manager	
	The Company	Parent company and all its invested businesses
Less than 1,000,000 yuan	none	none
1,000,000 yuan (inclusive) ~ 2,000,000 yuan (exclusive)	He Weiguang, Zhong Yiting, Lin Fangyu	Zhong Yiting
2,000,000 yuan (inclusive) ~ 3,500,000 yuan (exclusive)	Wu Mingxun, Ke Weixin, Chen Pengxuan, Cai Yufang	Wu Mingxun, Ke Weixin, Chen Pengxuan, Cai Yufang Lin Fangyu
3,500,000 yuan (inclusive) ~ 5,000,000 yuan (exclusive)	Liu Qingwen	Liu Qingwen, He Weiguang
5,000,000 yuan (inclusive) ~ 10,000,000 yuan (exclusive)	Yang Hongren	none
10,000,000 yuan (inclusive) ~ 15,000,000 yuan (exclusive)	none	Yang Hongren
15,000,000 yuan (inclusive) ~ 30,000,000 yuan (exclusive)	none	none
RMB 30,000,000 (inclusive) to RMB 50,000,000 (exclusive)	none	none
50,000,000 yuan (inclusive) ~ 100,000,000 yuan (exclusive)	none	none
100,000,000 Yuan or more	none	none
total	9	9

5. Name of the manager who distributes employee remuneration and the distribution situation:

Unit: NT\$ thousand; %

April 20 , 2026

project	job title	Name	Stock Amount	Cash Amount	total	Total as a percentage of net profit after tax The proportion (%)
Manager	CEO	Yang Hongren	0	4,678	4,678	3.30%
	President	Liu Qingwen				
	Deputy General Manager	Wu Mingxun				
	Deputy General Manager	Kovison				
	Deputy General Manager	Chen Pengxuan				
	Deputy General Manager	He Weiguang				
	Deputy General Manager	Cai Yufang				
	Deputy General Manager	Zhong Yiting				
	Chief Financial Officer	Lin Fangyu				
	Accounting supervisor	Huang Yamei				
	Audit supervisor	Ye Peiyu				

Note 1: Individual names and titles should be disclosed, but profit distribution may be disclosed in aggregate form.

Note 2: This is the actual amount of employee remuneration (including stocks and cash) distributed to managers in the most recent year approved by the board of directors. If it is impossible to estimate, the proposed distribution amount for the current year will be calculated based on the proportion of the actual distribution amount last year. Net profit after tax refers to the net profit after tax of the most recent year. For those that have adopted International Financial Reporting Standards, net profit after tax refers to the net profit after tax of the most recent year's individual or separate financial reports.

Note 3: The scope of application of managers is as follows, in accordance with the SFC's Order No. 0920001301 dated March 27, 2003:

- (1) General Manager and persons of equivalent rank
- (2) Deputy General Manager and persons of equivalent rank
- (3) Associate and equivalent
- (4) Head of Finance Department
- (5) Head of Accounting Department
- (6) Other persons who have the right to manage the company's affairs and sign

Note 4: If the director, general manager and deputy general manager receive employee remuneration (including stocks and cash), they should fill in this form in addition to filling in Appendix 1-2.

Note 5: The Company's employee remuneration for 2025 has not yet been approved by the shareholders' meeting and is only expressed as an estimated amount of the proposed distribution.

Note 6: Special Assistant Lin Fangyu will act as Chief Financial Officer.

## 6. Remuneration policy:

### (1) Remuneration determination and payment policy:

Directors' remuneration (including independent directors') is mainly divided into two parts: directors' remuneration, fixed travel expenses, meeting attendance fees and business execution expenses.

Remuneration of directors and concurrent employees: including concurrent employees' salaries, various additional allowances and bonuses.

Directors' remuneration is based on Article 21 of the Company's Articles of Association, which stipulates that if the Company makes a profit in a given year, the Board of Directors may allocate no more than 3% of the aforementioned profit as directors' remuneration. In accordance with this principle, the allocation for individual directors in 2025 was 1% of pre-tax net profit. This allocation was approved by the Company's 8th Board of Directors at its 12th meeting and is proposed to be submitted to the 2026 Annual General Meeting of Shareholders for approval before disbursement.

The remuneration of directors for performing their duties is based on the directors' attendance rate, personal industry experience and professional involvement in the company's operating performance and company operations. In addition, performance evaluation is conducted once a year in accordance with company regulations, and directors participate in the distribution of directors' remuneration after weighted data calculation based on each evaluation item. The remuneration ratio is calculated based on comprehensive considerations including but not limited to the director's status, concurrent manager, meeting attendance rate, tenure, financing joint guarantees, and the board's self-evaluation of performance. The remuneration of directors and supervisors of other subsidiaries is also allocated in accordance with the company's articles of association and can only be paid after approval in accordance with legal procedures. Fixed travel expenses are set according to market conditions, and meeting attendance fees are paid based on actual attendance when the board of directors, compensation committee or audit committee are convened.

The remuneration of employees (including managers) is based on the employee remuneration method established by the company, and is assessed based on the scope of each job responsibility and with reference to the industry standards, including: salary, various allowances and bonuses, employee remuneration, etc.

Employee compensation is stipulated in Article 21 of the Company's Articles of Association: If the Company makes a profit in a given year, it shall allocate 6% to 10% as employee compensation (with no less than 10% allocated to lower-level employees) . The Board of Directors shall decide on the distribution in the form of shares or cash, and the recipients include employees of subsidiary companies who meet certain conditions . Based on this principle, the allocation ratio for the individual portion of the Company in 2025 was 6% of the pre-tax net profit. This ratio has been approved by the Company's Eighth Board

of Directors at its Twelfth Meeting and is proposed to be submitted to the 2026 Annual General Meeting of Shareholders for approval. The Company considers the talent conditions required for the Company's operation and development and submits the salary and remuneration to the Remuneration Committee for review and approval by the Board of Directors in accordance with the scope of job responsibilities. In the performance evaluation, the Company implements a performance appraisal system for managers. The evaluation of this system includes the value of the individual's overall performance to the organization, the ability to cooperate with members and team spirit, the risk of poor performance, whether there is work potential, and promotion evaluation. The scoring mechanism includes category selection and score evaluation, and the principle of payment is based on comprehensive considerations such as the target achievement rate of the management department and the company's profitability, so as to build a reasonable, fair, incentive and business performance-linked compensation structure.

(2) Relationship with operating performance and future risks:

The Company's managers' performance evaluation is based on the principle of risk management to ensure that possible risks within the scope of their duties are managed and prevented. Rating results are determined based on actual performance and are linked to relevant rewards. The relevant remuneration payment standards and systems are based on the company's overall operating conditions as the main consideration, and the payment standards are determined based on performance achievement rate and contribution. We also refer to the industry salary standards to ensure that the remuneration of the company's management is competitive in the industry so as to retain outstanding management talents.

In line with the company's ESG policy and sustainable development, it is planned to link ESG performance with the remuneration of the company's senior managers. The performance evaluation items include but are not limited to the following:

(1) Financial indicators, accounting for 90%, are based on the following achievement rates: department target achievement rate, operating income, ROA, EPS, etc.

(2) Sustainable development indicators, accounting for 10%, including:

Environmental aspect (E): Greenhouse gas inventory and certification, energy management.

Social dimension (S): community care participation, implementation of labor laws, and employee health management.

Corporate governance aspect (G): Strengthen communication channels with stakeholders and investor relationship management.

Important decisions made by management are based on a consideration of various risk factors. The performance of related decisions is reflected in the company's profitability. In addition to the linkage with the performance bonuses of business departments, it is also reflected in the distribution of annual year-end bonuses. The remuneration of the company's managers is reviewed by the Remuneration Committee and submitted to the Board of Directors for

approval before being paid and reviewed and adjusted in a timely manner to comply with the remuneration policy and the spirit of sustainable operation of the company.

Proportion of directors' remuneration and general manager and deputy general manager's remuneration in the company's net profit after tax in the most recent two years

Unit: NT\$ thousand ; %

project job title	The Company				Consolidated financial statements for all companies			
	2024		2025		2024		2025	
	lump sum	Proportion of net profit after tax	lump sum	Proportion of net profit after tax	lump sum	Proportion of net profit after tax	lump sum	Proportion of net profit after tax
Directors' remuneration	7,309	3.65%	7,057	4.98%	7,309	3.65%	7,185	5.07%
Remuneration of directors and employees	28,746	14.37%	17,052	12.03%	28,746	14.37%	17,355	12.25%
Remuneration of General Manager and Deputy General Manager	34,476	17.23%	27,635	19.50%	34,476	17.23%	30,740	21.69%
Net profit after tax	200,097		141,726		200,097		141,726	

Note: In 2025 , a nomination committee was added, and the number of independent directors attending meetings increased slightly.

The net profit after tax in fiscal year 2025 decreased compared to fiscal year 2024, therefore the directors' remuneration also decreased accordingly.

The difference in managerial compensation also arises due to the decrease in net profit. Employee compensation for 2025 has not yet been approved by the shareholders' meeting; therefore, the proposed figures are used for the initial allocation estimate.

## 2.2 Corporate Governance Operation

### (I) Information on the operation of the board of directors

The most recent annual board meeting was held 6 times (A) , and the attendance of directors and supervisors was as follows:

Job Title	Name (Note 1)	Actual attendance Number of times ( B )	Delegated Attendance frequency	Actual output (column) Attendance rate (%) 【 B/A 】 (Note 2)	Remark
Chairman	Minsheng Medical Control Co., Ltd. Representative : Yang Hongren	6	0	100%	none
Vice President Chairman	Minsheng Medical Control Co., Ltd. Representative : Xu Shengxin	6	0	100%	none
director	Minsheng Medical Control Co., Ltd. Representative : Liu Qingwen	6	0	100%	none
director	Minsheng Medical Control Co., Ltd. Representative : Sun Zhili	6	0	100%	none
director	Minsheng Medical Control Co., Ltd. Representative : Chen Wenzhong	6	0	100%	none
director	Rong Yang Management Consultants Limited Representative: Zhang Changrong	6	0	100%	none
director	Yang Chen Caibi	3	3	50%	none
independent director	Wu Genzai	6	0	100%	none
independent director	Li Shuxing	6	0	100%	none
independent director	Chen Houming	6	0	100%	none
independent director	Yao Xiubi	6	0	100%	none

Other matters that should be recorded:

— 、 If the operation of the board of directors involves any of the following circumstances, the date, period, content of the proposals, opinions of all independent directors, and the company's handling of the opinions of the independent directors shall be stated.

(一) The Company has established an Audit Committee. All matters listed in Article 14-3 of the Securities and Exchange Act shall be reviewed and approved by the Audit Committee before being submitted to the Board of Directors for resolution. For details, please refer to pages 43-45 ,Other Matters to be Recorded by the Audit Committee 1. (I) Matters listed in Article 14-5 of the Securities and Exchange Act.

(二) In addition to the above matters, other board meeting decisions that have been objected to or reserved by independent directors and have records or written statements  
Item: None.

二、 The implementation of directors' recusal of resolutions with conflicts of interest shall state the director's name, resolution content, reason for recusal and voting participation:

Board of Directors date	Period	Contents of the proposal	Avoidance of interest and reasons	Voting situation
2025/10/17	The 8th and 9th	Adjustment of the operating deposit of medical institutions under the company's management	In this case, directors Yang Hongren and Chen Wenzhong had a conflict of interest and therefore recused themselves from the conflict of interest.	The motion was passed as agreed by the acting chairman after consulting with the other attending directors.
2025/12/19	The 8th Session , 11th	Donation of NT\$1 million to the United Medical Foundation	Directors Yang Hongren , Zhang Changrong, Chen Wenzhong, and Liu Qingwen in this case have a conflict of interest and therefore recused themselves from such conflict of interest.	The motion was passed as agreed by the acting chairman after consulting with the other attending directors.
2025/12/19	The 8th Session , 11th	Precision Health (Stock) Co., Ltd. 2025 Cash Capital Increase Share Subscription Case	In this case, Director Yang Hongren had a conflict of interest and therefore recused himself from the conflict of interest.	The motion was passed as agreed by the acting chairman after consulting with the other attending directors.
2025/12/19	The 8th Session , 11th	Company Managers' Year-End Bonus Distribution Principles	In this case, directors Yang Hongren and Liu Qingwen had a conflict of interest and therefore recused themselves from the conflict of interest.	The motion was passed as agreed by the acting chairman after consulting with the other attending directors.

3. Listed or OTC companies shall disclose information such as the evaluation cycle and period, evaluation scope, method and content of the board of directors' self-evaluation (or peer evaluation), and the daily implementation status.

Evaluation cycle ( Note 1)	Evaluation period ( Note 2)	Scope of assessment ( Note 3)	Evaluation method ( Note 4)	Evaluation Content ( Note 5)
Once a year	January 1, 114 to December 31, 114	Performance evaluation of the Board of Directors, functional committees and	Board of Directors' Internal Self-Assessment and Directors'	<b>1. Board of Directors Performance Evaluation :</b> A. Degree of involvement in company operations B. Improve the quality of board decisions

		individual board members	Self-Assessment	<p>C. Board Composition and Structure  D. Selection and Continuing Education of Directors  E. Internal control.</p> <p><b>2. Individual Board Member Performance Evaluation</b></p> <p>A. Understanding Company Goals and Tasks  B. Understanding of Directors' Responsibilities  C. Degree of involvement in company operations  D. Internal Relationship Management and Communication  E. The professional development and continuing education of directors  F. Internal Control</p> <p><b>3. Functional Committee Performance Evaluation</b></p> <p>A. Degree of involvement in company operations  B. Understanding the Responsibilities of Functional Committees  C. Improve the quality of decision-making by functional committees  D. Composition and selection of members of functional committees  E. Internal Control</p>
--	--	--------------------------	-----------------	---

Note 1: This is the execution cycle of the board evaluation, for example: once a year.

Note 2: This is the period covered by the board evaluation, for example: evaluating the performance of the board of directors from January 1, 2019 to December 31, 2019.

Note 3: The scope of the evaluation includes the performance evaluation of the Board of Directors, individual directors and functional committees.

Note 4: Evaluation methods include internal self-evaluation by the Board, self-evaluation by directors, peer evaluation, and performance evaluation by external professional institutions, experts or other appropriate methods.

Note 5: The assessment content shall include at least the following items according to the assessment scope:

- (1) Board performance evaluation: at least including the degree of participation in the company's operations, the quality of the board's decision-making, the composition and structure of the board, the selection and continuing education of directors, and internal control.
- (2) Performance evaluation of individual directors: at least including the understanding of the company's goals and tasks, the director's understanding of responsibilities, the degree of participation in the company's operations, the management of internal relationships and communication, the director's professional and continuing education, and internal control.
- (3) Functional committee performance evaluation: level of participation in company operations, awareness of functional committee responsibilities, quality of functional committee decision-making, composition of functional committees and selection of members, internal control, etc.

Board of Directors Performance Appraisal : The performance appraisal for the Board of Directors was conducted from January 1st to December 31st, 2025. Eleven self-assessment questionnaires were distributed to board members, and all eleven were returned, with an average self-assessment score of 98.9. Self-assessment questionnaires for the Board of Directors, Audit Committee, Remuneration Committee, and Sustainable Development Committee were also distributed and scored by the corporate governance unit. The Board of Directors' self-assessment score was 98.5, while the Audit Committee, Remuneration Committee, Sustainable Development Committee, and Nomination Committee's self-assessment scores were 100, 100, 100, and 100 respectively. The results were reported as item 8 of the 12th meeting of the 8th Board of Directors on March 13th, 2026.

4. Strengthening the functions of the board of directors: The goals for strengthening the functions of the board of directors in the current year and the most recent year (e.g., establishing an audit committee, improving information transparency, etc.) and an evaluation of the implementation status.
  1. Our company established an audit committee on June 27, 2018 to oversee and improve the quality of board decisions.
  2. Regarding strengthening the functions of the Board of Directors: The Company has established the "Rules of Procedure for Board Meetings", "Organizational Procedures for the Audit Committee" , " Organizational Procedures for the Compensation and Remuneration Committee" , "Organizational Procedures for the Sustainability Committee" , "Organizational Procedures for the Nomination Committee" and "Performance Evaluation Methods for the Board of Directors and Functional Committees", and the operation, evaluation and assessment of the Board of Directors and functional committees are all carried out in accordance with these rules.
  3. Regarding enhancing information transparency: The company has spokespersons and acting spokespersons to respond to external inquiries, and has set up a company website (<https://www.share-hope.com/>) which includes sections on business development, investor relations, corporate governance, stakeholders, and ESG sustainability.
  4. In May 2019, the company established the "Standard Operating Procedures for Handling Directors' Requests" and in November 2021, it appointed a Corporate Governance Officer to assist directors in obtaining appropriate and sufficient information on the company's operations and to provide the latest information on revisions to laws and regulations related to corporate governance.
  5. In accordance with regulatory requirements, the Company conducted two Directors' Training Courses on August 8 and November 7 , 2025 , in order to ensure that the Directors meet the annual training hour requirements.

Note 1 : If the director or supervisor is a legal person, the name of the legal person shareholder and the name of its representative shall be disclosed.

Note 2 : (1) If a director or supervisor resigns before the end of the year, the date of resignation shall be noted in the remarks column. The actual attendance rate (%) shall be calculated based on the number of board meetings held during his/her tenure and the number of his /her actual attendance .

(2) If there is a re-election of directors and supervisors before the end of the year, both the new and old directors and supervisors should be listed, and the remarks column should indicate whether the director and supervisor is the old, new or re-elected director and supervisor and the date of re-election. The actual attendance rate (%) is calculated based on the number of board meetings held during the term of office and the number of actual attendances .

## (II) Operation of the audit committee or participation of supervisors in the operation of the board of directors

1. The Company established an Audit Committee at its June 27, 2018, general meeting of shareholders in accordance with Article 14-4 of the Securities and Exchange Act.

2. Annual work priorities of the Audit Committee

The Company's Audit Committee is composed of four independent directors. The main purpose of the Audit Committee is to supervise the fair presentation of the Company's financial statements , the selection ( dismissal ) and independence and performance of the certifying accountants, the effective implementation of internal controls, compliance with relevant laws and regulations, and the control of existing or potential risks. The annual work highlights are summarized as follows :

### (1) Review financial reports

The board of directors prepared the company's 2025 annual business report, financial statements and profit distribution proposal, among which the financial statements have been audited by Anhou Jianye Joint Accounting Firm and an audit report has been issued. The above business report, financial statements and profit distribution proposal have been reviewed by this Audit Committee and are considered to be in good condition .

### (2) Review the effectiveness of internal control

The Audit Committee reviews the procedures and implementation results of the company's internal control self-assessment system and reviews the audit department's audit reports, including risk management and legal compliance. The Audit Director regularly meets with the convener of the Audit Committee to understand the problems that may be faced in the internal audit execution review process. Therefore, the Audit Committee believes that the company's risk management and internal control systems are effective and the company has adopted necessary control mechanisms to monitor and correct violations .

### (3) Review the independence and performance evaluation of the certified public accountants

The Audit Committee assesses the independence and competence of its certified public accountants annually. In addition to requiring certified public accountants to provide an "Independence Declaration" and "Audit Quality Indicators (AQIs)," the Committee develops an independence assessment form and 13 AQI indicators based on the content of the Republic of China Accountant Ethics Code Bulletin No. 10 , "Independence of Verification and Review ." The assessment

results for the most recent year were discussed and approved by the Audit Committee on March 13 , 2026 , and submitted to the Board of Directors for approval on March 13 , 206 , for the Board's resolution on the assessment of the accountants' independence and competence.

(4) Supervision of legal compliance and risk control

The Audit Committee shall review in advance the Company's major investment benefits and possible risks of asset transactions, the appointment and removal of audit supervisors, endorsements and guarantees, and report the results of the review to the Board of Directors.

3. term of office for the current Audit Committee is from June 24, 2024 to June 23 , 2027. The operational status for the most recent year up to the date of publication of the annual report is as follows:

The operation is as follows :

The Audit Committee held 6 meetings (A), with independent directors attending as follows:

job title	Name	Actual attendance (B)	Number of delegated attendances	Actual attendance rate (%) (B/A)(Note)	Remark
Independent Director	Wu Genzai	7	0	100%	none
Independent Director	Li Shuxing	7	0	100%	none
Independent Director	Chen Houming	7	0	100%	none
Independent Director	Yao Xiubi	7	0	100 %	none

Other matters that should be recorded:

1. If the operation of the Audit Committee involves any of the following circumstances , the date , period, content of the board of directors meeting, the Audit Committee's resolution, and the company's handling of the Audit Committee's opinion shall be stated.

( 1) Matters listed in Article 14-5 of the Securities and Exchange Act :

Audit Committee Date	Period	Contents of the proposal	Audit Committee Decision Results	The Company's Response to the Audit Committee's Opinions
2025.03.14	The 3rd Session , 5th	1、2024 Annual Business Report and Financial Statements. 2、2024 fiscal year profit distribution plan. 3、The case of transferring surplus to capital and issuing new shares. 4、Assessment of the Independence of the and	Passed as per the plan	After being submitted to the board of directors for discussion, the resolution was passed.

		<p>Competency of Visa Accountants in 2025</p> <p>5、Appointment of visa accountants for the 2025 year.</p> <p>6、Internal control system declaration review proposal.</p> <p>7、Amendments to the Company's "Internal Control System" and "Internal Audit Implementation Rules".</p>		
2025.05.09	The 6th session of the 3rd	1. The consolidated financial statements for the first quarter of 2025 .	Passed as per the plan	After being submitted to the board of directors for discussion, the resolution was passed.
2025.08.08	The 3rd 7th	1. The consolidated financial statements for the second quarter of 2025 .	Passed as per the plan	After being submitted to the board of directors for discussion, the resolution was passed.
		2. The proposed loan is 70 million to Precision Health (stock) Co., Ltd.	The resolution is reserved and will be submitted to the board of directors for full discussion before a final decision is made.	After being submitted to the board of directors for discussion, the resolution was shelved.
2025.10.17	The 3rd Session , 8th	<p>1. Adjustment to the operating deposit of medical institutions under the company's management .</p> <p>2. Appointment of the company's chief financial officer.</p>	Passed as per the plan	After being submitted to the board of directors for discussion, the resolution was passed.
2025.11.07	The 3rd 9th	<p>1. The consolidated financial statements for the third quarter of 2025 .</p> <p>1. Amendments to the Company's "Internal Control System" and "Internal Audit Implementation Rules".</p>	Passed as per the plan	After being submitted to the board of directors for discussion, the resolution was passed.
2025.12.19	The 10th session of the 3rd	<p>1. Draft the audit plan for 2026.</p> <p>2. The 2025 cash capital increase and share subscription case of the investment business Precision Health (stock) Company.</p>	Passed as per the plan	After being submitted to the board of directors for discussion, the resolution was passed.

2026.03.13	The 11th session of the 3rd	1. 2025 Annual Business Report and Financial Statements .	Passed as per the plan	After being submitted to the board of directors for discussion, the resolution was passed.
		2. The 2026 year saw the replacement of the visa accountant and the assessment and appointment of the visa accountant's independence and competence .		
		3. Internal control system declaration review proposal .		
		4. The proposed disposal of the shares of BenQ BM Holding Cayman Corporation (BBHC) held by the Company .	The resolution was passed , and an attached resolution requires a complete internal assessment and analysis report to be issued prior to the sale.	After being submitted to the board of directors for discussion, it was approved in accordance with the accompanying resolution of the audit committee .

(2) In addition to the above matters, other matters that have not been approved by the Audit Committee but have been agreed upon by more than two-thirds of all directors : None.

2. The independent director's recusation of a proposal in which he has a conflict of interest shall be clearly stated, including the independent director's name, proposal content, reason for recusation and voting participation : None .

3. The communication between the independent directors and the internal audit director and the accountant ( including the major matters, methods and results of communication on the company's financial and business conditions ).

1. Communication between independent directors and audit supervisors

In addition to submitting monthly audit reports to independent directors to report on the implementation of internal audits, the company's internal audit director regularly reports audit results and improvements to internal control deficiencies to the Audit Committee. If a major violation is found or the company is at risk of suffering major damage, it will be reported to the Audit Committee members immediately.

The main communication situations are summarized as follows, and none of the independent directors expressed any objection.

(1) Communication with the Audit Committee:

date	Communication focus
2025/3/14	1. Audit performance in the fourth quarter of 2024 . 2. 2024 Self-assessment report of internal control system. 3. The company's "Internal Control System" and "Internal Audit Implementation Rules" have been amended .
2025/5/9	1. Audit performance in the first quarter of 2025 . 2. Project Report: Fangding, Medical Electronics.
2025/8/8	Audit performance in the second quarter of 2025 .
2025/11/7	1. Audit performance in the third quarter of 2025 . 2. The company's "Internal Control System" and "Internal Audit Implementation Rules" have been amended .
2025/12/19	1. internal audit findings and improvements made by the subsidiary, Mincheng Health Technology Co., Ltd., in the third quarter of 2025 . 2. 2026 audit plan .

2026/3/13	<ol style="list-style-type: none"> <li>1. Audit performance in the fourth quarter of 2025 .</li> <li>2. 2025 internal control system self-assessment report.</li> </ol>
-----------	---

(2) Communicate with independent directors individually:

date	Communication focus
2025/3/14	<ol style="list-style-type: none"> <li>1. Audit performance in the fourth quarter of 2024 .</li> <li>2. 2024 Self-assessment report of internal control system.</li> <li>3. The company's " Internal Control System" and "Internal Audit Implementation Rules" have been amended .</li> </ol>
2025/5/6	<ol style="list-style-type: none"> <li>1. Audit performance in the first quarter of 2025 .</li> <li>2. Project Report: Fangding, Medical Electronics.</li> </ol>
2025/8/5	Audit performance in the second quarter of 2025 .
2025/11/4	<ol style="list-style-type: none"> <li>1. Audit performance in the third quarter of 2025 .</li> <li>2. The company's "Internal Control System" and "Internal Audit Implementation Rules" have been amended .</li> </ol>
2025/12/16	<ol style="list-style-type: none"> <li>1. internal audit findings and improvements made by the subsidiary, Mincheng Health Technology Co., Ltd., in the third quarter of 2025 .</li> <li>2. 2026 audit plan .</li> </ol>
2026/3/10	<ol style="list-style-type: none"> <li>1. Audit performance in the fourth quarter of 2025 .</li> <li>2. 2025 internal control system self-assessment report.</li> </ol>

2. Communication between independent directors and certified public accountants

The Company's certified public accountants regularly report to the Audit Committee the results of the annual financial statement audit or review, as well as other communication matters required by relevant laws and regulations. If there are special circumstances, they will also report to the Audit Committee members immediately.

The main communications between the independent directors and the certifying accountants in 2025 are summarized as follows. None of the independent directors expressed any objection .

date	Communication focus
2025/3/14 Audit Committee Board of Directors	<ol style="list-style-type: none"> <li>1. Results of the audit of the financial statements and consolidated financial statements for the year 2024 .</li> <li>2. The company's independent and competent accountant assessment was passed .</li> <li>3. The accountant discussed and communicated with the participants regarding their questions.</li> </ol>
2025/5/9 Audit Committee Board of Directors	<ol style="list-style-type: none"> <li>1. Results of the audit of the consolidated financial statements for the first quarter of 2025.</li> <li>2. The accountant discussed and communicated with the participants regarding their questions.</li> </ol>
2025/8/8 Audit Committee Board of Directors	<ol style="list-style-type: none"> <li>1. for the second quarter of 2025 .</li> <li>2. The accountant discussed and communicated with the participants regarding their questions.</li> </ol>
2025/11/7 Audit Committee Board of Directors	<ol style="list-style-type: none"> <li>1. for the third quarter of 2025 .</li> <li>2. The accountant discussed and communicated with the participants regarding their questions.</li> </ol>
2026/3/13 Audit Committee Board of Directors	<ol style="list-style-type: none"> <li>1. Results of the audit of the 2025 financial statements and consolidated financial statements.</li> <li>2. The company's independent and competent accountant assessment was passed .</li> <li>3. The accountant discussed and communicated with the participants regarding their questions.</li> </ol>

3. Communication between independent directors, audit supervisors and accountants

date	Communication focus
2025/3/14	Report on the results of the consolidated and individual financial statements for the year 2024 and the status of internal control audits, and discuss and communicate on key audit matters , implementation status and results .
2025/11/7	Annual audit planning and communication .
2025/3/13	The report on the consolidated and individual financial statements for the 2025 and the status of internal control audits were presented , and discussions and communications were held regarding key audit items , implementation status, and results .

Continuing education for directors and supervisors

Directors and Supervisors	Name	Further studies date	Organizer	Course Title	Study Hours
Legal representative	Yang Hongren	2025/08/08	Chinese Association Corporate Governance Association	Directors' and Supervisors' Responsibilities in Corporate Mergers and Acquisitions	3
		2025/11/07	Chinese Association Corporate Governance Association	Labor dispute prevention and corporate governance (including gender equality)	3
Legal representative	Xu Shengxin	2025/08/08	Chinese Association Corporate Governance Association	Directors' and Supervisors' Responsibilities in Corporate Mergers and Acquisitions	3
		2025/11/07	Chinese Association Corporate Governance Association	Labor dispute prevention and corporate governance (including gender equality)	3
Legal representative	Liu Qingwen	2025/08/08	Chinese Association Corporate Governance Association	Directors' and Supervisors' Responsibilities in Corporate Mergers and Acquisitions	3
		2025/11/07	Chinese Association Corporate Governance Association	Labor dispute prevention and corporate governance (including gender equality)	3
Legal representative	Sun Zhili	2025/08/08	Chinese Association Corporate Governance Association	Directors' and Supervisors' Responsibilities in Corporate Mergers and Acquisitions	3
		2025/11/07	Chinese Association Corporate Governance Association	Labor dispute prevention and corporate governance (including gender equality)	3
Legal representative	Chen Wenzhong	2025/08/08	Chinese Association Corporate Governance Association	Directors' and Supervisors' Responsibilities in Corporate Mergers and Acquisitions	3
		2025/11/07	Chinese Association	Labor dispute prevention and corporate governance (including gender equality)	3

Directors and Supervisors	Name	Further studies date	Organizer	Course Title	Study Hours
			Corporate Governance Association		
Legal representative	Zhang Changrong	2025/08/08	Chinese Association Corporate Governance Association	Directors' and Supervisors' Responsibilities in Corporate Mergers and Acquisitions	3
		2025/11/07	Chinese Association Corporate Governance Association	Labor dispute prevention and corporate governance (including gender equality)	3
director	Yang Chen Caibi	2025/08/08	Chinese Association Corporate Governance Association	Directors' and Supervisors' Responsibilities in Corporate Mergers and Acquisitions	3
		2025/11/07	Chinese Association Corporate Governance Association	Labor dispute prevention and corporate governance (including gender equality)	3
Independent Director	Wu Genzai	2025/08/08	Chinese Association Corporate Governance Association	Directors' and Supervisors' Responsibilities in Corporate Mergers and Acquisitions	3
		2025/11/07	Chinese Association Corporate Governance Association	Labor dispute prevention and corporate governance (including gender equality)	3
Independent Director	Li Shuxing	2025/06/06	Financial supervision and management Committee Inspection Bureau	Internal Audit Symposium of Financial Holding Company	3
		2025/08/08	Chinese Association Corporate Governance Association	Directors' and Supervisors' Responsibilities in Corporate Mergers and Acquisitions	3
		2025/11/07	Chinese Association Corporate Governance Association	Labor dispute prevention and corporate governance (including gender equality)	3

Directors and Supervisors	Name	Further studies date	Organizer	Course Title	Study Hours
		2025/11/21	Chinese Association Independent Directors Association	[Fubon Cleaning & Sanitary Ware Lecture - Fintech] More Than Just Cryptocurrency - Exploring Blockchain's Future Vision for the Financial System	3
Independent Director	Chen Houming	2025/07/24	Chinese Association Corporate Governance Association	Corporate Risk and Corporate Social Responsibility	3
		2025/07/24	Chinese Association Corporate Governance Association	Trade secret protection and fraud prevention practices	3
		2025/08/08	Chinese Association Corporate Governance Association	Directors' and Supervisors' Responsibilities in Corporate Mergers and Acquisitions	3
		2025/11/07	Chinese Association Corporate Governance Association	Labor dispute prevention and corporate governance (including gender equality)	3
Independent Director	Yao Xiubi	2025/05/27	Chinese Association Corporate Governance Association	Competitive advantage vs. survivability: ESG trends and strategies	3
		2025/05/27	Chinese Association Corporate Governance Association	Discussing Money Laundering Prevention and Counter-Terrorism Financing Through Illegal Cases	3
		2025/08/08	Chinese Association Corporate Governance Association	Directors' and Supervisors' Responsibilities in Corporate Mergers and Acquisitions	3
		2025/11/07	Chinese Association Corporate Governance Association	Labor dispute prevention and corporate governance (including gender equality)	3

( III ) Corporate governance operations and differences between the corporate governance practices of listed and OTC companies and their causes

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
1. Has the company formulated and disclosed its corporate governance code of practice in accordance with the corporate governance code of practice for listed and OTC companies?	√		<p>1. The Company has formulated its own "Corporate Governance Code" in accordance with the "Corporate Governance Practice Guidelines for Listed Companies " and it was approved by the 19th meeting of the 4th Board of Directors on March 18, 2015.</p> <p>2. The Company approved the revision of the "Corporate Governance Code " at the third meeting of the eighth board of directors on November 8 , 2024 .</p> <p>3. The Company's current operating methods are in line with the spirit of the "Code of Practice for Corporate Governance of Listed Companies". Based on the "Code of Practice for Corporate Governance of Listed Companies" and taking into account the actual operating needs of the Company, the Company has established "Rules of Procedure for Board Meetings", "Rules of Procedure for Shareholder Meetings", "Code of Ethical Conduct", "Director Election Methods", "Corporate Governance Code", " Sustainable Development Code of Practice", "Integrity Management Operating Procedures and Behavior Guidelines" and other methods, requiring all employees to strictly comply with the regulations.</p> <p>4. The Company's corporate governance code and various related corporate governance measures have been disclosed on the Company's website, annual report and public information observatory. Investors can download them at the Company's website\Corporate Governance\Corporate Governance Regulations.</p>	Comply with the Code of Practice on Corporate Governance for Listed Companies

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
<p>2. Company Equity Structure and Shareholders' Equity</p> <p>(1) Has the company established internal operating procedures to handle shareholder suggestions, doubts, disputes and litigation, and has it implemented them in accordance with the procedures?</p>	√		<p>1. The Company has formulated "Spokesperson System Specifications", whereby the spokesperson or proxy spokesperson will work with the shareholder agency to jointly handle shareholders' suggestions and questions.</p> <p>2. If there are any shareholder disputes or litigations, the Legal Affairs Office will be responsible for handling them together with the company's legal advisors and appointed lawyers.</p> <p>3. Our company's website\ Investor Relations \ Investor Services contains specific contacts and contact information to specifically respond to investors' questions.</p>	Comply with the Code of Practice on Corporate Governance for Listed Companies
<p>(2) Does the company have a list of the major shareholders who actually control the company and the ultimate controllers of the major shareholders?</p>	√		<p>1. The Company has designated a dedicated person in the Finance Department to update the major shareholders who actually control the company with the stock affairs agency at any time; and to establish communication channels with relevant personnel designated by the major shareholders to obtain information about the major shareholders.</p> <p>2. Economic Affairs' business registration website regularly to check the major corporate shareholders and the change registration status of their corporate shareholders.</p> <p>3. The major shareholders of the legal person shareholders of the Company, and the major shareholders and shareholdings of the major shareholders who are legal persons, are disclosed on the Company's website, annual report and public information observation station . Investors can go to the Company's website\ Investor Relations \ Shareholders' Meeting Information\Top Ten Shareholders for enquiries .</p>	Comply with the Code of Practice on Corporate Governance for Listed Companies
<p>(3) Has the company established and implemented risk control and firewall mechanisms with related companies?</p>	√		<p>1. The Company has formulated "Subsidiary Supervision Operation Guidelines" and " Financial and Business Related Operation Standards among Related Parties " to ensure that the invested businesses have clear strategies and specific operation standards in terms of operation, finance and business management . In addition to requiring that business dealings between the Company and its affiliated companies must comply with the principles of fairness, openness and impartiality , the Company also requires and assists its subsidiaries in establishing sound</p>	Comply with the Code of Practice on Corporate Governance for Listed Companies

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
			<p>accounting, financial systems, important operational controls , etc., and guides them in establishing internal control systems .</p> <p>2. The Company's auditors conduct audits on subsidiaries based on the "Annual Audit Plan" to confirm that the subsidiaries' operating activities and related control operations are operating effectively.</p> <p>3. For subsidiaries that have not yet been publicly issued, their major business and financial matters and proposals submitted to the board of directors must be reviewed in advance by the company's investment management unit and responsible supervisor before they can be carried out.</p>	
(iv) Has the company established internal regulations to prohibit company insiders from using undisclosed information in the market to buy or sell securities?	√		<p>1. In order to prevent insiders from using undisclosed market information to buy and sell securities, the Company has formulated "Insider Trading Prevention Management Measures" and requires all personnel to strictly implement them.</p> <p>2. The Company has amended the "Administrative Measures for Preventing Insider Trading" in accordance with the Financial Supervisory Commission's letter No. 1100373495 issued on December 6, 2021. The amendment was approved by the 6th meeting of the 7th Board of Directors on March 25, 2022, adding new colleagues in charge of stock affairs and the board of directors' meeting, who are responsible for fulfilling the reminder responsibilities for the closed period before the announcement of financial reports.</p>	Comply with the Code of Practice on Corporate Governance for Listed Companies

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
<p>3. Composition and Responsibilities of the Board of Directors</p> <p>1. Does the board of directors formulate a diversity policy , specific management objectives , and implement them?</p>	√		<p>1. On May 9, 2018, the 22nd meeting of the 5th Board of Directors of our company approved the revision of the "Director Election Rules" . Article 3 of this rule clearly stipulates that the composition of the board of directors should consider the policy of diversity. In addition to the basic conditions, there are also standards for professional qualities, skills, and management capabilities to achieve the purpose of comprehensive supervision.</p> <p>2. The company currently has 11 directors , 36% of whom are employees and 27 % are women . We will continue to work hard to increase the proportion of women directors in the future.</p> <p>3. The Company has four independent directors who possess the professional qualifications and work experience in business management , finance, and accounting required by the Company, which will be of substantial help to the Company in implementing investor protection and strengthening corporate governance. Independent directors account for 33% of the board seats, and their terms of office have not exceeded three terms. They include Wu Genzai, who took office as independent director on June 27, 2018, Li Shuxing, who took office as independent director on June 28, 2019, Chen Houming, who took office on July 30, 2021 , and Yao Xiubi, who took office on June 30, 2023.</p> <p>4. This term has eleven board seats, including seven directors and four independent directors. The diverse work experience and professional qualifications of the board members are complementary. The relevant implementation is shown in the following table, which is disclosed on the company's website and annual report. Investors can go to the company's website\Corporate Governance\Board of Directors\Member Diversity and Professional Competence Matrix for information.</p>	Comply with the Code of Practice on Corporate Governance for Listed Companies

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies																																																																																																																																														
	yes	no	Summary																																																																																																																																															
			<p>Implementation of the diversity policy by members of board directors</p> <table border="1"> <thead> <tr> <th rowspan="2">Director Name</th> <th colspan="10">Core Project</th> </tr> <tr> <th>Staff</th> <th>Seniority of Independent Director</th> <th>Operational Judgment</th> <th>Accounting and Financial Analysis Ability</th> <th>Management ability</th> <th>Crisis handling ability</th> <th>Industry knowledge</th> <th>International Market View</th> <th>Leadership</th> <th>Decision-making capacity</th> </tr> </thead> <tbody> <tr> <td>Yang Hongren</td> <td>V</td> <td>0</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> </tr> <tr> <td>Xu Shengxin</td> <td></td> <td>0</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> </tr> <tr> <td>Liu Qingwen</td> <td>V</td> <td>0</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> </tr> <tr> <td>Sun Zhili</td> <td></td> <td>0</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> </tr> <tr> <td>Chen Wenzhong</td> <td>V</td> <td>0</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> </tr> <tr> <td>Zhang Changrong</td> <td>V</td> <td>0</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> </tr> <tr> <td>Yang Chen Caibi</td> <td></td> <td>0</td> <td>V</td> <td>V</td> <td></td> <td></td> <td>V</td> <td></td> <td></td> <td>V</td> </tr> <tr> <td>Wu Genzai</td> <td></td> <td>6</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td></td> <td>V</td> <td>V</td> </tr> <tr> <td>Li Shuxing</td> <td></td> <td>5</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> </tr> <tr> <td>Chen Houming</td> <td></td> <td>3</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> </tr> <tr> <td>Yao Xiubi</td> <td></td> <td>2</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> </tr> </tbody> </table>	Director Name	Core Project										Staff	Seniority of Independent Director	Operational Judgment	Accounting and Financial Analysis Ability	Management ability	Crisis handling ability	Industry knowledge	International Market View	Leadership	Decision-making capacity	Yang Hongren	V	0	V	V	V	V	V	V	V	V	Xu Shengxin		0	V	V	V	V	V	V	V	V	Liu Qingwen	V	0	V	V	V	V	V	V	V	V	Sun Zhili		0	V	V	V	V	V	V	V	V	Chen Wenzhong	V	0	V	V	V	V	V	V	V	V	Zhang Changrong	V	0	V	V	V	V	V	V	V	V	Yang Chen Caibi		0	V	V			V			V	Wu Genzai		6	V	V	V	V	V		V	V	Li Shuxing		5	V	V	V	V	V	V	V	V	Chen Houming		3	V	V	V	V	V	V	V	V	Yao Xiubi		2	V	V	V	V	V	V	V	V	
Director Name	Core Project																																																																																																																																																	
	Staff	Seniority of Independent Director	Operational Judgment	Accounting and Financial Analysis Ability	Management ability	Crisis handling ability	Industry knowledge	International Market View	Leadership	Decision-making capacity																																																																																																																																								
Yang Hongren	V	0	V	V	V	V	V	V	V	V																																																																																																																																								
Xu Shengxin		0	V	V	V	V	V	V	V	V																																																																																																																																								
Liu Qingwen	V	0	V	V	V	V	V	V	V	V																																																																																																																																								
Sun Zhili		0	V	V	V	V	V	V	V	V																																																																																																																																								
Chen Wenzhong	V	0	V	V	V	V	V	V	V	V																																																																																																																																								
Zhang Changrong	V	0	V	V	V	V	V	V	V	V																																																																																																																																								
Yang Chen Caibi		0	V	V			V			V																																																																																																																																								
Wu Genzai		6	V	V	V	V	V		V	V																																																																																																																																								
Li Shuxing		5	V	V	V	V	V	V	V	V																																																																																																																																								
Chen Houming		3	V	V	V	V	V	V	V	V																																																																																																																																								
Yao Xiubi		2	V	V	V	V	V	V	V	V																																																																																																																																								
(II) In addition to establishing a salary and remuneration committee and an audit committee in accordance with the law, does the company voluntarily establish other functional committees?	√		<p>1. In addition to the “Salary and Compensation Committee” and the “Audit Committee”, the Company has also established a “ Mergers and Acquisitions Special Committee ” to improve its corporate governance structure ; in addition, in order to fulfill its corporate social responsibility and achieve the goal of sustainable operation, the Board of Directors approved the establishment of a “ Sustainability Development Committee ” on August 9, 2025 ; and voluntarily approved the establishment of a “Nomination Committee” on November 7, 2025 .</p> <p>2. On July 6, 2016, the Company’s Fifth Board of Directors, at its Eighth Meeting, passed the “ Organizational Regulations of the Special Committee on Mergers and Acquisitions ”, which came into effect in 2016 ; on May 10, 2024, the Company’s Seventh Board of Directors, at its Nineteenth Meeting, passed the “Organizational Regulations of the Sustainable Development Committee” , which came into effect in</p>	Comply with the Code of Practice on Corporate Governance for Listed Companies																																																																																																																																														

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
			<p>2024 ; and on November 7, 2025, the Company's Eighth Board of Directors, at its Tenth Meeting, passed the " Organizational Regulations of the Nomination Committee" .</p> <p>3. The Company has established the "Organizational Regulations of the Salary and Compensation Committee", the "Organizational Regulations of the Audit Committee" , the " Organizational Regulations of the Mergers and Acquisitions Special Committee " , the " Organizational Regulations of the Sustainability Committee" and the " Organizational Regulations of the Nomination Committee" , which serve as the management basis for the "Salary and Compensation Committee", the "Audit Committee" , the " Mergers and Acquisitions Special Committee " , the " Sustainability Committee " and the " Nomination Committee" , respectively.</p>	
<p>(3) Does the company establish performance evaluation methods for the board of directors and conduct performance evaluations on a regular basis every year? Does the company submit the results of the performance evaluations to the board of directors and use them as a reference for the remuneration and nomination of individual directors?</p>	√		<p>1. The Company approved the "Board of Directors Performance Evaluation Measures" and its evaluation method at the fifth meeting of the fifth board of directors on December 23, 2015, and began to implement the performance evaluation of the Board of Directors and individual directors since 2015.</p> <p>2. In 2018, the Company added performance evaluation of functional committees, and on August 9, 2024 , the 2nd meeting of the 8th Board of Directors approved the revision of the "Performance Evaluation Methods of the Board of Directors and Functional Committees".</p> <p>3. The performance evaluation method, evaluation approach and evaluation results of the Board of Directors and functional committees are disclosed on the Company's website and annual report . Investors may visit the Company's website\Corporate Governance for inquiries.</p> <p>4. In August 2023, our company commissioned the Chinese Corporate Governance Association, an external foundation, to evaluate the effectiveness of the Board of Directors, and issued a Board of Directors Performance Evaluation Report on October 16, 2023.</p> <p>5. The 2024 annual performance evaluation results of the Board of Directors were</p>	Comply with the Code of Practice on Corporate Governance for Listed Companies

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
			<p>reported as item six at the 12th meeting of the 8th Board of Directors on March 13, 2025. The evaluation period was from January 1, 2024 to December 31, 2024. The self-assessment questionnaires for the Board of Directors' performance evaluation and the functional committees' performance evaluation were scored by the corporate governance unit. The self-assessment score for the Board of Directors' performance evaluation was 98.9 points, the self-assessment score for the Audit Committee's performance evaluation was 100 points , the self-assessment score for the Compensation and Remuneration Committee's performance evaluation was 100 points , the self-assessment score for the Sustainability Committee's performance evaluation was 100 points , and the self-assessment score for the Nomination Committee's performance evaluation was 100 points .</p> <p>6. The Company's "Remuneration Committee" takes into account the Board's performance evaluation results, as well as each Director's attendance rate, industry experience, professional skills, personal performance , the Company's long-term operating performance , and the duty of exercising independence as a reference for the remuneration of Board members.</p> <p>7. Regarding the suitability of the Company's Board of Directors members, in accordance with the foregoing, performance evaluations will be used as the basis for nominations for reappointment as directors or independent directors of the Company. After discussion by the Board of Directors, these nominations will be submitted to the Shareholders' Meeting for a vote.</p>	
4. Does the company regularly assess the independence of its certified public accountants?	√		<p>1. The Company's Audit Committee shall regularly evaluate the independence and suitability of the certifying accountants each year and submit the evaluation results to the Board of Directors.</p> <p>2. The company 's evaluation results were approved by the Audit Committee on March 15 , 2025 , and submitted to the Board of Directors for approval on March 15 , 2025 . The evaluation mechanism is as follows:</p> <p>2.1 . With reference to Article 47 of the Accounting Act and the Code of Ethics for Accounting Professionals No. 10, the Company shall self-assess the</p>	Comply with the Code of Practice on Corporate Governance for Listed Companies

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
			<p>independence and competence of accountants based on the independence statement and audit quality indicators (AQIs) provided by the accountants .</p> <p>2.2. There are 15 items in total for the independence assessment, which are described as follows:</p> <ol style="list-style-type: none"> <li>(1) As of the last visa application, the visa has not been renewed for seven years.</li> <li>(2) Has no significant financial interest in the client.</li> <li>(3) Avoid any inappropriate relationship with the client.</li> <li>(4) Accountants should ensure that their assistants observe honesty , impartiality and independence.</li> <li>(5) The financial statements of the service agencies within the two years before practicing shall not be audited and certified.</li> <li>(6) The name of the accountant shall not be used by any other person.</li> <li>(7) Does not hold any shares in the Company or its affiliated companies.</li> <li>(8) There is no monetary loan or borrowing between the Company and its affiliated companies.</li> <li>(9) Has no joint investment or profit-sharing relationship with the Company or its affiliated companies.</li> <li>(10) Not holding regular work for the Company or its affiliated companies and receiving a fixed salary.</li> <li>(11) Has no management function involving decision-making for the Company or its affiliates.</li> <li>(12) It does not engage in other businesses that might cause it to lose its independence.</li> <li>(13) No spouse , direct blood relative, direct in-law, or collateral blood relative within the second degree of kinship with any of the Company's management personnel.</li> <li>(14) No commission was received in connection with the business.</li> <li>(15) To date, there has been no disciplinary action or any violation of the</li> </ol>	

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
			principle of independence. 2.3 . The above-mentioned assessment contents are in compliance with the independence and competence of the accountants.	
4. Does the listed company have an appropriate number of qualified corporate governance personnel and has designated a corporate governance supervisor to be responsible for corporate governance-related matters ( including but not limited to providing directors and supervisors with information necessary for performing their duties, assisting directors and supervisors in complying with laws and regulations , handling matters related to board and shareholders meetings in accordance with the law , and preparing minutes of board and shareholders meetings, etc. ) ?	√		<p>1. In order to cooperate with the Corporate Governance 3.0 issued by the Financial Supervisory Commission and strengthen the functions of the board of directors to enhance the sustainable value of the enterprise , the Company, in accordance with Articles 20 and 23 of the "Main Points for the Establishment and Exercise of Powers of the Board of Directors of OTC Companies", approved the appointment of Deputy General Manager Cai Yufang of the Administration Department as the Director of Corporate Governance at the 18th Meeting of the Seventh Board of Directors on March 15 , 2024 , to assist in handling corporate governance evaluation work. Deputy General Manager Cai Yufang has served as the company's legal director for more than 10 years and is qualified to be the corporate governance director. The main business contents are as follows :</p> <p>1.1 Assist the board of directors in the operation of meeting affairs. 1.2 Provide board members with the latest corporate governance-related legal and regulatory revision information. 1.3 Promote corporate governance evaluation work. 1.4 External Assessment of Executive Board Performance. 1.5 Review the qualifications of independent director nominees and report the results to the board of directors .</p> <p>2. The Board of Directors of the Company has designated the Finance Department to be responsible for the Board of Directors' meeting affairs , and a dedicated person is responsible for coordinating and providing the information required by the directors to perform their duties and matters related to corporate governance , including :</p> <p>2.1 Seven days before the Board of Directors /Audit/Remuneration Committee</p>	Comply with the Code of Practice on Corporate Governance for Listed Companies

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
			<p>meeting, the meeting shall be convened with the reason and sufficient meeting materials and notified to each meeting member. The minutes of each meeting shall also be signed or stamped by the chairman and recorder of each meeting , and distributed to each meeting member within 20 days after the meeting and included in the company's important files for safekeeping.</p> <p>2.2 Assist directors to take office and comply with laws and regulations; and assist directors to complete annual training courses.</p> <p>2.3 Provide the company information required by the directors, maintain smooth communication and exchanges between the directors and the supervisors, and assist in arranging communication meetings between the independent directors and the internal audit supervisor, certifying accountants, or supervisors of other internal units to facilitate the independent directors to perform their duties.</p> <p>2.4 In accordance with the latest laws and regulations related to the company's business areas and corporate governance, revise internal regulations related to corporate governance and submit them to the board of directors for resolution.</p> <p>2.5 Complete the insurance or renewal of the directors ' liability insurance of the Company .</p> <p>2.6 Prepare, hold, and prepare minutes of shareholders' meetings and other stock-related matters, and provide sufficient information to shareholders to ensure that the interests of shareholders are well protected.</p> <p>2.7 Responsible for reviewing the release of important information, ensuring the legality and accuracy of the content of important information, so as to protect the equality of investors' trading information.</p>	
5. Has the company established communication channels with stakeholders (including but not limited to shareholders, employees, customers and suppliers, etc.), set up a stakeholder area on the	√		The company is happy to assume corporate social responsibility to its employees , customers , shareholders , suppliers , the community and the overall environment. It not only plays a role in sustainable growth, but also actively implements corporate responsibility. The company has good communication channels and dedicated personnel who are responsible for listening to the needs of various stakeholders, and responding to and tracking the feedback information collected through different	Comply with the Code of Practice on Corporate Governance for Listed

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies															
	yes	no	Summary																
company website, and appropriately responded to important corporate social responsibility issues of concern to stakeholders ?			<p>communication channels according to the status of the issue. A stakeholder area is set up on the company website. The following are the priority topics and communication status of the Company's stakeholders:</p> <table border="1"> <thead> <tr> <th>Types of interested parties</th> <th>Priority issues</th> <th>Communication and response mechanism</th> <th>Response Department</th> <th>Contact Window</th> </tr> </thead> <tbody> <tr> <td>Investors</td> <td> <ul style="list-style-type: none"> <li>• Company Vision</li> <li>• Operational performance and financial information</li> <li>• Shareholders' equity</li> <li>• Corporate Governance</li> <li>• Sustainable development strategy</li> <li>• Risk Management</li> <li>• Regulatory compliance</li> <li>• Corporate image</li> </ul> </td> <td> <ol style="list-style-type: none"> <li>1. Annual report and shareholders meeting : financial performance of the company's operations each year</li> <li>2. Company website: Investor area updates information from time to time</li> <li>3. Spokesperson and stock affairs department</li> <li>4. Public Information Observation Station</li> <li>5. Legal seminars</li> </ol> </td> <td> <ul style="list-style-type: none"> <li>•spokesman</li> <li>•Acting Spokesperson</li> <li>•Stock Affairs</li> </ul> </td> <td> <p>【spokesman Mr. Liu】 (02)3322-1589#210 <a href="mailto:spokesperson@share-hope.com">spokesperson@share-hope.com</a></p> </td> </tr> <tr> <td>client</td> <td> <ul style="list-style-type: none"> <li>•Customer Privacy &amp; Satisfaction</li> <li>•Customer rights protection</li> <li>•Customer relationship</li> </ul> </td> <td> <ol style="list-style-type: none"> <li>1. Personnel from each business department visit customers from time to time to communicate and understand service quality .</li> </ol> </td> <td> <ul style="list-style-type: none"> <li>•Each business department</li> </ul> </td> <td> <p>【General Manager's Office Ms. Zheng】 (03)346-9595 # 6648 <a href="mailto:A003799@share-hope.com">A003799@share-hope.com</a></p> </td> </tr> </tbody> </table>	Types of interested parties	Priority issues	Communication and response mechanism	Response Department	Contact Window	Investors	<ul style="list-style-type: none"> <li>• Company Vision</li> <li>• Operational performance and financial information</li> <li>• Shareholders' equity</li> <li>• Corporate Governance</li> <li>• Sustainable development strategy</li> <li>• Risk Management</li> <li>• Regulatory compliance</li> <li>• Corporate image</li> </ul>	<ol style="list-style-type: none"> <li>1. Annual report and shareholders meeting : financial performance of the company's operations each year</li> <li>2. Company website: Investor area updates information from time to time</li> <li>3. Spokesperson and stock affairs department</li> <li>4. Public Information Observation Station</li> <li>5. Legal seminars</li> </ol>	<ul style="list-style-type: none"> <li>•spokesman</li> <li>•Acting Spokesperson</li> <li>•Stock Affairs</li> </ul>	<p>【spokesman Mr. Liu】 (02)3322-1589#210 <a href="mailto:spokesperson@share-hope.com">spokesperson@share-hope.com</a></p>	client	<ul style="list-style-type: none"> <li>•Customer Privacy &amp; Satisfaction</li> <li>•Customer rights protection</li> <li>•Customer relationship</li> </ul>	<ol style="list-style-type: none"> <li>1. Personnel from each business department visit customers from time to time to communicate and understand service quality .</li> </ol>	<ul style="list-style-type: none"> <li>•Each business department</li> </ul>	<p>【General Manager's Office Ms. Zheng】 (03)346-9595 # 6648 <a href="mailto:A003799@share-hope.com">A003799@share-hope.com</a></p>	Companies
Types of interested parties	Priority issues	Communication and response mechanism	Response Department	Contact Window															
Investors	<ul style="list-style-type: none"> <li>• Company Vision</li> <li>• Operational performance and financial information</li> <li>• Shareholders' equity</li> <li>• Corporate Governance</li> <li>• Sustainable development strategy</li> <li>• Risk Management</li> <li>• Regulatory compliance</li> <li>• Corporate image</li> </ul>	<ol style="list-style-type: none"> <li>1. Annual report and shareholders meeting : financial performance of the company's operations each year</li> <li>2. Company website: Investor area updates information from time to time</li> <li>3. Spokesperson and stock affairs department</li> <li>4. Public Information Observation Station</li> <li>5. Legal seminars</li> </ol>	<ul style="list-style-type: none"> <li>•spokesman</li> <li>•Acting Spokesperson</li> <li>•Stock Affairs</li> </ul>	<p>【spokesman Mr. Liu】 (02)3322-1589#210 <a href="mailto:spokesperson@share-hope.com">spokesperson@share-hope.com</a></p>															
client	<ul style="list-style-type: none"> <li>•Customer Privacy &amp; Satisfaction</li> <li>•Customer rights protection</li> <li>•Customer relationship</li> </ul>	<ol style="list-style-type: none"> <li>1. Personnel from each business department visit customers from time to time to communicate and understand service quality .</li> </ol>	<ul style="list-style-type: none"> <li>•Each business department</li> </ul>	<p>【General Manager's Office Ms. Zheng】 (03)346-9595 # 6648 <a href="mailto:A003799@share-hope.com">A003799@share-hope.com</a></p>															

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies										
	yes	no	Summary											
			<table border="1"> <tr> <td></td> <td> <ul style="list-style-type: none"> <li>• maintenance</li> <li>• Service (product) quality</li> <li>• Information transparency &amp; security</li> </ul> </td> <td> <ol style="list-style-type: none"> <li>2. Each department conducts customer satisfaction surveys regularly</li> </ol> </td> <td></td> <td></td> </tr> <tr> <td>staff</td> <td> <ul style="list-style-type: none"> <li>• Employee compensation and benefits policy</li> <li>• Labor-Management Relations</li> <li>• Talent training and development</li> <li>• Occupational Health and Safety</li> <li>• Employee assessment mechanism</li> </ul> </td> <td> <ol style="list-style-type: none"> <li>1. Announce company policies and employee benefits from time to time through the company's internal network</li> <li>2. Set up an employee welfare committee and hold regular meetings every quarter to communicate</li> <li>3. Hold labor-management meetings once a quarter</li> <li>4. Provide free health check-up for employees every year</li> <li>5. Conduct employee performance appraisal every six months</li> <li>6. Set up an</li> </ol> </td> <td> <ul style="list-style-type: none"> <li>• Human Resources Office</li> </ul> </td> <td> <p>【 Human Resources Department Miss Li】  (03)346-9595 #6623 , 6627  <a href="mailto:sh_hr@e-ms.com.tw">sh_hr@e-ms.com.tw</a></p> </td> </tr> </table>		<ul style="list-style-type: none"> <li>• maintenance</li> <li>• Service (product) quality</li> <li>• Information transparency &amp; security</li> </ul>	<ol style="list-style-type: none"> <li>2. Each department conducts customer satisfaction surveys regularly</li> </ol>			staff	<ul style="list-style-type: none"> <li>• Employee compensation and benefits policy</li> <li>• Labor-Management Relations</li> <li>• Talent training and development</li> <li>• Occupational Health and Safety</li> <li>• Employee assessment mechanism</li> </ul>	<ol style="list-style-type: none"> <li>1. Announce company policies and employee benefits from time to time through the company's internal network</li> <li>2. Set up an employee welfare committee and hold regular meetings every quarter to communicate</li> <li>3. Hold labor-management meetings once a quarter</li> <li>4. Provide free health check-up for employees every year</li> <li>5. Conduct employee performance appraisal every six months</li> <li>6. Set up an</li> </ol>	<ul style="list-style-type: none"> <li>• Human Resources Office</li> </ul>	<p>【 Human Resources Department Miss Li】  (03)346-9595 #6623 , 6627  <a href="mailto:sh_hr@e-ms.com.tw">sh_hr@e-ms.com.tw</a></p>	
	<ul style="list-style-type: none"> <li>• maintenance</li> <li>• Service (product) quality</li> <li>• Information transparency &amp; security</li> </ul>	<ol style="list-style-type: none"> <li>2. Each department conducts customer satisfaction surveys regularly</li> </ol>												
staff	<ul style="list-style-type: none"> <li>• Employee compensation and benefits policy</li> <li>• Labor-Management Relations</li> <li>• Talent training and development</li> <li>• Occupational Health and Safety</li> <li>• Employee assessment mechanism</li> </ul>	<ol style="list-style-type: none"> <li>1. Announce company policies and employee benefits from time to time through the company's internal network</li> <li>2. Set up an employee welfare committee and hold regular meetings every quarter to communicate</li> <li>3. Hold labor-management meetings once a quarter</li> <li>4. Provide free health check-up for employees every year</li> <li>5. Conduct employee performance appraisal every six months</li> <li>6. Set up an</li> </ol>	<ul style="list-style-type: none"> <li>• Human Resources Office</li> </ul>	<p>【 Human Resources Department Miss Li】  (03)346-9595 #6623 , 6627  <a href="mailto:sh_hr@e-ms.com.tw">sh_hr@e-ms.com.tw</a></p>										

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies															
	yes	no	Summary																
			<table border="1"> <tr> <td></td> <td></td> <td>employee mailbox to provide employees with a channel for feedback and complaints</td> <td></td> <td></td> </tr> <tr> <td>Government and competent authorities</td> <td> <ul style="list-style-type: none"> <li>•Regulatory compliance</li> <li>•Corporate Governance</li> <li>•Communication with competent authorities</li> <li>•Risk Management</li> </ul> </td> <td> <ol style="list-style-type: none"> <li>1. Government policy advocacy and promotion of related systems</li> <li>2. Attend relevant units from time to time and participate in the competent authority's seminars/public hearings/policy briefings, etc.</li> <li>3. Exchange of official documents</li> <li>4. Cooperate with the competent authorities in supervision and inspection</li> <li>5. Visit competent authorities and establish direct communication opportunities</li> </ol> </td> <td> <ul style="list-style-type: none"> <li>•spokesman</li> <li>•Acting Spokesperson</li> <li>•Audit Department</li> </ul> </td> <td> <p>【 Audit Office Miss Ye (03)346-9595 #6607】</p> <p><a href="mailto:A003976@share-hope.com">A003976@share-hope.com</a></p> <p><a href="mailto:convener@share-hope.com">convener@share-hope.com</a></p> </td> </tr> <tr> <td>supplier</td> <td> <ul style="list-style-type: none"> <li>•Supplier Management</li> <li>•Information transparency &amp;</li> </ul> </td> <td> <ol style="list-style-type: none"> <li>1. Ask suppliers to sign a letter of commitment to honest management</li> </ol> </td> <td> <ul style="list-style-type: none"> <li>•General Manager's Office</li> </ul> </td> <td> <p>【 General Manager's Office Ms. Zheng】</p> <p>(03) 346 - 9595 # 6648</p> <p><a href="mailto:A003799@share-hope.com">A003799@share-hope.com</a></p> </td> </tr> </table>			employee mailbox to provide employees with a channel for feedback and complaints			Government and competent authorities	<ul style="list-style-type: none"> <li>•Regulatory compliance</li> <li>•Corporate Governance</li> <li>•Communication with competent authorities</li> <li>•Risk Management</li> </ul>	<ol style="list-style-type: none"> <li>1. Government policy advocacy and promotion of related systems</li> <li>2. Attend relevant units from time to time and participate in the competent authority's seminars/public hearings/policy briefings, etc.</li> <li>3. Exchange of official documents</li> <li>4. Cooperate with the competent authorities in supervision and inspection</li> <li>5. Visit competent authorities and establish direct communication opportunities</li> </ol>	<ul style="list-style-type: none"> <li>•spokesman</li> <li>•Acting Spokesperson</li> <li>•Audit Department</li> </ul>	<p>【 Audit Office Miss Ye (03)346-9595 #6607】</p> <p><a href="mailto:A003976@share-hope.com">A003976@share-hope.com</a></p> <p><a href="mailto:convener@share-hope.com">convener@share-hope.com</a></p>	supplier	<ul style="list-style-type: none"> <li>•Supplier Management</li> <li>•Information transparency &amp;</li> </ul>	<ol style="list-style-type: none"> <li>1. Ask suppliers to sign a letter of commitment to honest management</li> </ol>	<ul style="list-style-type: none"> <li>•General Manager's Office</li> </ul>	<p>【 General Manager's Office Ms. Zheng】</p> <p>(03) 346 - 9595 # 6648</p> <p><a href="mailto:A003799@share-hope.com">A003799@share-hope.com</a></p>	
		employee mailbox to provide employees with a channel for feedback and complaints																	
Government and competent authorities	<ul style="list-style-type: none"> <li>•Regulatory compliance</li> <li>•Corporate Governance</li> <li>•Communication with competent authorities</li> <li>•Risk Management</li> </ul>	<ol style="list-style-type: none"> <li>1. Government policy advocacy and promotion of related systems</li> <li>2. Attend relevant units from time to time and participate in the competent authority's seminars/public hearings/policy briefings, etc.</li> <li>3. Exchange of official documents</li> <li>4. Cooperate with the competent authorities in supervision and inspection</li> <li>5. Visit competent authorities and establish direct communication opportunities</li> </ol>	<ul style="list-style-type: none"> <li>•spokesman</li> <li>•Acting Spokesperson</li> <li>•Audit Department</li> </ul>	<p>【 Audit Office Miss Ye (03)346-9595 #6607】</p> <p><a href="mailto:A003976@share-hope.com">A003976@share-hope.com</a></p> <p><a href="mailto:convener@share-hope.com">convener@share-hope.com</a></p>															
supplier	<ul style="list-style-type: none"> <li>•Supplier Management</li> <li>•Information transparency &amp;</li> </ul>	<ol style="list-style-type: none"> <li>1. Ask suppliers to sign a letter of commitment to honest management</li> </ol>	<ul style="list-style-type: none"> <li>•General Manager's Office</li> </ul>	<p>【 General Manager's Office Ms. Zheng】</p> <p>(03) 346 - 9595 # 6648</p> <p><a href="mailto:A003799@share-hope.com">A003799@share-hope.com</a></p>															

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies										
	yes	no	Summary											
			<table border="1"> <tr> <td></td> <td>safety</td> <td>2. When signing contracts with major suppliers , the content must comply with the company's corporate integrity and business ethics requirements.</td> <td></td> <td><a href="http://hope.com">hope.com</a></td> </tr> <tr> <td>media</td> <td> <ul style="list-style-type: none"> <li>•Corporate image</li> <li>•Operational strategy</li> <li>•Operational Performance &amp; Financial Information</li> <li>•Social responsibility and care</li> <li>•Communicate with the public and investors</li> </ul> </td> <td> <ol style="list-style-type: none"> <li>1. Conduct two-way communication with the media from time to time through public relations companies to convey the company's business philosophy and important operating strategies to the public and investors.</li> <li>2. Issue operation-related press releases from time to time</li> <li>3. Accept media interviews and inquiries from time to time (immediately)</li> </ol> </td> <td> <ul style="list-style-type: none"> <li>•spokesman</li> <li>•PR company</li> </ul> </td> <td> <b>【spokesman Mr. Liu】</b>            (02)3322-1589#210  <a href="mailto:spokesperson@share-hope.com">spokesperson@share-hope.com</a> </td> </tr> </table>		safety	2. When signing contracts with major suppliers , the content must comply with the company's corporate integrity and business ethics requirements.		<a href="http://hope.com">hope.com</a>	media	<ul style="list-style-type: none"> <li>•Corporate image</li> <li>•Operational strategy</li> <li>•Operational Performance &amp; Financial Information</li> <li>•Social responsibility and care</li> <li>•Communicate with the public and investors</li> </ul>	<ol style="list-style-type: none"> <li>1. Conduct two-way communication with the media from time to time through public relations companies to convey the company's business philosophy and important operating strategies to the public and investors.</li> <li>2. Issue operation-related press releases from time to time</li> <li>3. Accept media interviews and inquiries from time to time (immediately)</li> </ol>	<ul style="list-style-type: none"> <li>•spokesman</li> <li>•PR company</li> </ul>	<b>【spokesman Mr. Liu】</b> (02)3322-1589#210 <a href="mailto:spokesperson@share-hope.com">spokesperson@share-hope.com</a>	
	safety	2. When signing contracts with major suppliers , the content must comply with the company's corporate integrity and business ethics requirements.		<a href="http://hope.com">hope.com</a>										
media	<ul style="list-style-type: none"> <li>•Corporate image</li> <li>•Operational strategy</li> <li>•Operational Performance &amp; Financial Information</li> <li>•Social responsibility and care</li> <li>•Communicate with the public and investors</li> </ul>	<ol style="list-style-type: none"> <li>1. Conduct two-way communication with the media from time to time through public relations companies to convey the company's business philosophy and important operating strategies to the public and investors.</li> <li>2. Issue operation-related press releases from time to time</li> <li>3. Accept media interviews and inquiries from time to time (immediately)</li> </ol>	<ul style="list-style-type: none"> <li>•spokesman</li> <li>•PR company</li> </ul>	<b>【spokesman Mr. Liu】</b> (02)3322-1589#210 <a href="mailto:spokesperson@share-hope.com">spokesperson@share-hope.com</a>										

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
6. Has the company appointed a professional stock affairs agency to handle shareholders' meeting affairs?	√		The Company has appointed a professional stock affairs agency, "Stock Affairs Agency Department of Qunyi Jinding Securities Co., Ltd." to handle matters related to the shareholders' meeting in order to safeguard the interests of shareholders.	Comply with the Code of Practice on Corporate Governance for Listed Companies
VII. Information Disclosure 1. Does the company have a website to disclose its financial, business and corporate governance information?	√		The Company's corporate governance and financial business information has been disclosed on the Company's website at: <a href="http://www.share-hope.com">http://www.share-hope.com</a> . Investors may inquire on the Company's website.	Comply with the Code of Practice on Corporate Governance for Listed Companies
(2) Does the company adopt other methods of information disclosure (such as setting up an English website, designating a person to be responsible for the collection and disclosure of company information, implementing a spokesperson system, placing information on the company website during corporate briefings, etc.)?	√		<ol style="list-style-type: none"> <li>1. The company's website has set up an English version for the general public to inquire .</li> <li>2. All information that should be disclosed in our company is handled by a dedicated person .</li> <li>3. The briefing and recording files of the legal representative briefing have been disclosed on the company's website. Investors can go to the company's website\Investor Relations \Major Information for inquiries.</li> <li>4. The Company implements a spokesperson system. The investing public can use the Company's website\Investor Relations\Investor Services to contact spokespersons and proxy spokespersons by phone or email .</li> </ol>	Comply with the Code of Practice on Corporate Governance for Listed Companies

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
(3) Does the company announce and file its annual financial report within two months after the end of the fiscal year , and announce and file its first , second , and third quarter financial reports and monthly operating results in advance of the prescribed deadline ?		√	The Company currently reports financial reports and monthly operating conditions on the dates specified in the "Business Matters to be Performed by Issuers of Listed Securities" , but has not yet announced and reported the annual financial report within two months after the end of the fiscal year, nor has it announced the work in advance before the prescribed deadline.	Announcement and reporting must be completed before the deadline specified by law
8. Does the company have other important information that is helpful in understanding the operation of corporate governance (including but not limited to employee rights, employee care, investor relations, supplier relations, rights of stakeholders, training for directors and supervisors, implementation of risk management policies and risk measurement standards, implementation of customer policies, and the company's purchase of liability insurance for directors and supervisors, etc.)?	√		<ol style="list-style-type: none"> <li>1. Important information on the Company's corporate governance operations , including corporate governance regulations, investor relations information, stakeholder priority issues and communication status, ESG sustainable development promotion policies and implementation status, etc., have been disclosed on the Company's website. Investors can visit the Company's website for inquiries.</li> <li>2. Our company website\ Stakeholders \ Stakeholders' priority issues, providing contact information and response mechanisms for employees, suppliers, customers, investors, suppliers, government and regulatory authorities , media, and business ethics.</li> <li>3. The company has always attached great importance to employee rights and employee care , holding regular employee welfare meetings and labor-management meetings every quarter , and providing regular health checks for employees .</li> <li>4. The Company provides multiple channels to enable shareholders , stakeholders and customers to be informed of the Company's operating and financial status in real time , maintaining smooth communication channels and operating well .</li> <li>5. Our company adheres to the business philosophy of eternal integrity , establishes long-term cooperative relationships with suppliers, and has required suppliers to sign a commitment to honest business practices since 2011. By 2025 , 44 such commitments had been completed ..</li> </ol>	Comply with the Code of Practice on Corporate Governance for Listed Companies

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
			<p>6. All major proposals concerning the Company's major operating policies , investments , bank financing, endorsements and guarantees, and capital loans are evaluated and analyzed by the responsible units in accordance with the relevant regulations of the Company, and then submitted to the Board of Directors and the Audit Committee for decision, and the supervision and risk control mechanisms are implemented .</p> <p>7. The Company arranges for directors to participate in relevant professional knowledge training from time to time and obtain training hour certificates .</p> <p>8. The Company approved the "Risk Management Code of Practice" at the 12th meeting of the 7th Board of Directors on December 23, 2022 , which includes the Company's risk management policies and procedures, and established a risk management working group under the Audit Committee to promote the work.</p> <p>9. The Company purchases liability insurance for directors and supervisors : On May 9, 2025 , the 8th Board of Directors held its 7th meeting and reported on the Directors and Officers Liability Insurance coverage for the year 2025. The insurance period was from May 1, 2025 to May 1, 2026 , with a total insured amount of NT\$30 million.</p>	
<p>9. Please explain the improvements that have been made based on the corporate governance evaluation results released by the Corporate Governance Center of the Taiwan Stock Exchange Corporation in the most recent year, and propose priority improvement items and measures for those that have not yet been improved. (Companies not included in the rated list do not need to fill in)</p> <p>Our company's 2025 ( 12th ) Corporate Governance Assessment ranking among listed companies is as follows: 6% ~ 20 %</p> <p>( 1 ) Improved situation:</p> <ol style="list-style-type: none"> <li>1. The company has established a nomination committee.</li> <li>2. The company's shareholders' meeting will be uploaded in its entirety without interruption after the meeting.</li> <li>3. The company has adopted the ISO27001 information security management system standard and obtained third-party verification.</li> <li>4. The company has developed an employee training and development plan to enhance employees' career capabilities and conducts employee satisfaction surveys.</li> </ol>				

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
5. The company has established environmental management systems and energy management plans. ( II ) Priority Items and Measures: The Company will discuss the follow-up directions for improvement regarding the unscored items and continue to improve corporate governance in accordance with the "Corporate Governance 3.0 - Sustainable Development Blueprint" and the "Action Plan for Sustainable Development of Listed Companies".				

Note: Regardless of whether you tick "Yes" or "No", the operating status should be stated in the summary column.

( IV ) If the company has established a remuneration committee or nomination committee , it should disclose their composition, responsibilities, and operation:

※Salary and Compensation Committee

1. Information on members of the Compensation and Remuneration Committee

April 20,2026

Separation of body (Note 1 )	condition Name	Professional qualifications and experience (Note 2)	Independence conditions met (Note 3)	Number of companies concurrently serving as members of the remuneration committee of other publicly traded companies
Independent Director (convener)	Li Shuxing	<ol style="list-style-type: none"> <li>1. Period of office: 08/09/2024-06/23/2027.</li> <li>2. Professional background: PhD in Accounting from New York University; Lecturer at a public or private college or university with relevant academic background required for the company's business; Possesses professional experience in business, finance, accounting, and the company's business.</li> <li>3. Experience: Chair Professor, Department of Accounting, and Dean, College of Management, Tunghai University Vice President of Finance/Dean of the College of Management, National Taiwan University Chairman of the Chinese Accounting Education Association</li> <li>4. Independent Director Li possesses accounting expertise and has many years of experience as an independent director in other industries. He can share his experience in operating the company's diverse industries and provide management decision-making opinions on industry integration analysis and risk management. Therefore, when exercising the</li> </ol>	<ol style="list-style-type: none"> <li>1. The Company has obtained the election statement of independent director Li Shuxing and complied with all provisions of the Securities and Exchange Act.</li> <li>2. Meet the following independence qualifications:               <ol style="list-style-type: none"> <li>(1) The individual and his/her spouse's relatives within the second degree of kinship are not directors, supervisors or employees of the company or its affiliated companies.</li> <li>(2) The person and his/her spouse's second degree relatives do not hold any company shares.</li> <li>(3) No circumstances are covered by the provisions of Article 6, Paragraph 1, Items 5-8 of the Regulations Governing the Establishment and Exercise of Powers of the Compensation and Remuneration Committee of Companies with Stocks Listed or Traded on Over-the-Counter Markets.</li> <li>(4) None of the</li> </ol> </li> </ol>	3

Separation of body (Note 1)	condition Name	Professional qualifications and experience (Note 2)	Independence conditions met (Note 3)	Number of companies concurrently serving as members of the remuneration committee of other publicly traded companies
		<p>powers of an independent director, we can leverage his expertise to improve the operational quality of the remuneration committee.</p>	<p>circumstances set out in Article 30 of the Company Act exists.</p> <p>3. Not receiving compensation for business, legal, financial, accounting, etc. services provided by the Company or its affiliates .</p>	
Independent Director	Wu Genzai	<ol style="list-style-type: none"> <li>1. Period of office: 08/09/2024-06/23/2027.</li> <li>2. Major: Department of Accounting, National Taiwan University (passed the 1991 Certified Public Accountant Examination); possesses work experience in accounting, finance, and business operations required by this company.</li> <li>3. Experience: Auditor/Audit Team Leader at Deloitte Touche Tohmatsu, Finance Director and Management Director at the Manufacturing Industry, Partner Accountant at Cheng Hsin Certified Public Accountants, Special Lecturer at the Small and Medium Enterprise Administration, Ministry of Economic Affairs, and Management Consulting Company.</li> <li>4. Independent Director Wu possesses extensive practical experience in accounting, and through his expertise, he can provide insightful guidance and appropriate suggestions on various aspects of data review. Therefore, in exercising the powers of an independent director, he can enhance the operational quality of the remuneration committee.</li> </ol>	<ol style="list-style-type: none"> <li>1. The Company has obtained Wu Genzai's election statement as independent director and complied with all provisions of the Securities and Exchange Act.</li> <li>2. Meet the following independence qualifications: <ol style="list-style-type: none"> <li>(1) The individual and his/her spouse's relatives within the second degree of kinship are not directors, supervisors or employees of the company or its affiliated companies.</li> <li>(2) The person and his/her spouse's second degree relatives do not hold any company shares.</li> <li>(3) No circumstances are covered by the provisions of Article 6, Paragraph 1, Items 5-8 of the Regulations Governing the Establishment and Exercise of Powers of the Compensation and Remuneration Committee of Companies with Stocks Listed or Traded on Over-the-Counter Markets.</li> </ol> </li> </ol>	0

Separation of body (Note 1)	condition Name	Professional qualifications and experience (Note 2)	Independence conditions met (Note 3)	Number of companies concurrently serving as members of the remuneration committee of other publicly traded companies
			<p>(4) None of the circumstances set out in Article 30 of the Company Act exists.</p> <p>3. Not receiving compensation for business, legal, financial, accounting, etc. services provided by the Company or its affiliates .</p>	
Independent Director	Chen Houming	<ol style="list-style-type: none"> <li>1. 2024/08/09-2027/06/23.</li> <li>2. Professional background: PhD in Marketing, Graduate Institute of Business Administration, National Taiwan University; Lecturer at public or private colleges and universities with relevant majors required for the company's business; Professional experience in business and the company's business.</li> <li>3. Experience: Dean of the College of Social Sciences and Management, National Central University; Dean of the College of Social Sciences and Management, National Chung Hsing University President of the Institute for Business Development, Chairman of the Chinese Negotiation Management Association, and Chairman of the Taiwan Marketing Science Association</li> <li>4. Independent Director Chen possesses management expertise and experience as an independent director in other industries. He can provide diverse suggestions on operation and management in a timely manner and offer clear guidance in practical operations. Therefore, when</li> </ol>	<ol style="list-style-type: none"> <li>1. The Company has obtained the election statement of independent director Chen Houming and complied with all provisions of the Securities and Exchange Act.</li> <li>2. Meet the following independence qualifications: <ol style="list-style-type: none"> <li>(1) The individual and his/her spouse's relatives within the second degree of kinship are not directors, supervisors or employees of the company or its affiliated companies.</li> <li>(2) The person and his/her spouse's second degree relatives do not hold any company shares.</li> <li>(3) The circumstances specified in Article 6, Paragraph 1, Items 5-8 of the Regulations Governing the Establishment and Exercise of Powers of the Compensation Committee of a company that has no shares and whose stocks are not listed or traded on the over-the-counter market.</li> </ol> </li> </ol>	3

Separation of body (Note 1 )	condition Name	Professional qualifications and experience (Note 2)	Independence conditions met (Note 3)	Number of companies concurrently serving as members of the remuneration committee of other publicly traded companies
		exercising the powers of an independent director, he can improve the operational quality of the remuneration committee.	(4) There is no any of the circumstances specified in Article 30 of the Company Act. 3. Not receiving compensation for business, legal, financial, accounting, etc. services provided by the Company or its affiliates .	
Independent Director	Yao Xiubi	<p>1. Term of office: 2024/08/09-2027/06/23.</p> <p>2. Major: Department of Finance, National Chung Cheng University Tunghai University's Super EPOST, University of Missouri , and Columbia University's Master of Business Administration</p> <p>3. Experience: Ginko International Co.,LTD Spokesperson Director of the Chairman's Office, Yong Sheng Optics (Stock) Co., Ltd.</p> <p>4. Independent Director Yao possesses professional financial knowledge and extensive practical experience in company operations and investment management. She can provide industry experience and appropriate management advice and guidance. Therefore, in exercising the powers of an independent director, she can enhance the operational quality of the remuneration committee.</p>	<p>1. The Company has obtained the election statement of Yao Xiubi as independent director and complied with all provisions of the Securities and Exchange Act.</p> <p>2. Meet the following independence qualifications:</p> <p>(1) The individual and his/her spouse's relatives within the second degree of kinship are not directors, supervisors or employees of the company or its affiliated companies.</p> <p>(2) The person and his/her spouse's second degree relatives do not hold any company shares.</p> <p>(3) The circumstances specified in Article 6, Paragraph 1, Items 5-8 of the Regulations Governing the Establishment and Exercise of Powers of the Compensation Committee of a company that has no shares and whose stocks are not listed or traded on the over-the-counter market.</p> <p>(4) None of the circumstances set out</p>	0

Separation of body (Note 1)	Name	Professional qualifications and experience (Note 2)	Independence conditions met (Note 3)	Number of companies concurrently serving as members of the remuneration committee of other publicly traded companies
			in Article 30 of the Company Act exists. 3. Not receiving remuneration for business, legal, financial, accounting, etc. services provided by the Company or its affiliated companies .	

Note 1: Please specify in the table the relevant years of service, professional qualifications and experience, and independence of each member of the Remuneration Committee. If the member is an independent director, please indicate the relevant contents of Appendix 1 (Information of Directors and Supervisors (I)) on page 16 . Please fill in whether you are an independent director or others (if you are the convener, please add a note)

Note 2: Professional qualifications and experience: State the professional qualifications and experience of individual members of the Remuneration Committee.

Note 3: Independence: Describe whether the members of the Remuneration Committee meet the conditions for independence, including but not limited to whether the member, his/her spouse, or relatives within the second degree of kinship serve as directors, supervisors, or employees of the company or its affiliated companies; the number and proportion of company shares held by the member, his/her spouse, or relatives within the second degree of kinship (or using the names of others); whether the member serves as a director, supervisor , or employee of a company with a specific relationship with the company (refer to Article 6, Paragraph 1, Items 5-8 of the Regulations Governing the Establishment and Exercise of Rights of Remuneration Committees of Companies Listed or Traded at Over-the-Counter Securities Firms); and the amount of remuneration received for providing business, legal, financial, accounting, and other services to the company or its affiliated companies in the past two years.

Note 4: For disclosure methods, please refer to the best practice reference examples on the Taiwan Stock Exchange Corporate Governance Center website.

2. The Remuneration Committee of the Company shall, with the care of a good manager, faithfully perform the following duties and powers and submit its recommendations to the Board of Directors for discussion:

- (1) Establish and regularly review the performance evaluation methods and salary and remuneration policies, systems, standards and structures of the Company's directors and managers.
- (2) Regularly evaluate and determine the remuneration of directors and managers.

3. Information on the operation of the Remuneration Committee

- (1) The Company's Remuneration Committee has four members .
- (2) Term of office of the Sixth Committee: August 9, 2024 to June 23, 2027.
- (3) The number of meetings held in the most recent year up to the date of publication of the annual report was 5, and the attendance was as follows:

job title	Name	Actual attendance (B)	Delegated Attendance frequency	Actual attendance rate (%) (B/A)(Note)	Remark
Chairman	Li Shuxing	5	0	100%	
Member	Wu Genzai	5	0	100%	
Member	Chen Houming	5	0	100%	
Member	Yao Xiubi	4	1	80 %	
Other matters that should be recorded:					
— 、 The operation of the Remuneration Committee is as follows:					
Meeting Date	Period	Contents of the proposal	Resolution results	The Board of Directors' Response to the Remuneration Committee's Opinions	
2025.03.14	The Sixth Session, Second Session	1. The proposed remuneration for the Deputy General Manager of the Smart Healthcare City Business Unit of this company is submitted for discussion.	The proposal was passed by the attending committee members after the chairman consulted them, and was subsequently submitted to the board of directors for discussion.	The motion was passed by resolution of all attending directors after consultation with the Chairman.	
		2. The proposal regarding the proportion and amount of directors' remuneration and employees' remuneration in 2013 is submitted for discussion.	This case was decided after consultation with the Chairman. Committee members, no objections. The proposal was passed and submitted to Dong. The board will discuss this.	The motion was passed by resolution of all attending directors after consultation with the Chairman.	
		3. The definition of frontline employees and the proposed ratio for profit allocation to frontline employees are submitted for discussion.	This case was decided after consultation with the Chairman. Chairman, Correction Company Distribution of frontline employees It was subsequently approved and submitted to Dong. The board will discuss this.	The motion was passed by resolution of all attending directors after consultation with the Chairman.	
2025.05.09	The Sixth Third Session	1. The proposed adjustment to the attendance fees for the Company's directors	The proposal was passed by the attending committee members after the chairman consulted them, and without objection, it was	There is no risk that any director's personal interests may harm the company's interests in this	

		(including independent directors) is submitted for discussion.	submitted to the board of directors for discussion.	case; therefore, all directors are not required to recuse themselves. The resolution was passed by all attending directors after consultation with the chairman.
		2. We would like to submit our proposed policy linking the compensation and benefits of our senior managers with ESG performance evaluation for discussion.	The proposal was passed by the attending committee members after the chairman consulted them, and without objection, it was submitted to the board of directors for discussion.	The proposal was amended by the Chairman after consulting with all attending directors, and was subsequently passed as amended to 80% performance indicators and 20% ESG sustainability.
2025.11.07	The Sixth Session, Fourth Meeting	1. The proposed compensation for the company's chief financial officer is submitted for discussion.	The proposal was passed by the attending committee members after the chairman consulted them, and without objection, it was submitted to the board of directors for discussion.	The motion was passed by resolution of all attending directors after consultation with the Chairman.
2025.12.19	The 6th Fifth	1. The company's year-end bonus plan and manager's year-end bonus distribution proposal are submitted for discussion.	Please add to the following statement: Starting this year, the annual basic bonus will no longer be paid monthly. The remaining proposals, after being consulted by the Chairman and with no objections from the attending members, were passed as proposed and submitted to the Board of Directors for discussion.	The motion was passed by Vice Chairman Xu Shengxin acting as chairman, after consulting with the other attending directors.
12026.03.13	The 6th Sixth	1. The proposed percentage and amount of the Company's directors' and employees' remuneration for 2025 are	This case was decided after consultation with the Chairman. Committee members, no objections. The proposal was passed and submitted to the board of directors. We will discuss it.	The motion was passed by resolution of all attending directors after consultation with the Chairman.

		submitted for discussion .		
		2. The 2025 employee compensation distribution plan is submitted for discussion.	This case was decided after consultation with the Chairman. Committee members, no objections. The proposal was passed and submitted to the board of directors. We will discuss it.	The motion was passed by resolution of all attending directors after consultation with the Chairman.
<p>二、 If the Board of Directors does not adopt or amend the Remuneration Committee's recommendation, it shall state the date, period, content of the proposal, resolution of the Board of Directors, and the Company's handling of the disagreement of the Remuneration Committee (if the remuneration approved by the Board of Directors is better than the Remuneration Committee's recommendation, the difference and reason shall be stated: None.</p> <p>三、 If a member of the Remuneration Committee objects to or reserves an opinion on a resolution and there is a record or written statement, the date, term, content of the resolution, opinions of all members, and the handling of the opinions of the members shall be stated: None.</p>				

Note 1 : If a member of the Remuneration Committee resigns before the end of the year, the date of resignation should be noted in the remarks column. The actual attendance rate (%) is calculated based on the number of Remuneration Committee meetings held during his/her tenure and the number of actual attendances.

Note 2: If there is a re-election of the Remuneration Committee before the end of the year, both the new and old members of the Remuneration Committee should be listed, and the member should be indicated in the remarks column as old, new or re-elected, as well as the date of re-election. The actual attendance rate (%) is calculated based on the number of Remuneration Committee meetings held during the employee's tenure and the number of actual attendances.

#### ※Nomination Committee

##### 1. The qualifications and responsibilities of the members of the Nomination Committee .

The Nomination Committee is qualified to be composed of at least three directors nominated by the Company's Board of Directors , with more than half of them being independent directors . The committee members elect one person from among themselves as the convener . Its responsibilities include: establishing standards for the professional knowledge , skills, experience, gender diversity, and independence required for Board members and senior managers; identifying, reviewing, and nominating candidates for directors and senior managers; building and developing the organizational structure of the Board of Directors and its committees; conducting performance evaluations of the Board of Directors, its directors , and its committees; and establishing and regularly reviewing the directors' professional development program and the succession plan for directors and senior managers.

##### 2. Professional qualifications and experience of nominating committee members and operational status :

(1) Our nomination committee consists of seven members , whose professional qualifications and experience are as follows :

job title	Name	Professional qualifications and experience
convener	Chen Houming	<ol style="list-style-type: none"> <li>1. Professional background: PhD in Marketing from the Graduate Institute of Business Administration, National Taiwan University; Lecturer at a public or private college or university with relevant academic background required for the company's business; Professional experience in business and the company's business.</li> <li>2. Experience: Director of the Institute for Business Development, National Chung Hsing University; Dean of the College of Social Sciences and Management.</li> <li>3. Independent Director Chen possesses management expertise and experience as an independent director in other industries, enabling him to provide diverse suggestions on operation and management in a timely manner and offer clear guidance in practical operations.</li> </ol>
Committee	Wu Genzai	<ol style="list-style-type: none"> <li>1. Major: Department of Accounting, National Taiwan University (passed the 1991 Certified Public Accountant Examination); possesses work experience in accounting, finance, and business operations required by this company.</li> <li>2. Experience: Auditor/Audit Team Leader at Deloitte Touche Tohmatsu, Finance Director and Management Director at the Manufacturing Industry, Partner Accountant at Cheng Hsin United Accounting Firm, Special Lecturer at the Small and Medium Enterprise Administration of the Ministry of Economic Affairs and a Business Management Consulting Company.</li> <li>3. Independent Director Wu has extensive experience in accounting practice. Through his expertise, he can provide insightful guidance on the review of various documents and offer appropriate suggestions.</li> </ol>
Committee	Li Shuxing	<ol style="list-style-type: none"> <li>1. Professional Background: PhD in Accounting from New York University; Lecturer at a public or private college or university with relevant academic background required for the company's business; possesses professional experience in business, finance, accounting, and the company's business.</li> <li>2. Experience: Vice President of Finance/Dean of the College of Management/Head of the Department of Accounting, National Taiwan University; Acting Dean of the College of Management/Chair Professor of the Department of Accounting, Tunghai University; President of the Chinese Accounting Education Association</li> <li>3. Independent Director Li possesses accounting expertise and has many years of experience as an independent director in other industries; he can share his experience in operating the company's diverse industries and provide management decision-making advice in areas such as industry integration analysis and risk management.</li> </ol>
Committee	Yao Xiubi	<ol style="list-style-type: none"> <li>1. Major: Master of Business Administration from the University of Missouri-Columbia; possesses professional experience in applying financial statement analysis, evaluating industry mergers and acquisitions, and the business of this company.</li> <li>2. Experience: Executive spokesperson for Tunghai University's Super EPOST / Department of Finance, National Chung Cheng University / Ginko International Co., LTD / Director of the Chairman's Office, Yung Sheng Optical Co., Ltd.</li> <li>3. Independent Director Yao possesses management expertise and experience as a director in other industries. He can provide suggestions on the company's diversified business operations and offer management decision-making advice in analyzing financial statements and evaluating mergers and acquisitions.</li> </ol>
Committee	Yang Hongren	<p>Major: Department of Medicine, National Taiwan University; Possesses medical professional work experience and the operational judgment, international market perspective, and decision-making ability required by our company.</p> <p>Experience: Director of Kangning Hospital / Director of Beijing Yanran Angel Children's Hospital / Chief Physician at Minsheng General Hospital.</p>

Committee	Zhang Changrong	Professional background: Master of Public Administration, University of Southern California (USC); Experience in healthcare institution management and asset management, and leadership skills required by our company: Executive Vice President of Min Sheng Ching Kuo General Hospital / Deputy CEO of Asia Pacific Healthcare Co., Ltd. / 5th & 6th Board Member of the Republic of China Regional Hospital Association / Deputy Captain of Taoyuan County Patrol Brigade
Committee	Sun Zhili	Professional background: PhD from Cambridge School of Management, University of Cambridge; possesses professional experience required for academic and business operations, as well as business and industry knowledge required by the company. Experience: President of the Taiwan Economic Research Society and Director of the Sustainable Development Policy Research Center; Member of the 11th and 12th National Financial Stabilization Fund Management Committee of the Executive Yuan; Adjunct Associate Professor of the Institute of Biotechnology, National Taiwan University.

(2) The term of office for this committee is from November 7, 2025 to June 23, 2027. The committee has held 2 meetings in the most recent fiscal year up to the date of publication of the annual report (A). Attendance is as follows :

job title	Name	Actual attendance (B)	Attendance by proxy frequency	Actual attendance rate (%) (B/A)(Note)	Remark
convener	Chen Houming	2	0	100%	
Committee	Wu Genzai	2	0	100%	
Committee	Li Shuxing	2	0	100%	
Committee	Yao Xiubi	2	0	100%	
Committee	Yang Hongren	2	0	100%	
Committee	Zhang Changrong	2	0	100%	
Committee	Sun Zhili	2	0	100%	

Other matters that should be recorded:

— 、Nomination Committee operates as follows:

Meeting Dates	Period	Proposal content	Resolution results	The Board of Directors' handling of the Committee's opinions
2025.12.19	First Session, 1st	Elect a convener .	Independent Director Chen Houming was nominated to serve as the convener of the Company's first Nomination Committee .	No objection .
2026.03.13	First Session, Second Meeting	2026 board member training course program.	The selected courses are: [Trends and Risk Management in Digital Technology	The courses selected by the nominating committee were

				and Artificial Intelligence] and [Key Points of the New Corporate Governance Blueprint and Legal Compliance].	approved accordingly.	
--	--	--	--	---	-----------------------	--

Note 1 : If a member of the Nomination Committee leaves before the end of the year , the date of departure should be noted in the remarks column. The actual attendance rate (%) will be calculated based on the number of meetings of the Salary and Compensation Committee and the actual number of times the member attends during their tenure.

Note 2 : Nomination Committee before the end of the year, both the new and incumbent members of the Salary and Compensation Committee should be listed, and the remarks column should indicate whether the member is an incumbent, a new, or a re-elected member, as well as the date of the re-election. The actual attendance rate (%) is calculated based on the number of meetings of the Nomination Committee and the actual number of times the member attends during their term of office .

( V) Implementation of sustainable development and differences with the Code of Practice for Sustainable Development of Listed and OTC Companies and reasons:

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
1. Has the company established a governance structure to promote sustainable development and set up a dedicated (or part-time) unit to promote sustainable development? Has the board of directors authorized senior management to handle the matter, and has the board of directors provided supervision?	✓		<p>1. In order to fulfill our corporate social responsibility and promote economic, social and environmental progress to achieve sustainable development goals, our company has revised our Sustainable Development Practice Code with reference to the "Code of Practice for Sustainable Development of Listed Companies". The revision was approved at the 6th meeting of the 7th Board of Directors on March 25, 2022. Furthermore, at the 2nd meeting of the 8th Board of Directors on August 9, 2024, our company approved the establishment of a Sustainable Development Committee to specifically cooperate with the "Action Plan for Sustainable Development of Listed Companies" issued by the Financial Supervisory Commission, to achieve sustainable development goals, and to deepen the corporate culture of sustainable governance.</p> <p>2. The Company's Board of Directors fulfills its duty of care as a prudent manager, urging the Company to practice sustainable development and periodically reviewing the progress of its strategies. When necessary, it actively urges the management team to conduct reviews and adjustments to help ensure that sustainable development policies are concretely implemented in the Company's daily operations .</p>	Comply with the Code of Practice for Sustainable Development of Listed Companies

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			<p>3. The company 's responsible unit for sustainable development is the "Information Planning Office," which was appointed by the Chairman in 2019 to assist in integrating and implementing various internal functional organizations, and also to report the implementation status to the Board of Directors regularly.</p> <p>4. The Company 's progress in promoting and implementing sustainable business in 2025 was reported at the 11th meeting of the 8th Board of Directors held on December 19, 2025. In addition to reviewing the relevant implementation status for the year , the Board shared its opinions and provided guidance on the Company's short-, medium-, and long-term plans for sustainable business development. The relevant report is available on the Company's website under ESG Sustainability &gt; Goals and Performance.</p> <p>5. The Company's " Code of Practice for Sustainable Development " is disclosed in the Company's annual report, website and public information observation station. Investors can download it from the Company's website under Corporate Governance and Corporate Governance Regulations.</p>	
2. Does the company conduct risk assessments on environmental, social and corporate governance issues related to its operations in accordance with the principle of	✓		1. Our business is characterized by medical logistics services . Although we are not involved in manufacturing, we still pay attention to global risk trends to reduce operational impact, review and integrate the value of horizontal resources, actively	Comply with the Code of Practice for Sustainable Development of Listed Companies

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
materiality, and establish relevant risk management policies or strategies? (Note 2)			<p>align with international standards, and take into account multiple channels of quality and quantity to improve the management efficiency of corporate social responsibility and meet the expectations of stakeholders for corporate governance, environmental protection and social care.</p> <p>2. To establish a sound risk management system and steadily advance towards the goal of sustainable corporate development, our company has formulated its own Risk Management Practice Code, referencing the "Risk Management Practice Code for Listed and Over-the-Counter Companies" formulated by the competent authority, to strengthen the risk management system. On December 23, 2022, the 7th Board of Directors passed the "Risk Management Practice Code," resolving that the Audit Committee would replace the Risk Management Committee in its functions and report on the company's risk management policies, procedures, and scope ( the full details of which are disclosed on the company's website under Corporate Governance &gt; Functional Committees) .</p> <p>3. The Board of Directors is the highest governance body for risk management. Considering that supervising audit operations is one of the responsibilities of the Audit Committee, and that the auditors have identified various possible risks when performing audit operations, and have recorded risk analysis, assessment and response recommendations in the audit report, and regularly report the audit execution</p>	

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			<p>status to the Audit Committee members, the risk management function already exists. Therefore, no separate Risk Management Committee will be set up. Instead, the Audit Committee will replace the functions of the Risk Management Committee, and a working group will be set up under the Audit Committee as the risk management promotion and implementation unit.</p> <p>4. The Company also conducts risk assessments on important issues related to the principle of sustainability, and formulates relevant risk management policies based on the risks assessed ; the full details are disclosed on the Company's website \ESG Sustainability\Policy Promotion\Sustainability Policy .</p>	
<p>3. Environmental Issues</p> <p>(1) Has the company established an appropriate environmental management system based on the characteristics of its industry ?</p>	✓		<p>1. Our company's main businesses include pharmaceutical supply services , specialist services ( primarily medical equipment leasing ) , and health management services . We do not have manufacturing plants, and the waste generated from our operations is general waste; there is no air pollution , wastewater, or waste requiring special treatment. We employ dedicated cleaning staff to maintain our office environment, and our general affairs office supervises the environmental maintenance efforts.</p> <p>2. Environmental Management System: Our company has formally established an environmental management system applicable to all departments, offices , and business processes, and all employees are required to comply with it. Considering</p>	Comply with the Code of Practice for Sustainable Development of Listed Companies

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			<p>our company's role in the healthcare services industry, the system is designed to address aspects such as energy use, water consumption, waste disposal, and employee behavior in the workplace, establishing a management mechanism consistent with the characteristics of the industry. This system covers five major policy areas: regulatory compliance, energy consumption and carbon emission management, waste management, green procurement, and the promotion of digital work models. Our company sets specific quantitative targets annually for reducing water consumption, total waste weight, and carbon emissions by 0.5% to 1%. An environmental management team is responsible for monitoring the achievement of these targets and regularly reports environmental performance to the Sustainability Committee and the Board of Directors, ensuring that management responsibility is implemented at the governance level.</p> <p>Implementation Status in 2025: In 2025, the Company continued to promote management measures in three main areas: water conservation, waste management, and energy conservation and carbon reduction. Regarding greenhouse gas-related courses, a total of 9 internal consultant training courses were conducted in 2024, and company employees had received training in 11 external courses as of October, continuously deepening their professional capabilities in environmental management and greenhouse gas inventory. Regarding wastewater</p>	

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			<p>and waste management, the Wastewater and Waste Management Regulations were finalized in 2025 and were continuously implemented in 2025, with reviews and revisions as needed. Regarding greenhouse gas inventory, the Greenhouse Gas Inventory Management Regulations were formulated in 2024. In 2025, greenhouse gas inventory operations were conducted for the parent company and consolidated reporting subsidiaries, covering significant indirect emissions in Categories I, II, and III. External verification was completed on May 7, 2025, and will be submitted to the Board of Directors in accordance with regulations. In terms of energy conservation and carbon reduction measures, in 2025, a total of 14 sets of LED lights were replaced in the office area, including 8 sets in the Pharmaceutical Distribution Department and 6 sets in the Specialty Planning Office; slogans such as "Turn off lights when not in use" were posted at the switch locations; disposable tableware was discontinued in the employee cafeteria; and starting in 2024, meals will be provided to employees to reduce transportation carbon emissions and tableware waste generated from employees ordering food from outside.</p> <p>3. Energy Management Plan: Our company has established an energy management plan, with core management principles including continuously improving energy performance, complying with regulatory requirements, enhancing energy efficiency, and strengthening employees' energy-saving awareness. Considering our company</p>	

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			<p>operates in the healthcare service industry, and energy consumption primarily stems from daily office operations, management measures focus on controlling electricity usage in the office area. An energy management system (Smart Healthcare City) has been implemented for real-time power monitoring, allowing for immediate action on any anomalies and improving the accuracy of energy management decisions through data-driven approaches. Regarding performance targets, greenhouse gas inventory serves as the basis for energy management monitoring, with 2025 as the emission baseline year, aiming to reduce emissions by 5% every five years. Long-term plans include continuously expanding the application of energy-saving measures and actively moving towards low-carbon operations.</p> <p>Implementation status for 2025: In 2025, our company continued to implement various energy management measures. Regarding energy-saving labeled products, we procured dishwashing liquid and hand towels that meet national environmental protection labels and introduced PEFC-certified photocopying paper, implementing green consumption from the source. In terms of education and training, we held a public green living environmental education and training course on August 22, 2025, inviting Mr. Yang Zongwei as the lecturer, with 60 participants, continuously strengthening employees' awareness of environmental protection and energy conservation. Regarding greenhouse gas inventory, the scope of the</p>	

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			inventory was expanded in 2025 to include consolidated reporting subsidiaries (Categories 1 to 6), which is currently underway. Regarding the power management of the Smart Medical City, it was newly incorporated into the parent company as a business unit in 2025 and has been included in the company's energy consumption monitoring scope, continuously managing power consumption through the smart energy-saving monitoring system. Regarding green energy investment, our company continued to hold green bonds recognized by the Stock Exchange Standard Exchange Center. As of December 31, 2025, the face value of bonds held was NT\$46,850,000, with an additional NT\$310,000 invested in green bonds in 2025.	
(2) Is the company committed to improving energy efficiency and using recycled materials with low environmental impact?	✓		To implement the environmental awareness of a green Earth, our company aims to create a paperless office through appropriate IT planning. We are committed to helping customers and suppliers save time and manpower in verifying orders and shipping documents electronically, as well as reducing the need for printing documents and physical invoices. We also require employees to increase the recycling rate of paper and other items, encourage employees to use personal reusable tableware to reduce the use of various disposable tableware, and actively implement waste sorting and reduction. We hope to fulfill our responsibility as a member of the Earth and protect its resources.	Comply with the Code of Practice for Sustainable Development of Listed Companies

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
(3) Has the company assessed the potential risks and opportunities that climate change poses to the business now and in the future, and taken relevant response measures?		✓	<p>1.As a biotechnology-related company, in order to address the impact of climate change on business operations and to concretely disclose information related to climate change, in addition to regularly reporting to the Board of Directors, the Audit Committee, and their Risk Management Working Group to ensure the Board and senior management understand the impact of climate change on the company, since 2018, various departments within the company have also begun conducting business reviews and risk identification related to climate change. This includes analyzing the direct or indirect impacts of extreme weather events, the impact of regulatory, technological, or market demand transformations, and other human and social factors on the company's operations, as well as the risks and opportunities arising from these factors. Based on the analysis results, a risk management strategy plan has been developed as the core of the company's actions in response to climate change, which is used to estimate management costs and financial impacts. Through the aforementioned collected data, the company strengthens its climate change governance and systematically assesses financial relationships to reduce risks and seize business opportunities.</p> <p>2.Regarding climate change impact assessment, as our company is not in the manufacturing sector, the risk of climate change impact is relatively low. However, as a member of the global community, we still have relevant practical actions and measures to respond to</p>	Comply with the Code of Practice for Sustainable Development of Listed Companies

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			<p>and address climate change :</p> <ul style="list-style-type: none"> <li>· The related investments and construction of houses and buildings comply with the standards of the Green Building Certification.</li> <li>· When replacing equipment in accordance with government incentive policies for potential business development and energy sources, the company should cooperate with government subsidy policies and apply for relevant energy-saving subsidies.</li> <li>· When renovating office areas, in addition to ensuring that the decoration complies with green building standards, office equipment that meets energy efficiency standards should be purchased.</li> </ul>	
4. Has the company compiled statistics on greenhouse gas emissions, water consumption, and total weight of waste in the past two years, and formulated policies for greenhouse gas reduction, water reduction, or other waste management?	✓		<p>1. Our company's current business focuses on pharmaceutical supply services, specialist services ( primarily medical equipment leasing ) , and health management services. Its operations are minimally affected by climate change and the greenhouse effect. However, as a corporate citizen, in addition to establishing "Corporate Environmental and Energy Conservation and Carbon Reduction Management Regulations," and clearly defining environmental policies , energy conservation and carbon reduction plans, climate change assessments, and related response measures, we actively implement relevant energy conservation and carbon reduction measures. Furthermore, we are actively committed to reducing greenhouse gas emissions, water consumption, and waste. The specific results of our</p>	Comply with the Code of Practice for Sustainable Development of Listed Companies

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes																		
	yes	no	Summary																			
			<p>implementation over the past two years are as follows :</p> <table border="1"> <thead> <tr> <th></th> <th>2024 years (parent company))</th> <th>2025 (merged)</th> </tr> </thead> <tbody> <tr> <td>CO2 emissions (tCO2e)</td> <td>198.41</td> <td>6,367.26</td> </tr> <tr> <td>Water consumption (metric tons)</td> <td>1997.3</td> <td>28428.14</td> </tr> <tr> <td>Water consumption (tCO2e)</td> <td>0.47</td> <td>6.2247</td> </tr> <tr> <td>Total weight of waste (metric tons)</td> <td>22.21</td> <td>157.83</td> </tr> <tr> <td>Total weight of waste (tCO2e)</td> <td>16.37</td> <td>99.70</td> </tr> </tbody> </table> <p>Notes:</p> <ol style="list-style-type: none"> <li>1. Data on greenhouse gas emissions, water consumption, and total waste weight covers the parent company.</li> <li>2. The parent company operates in the healthcare services industry. Its original greenhouse gas emissions were within Category II (Taipower's imported electricity). Since 2024, a monitoring system has been implemented, covering Categories I to III.</li> <li>3. The waste weight (tons) is calculated based on the average daily general waste generation per person from Taoyuan City's key environmental statistics data on the Ministry of Environment's open environmental data platform. In 2024, this was 1.439 kg. In 2025, due to the inclusion of the parent and subsidiary companies in the monitoring scope, the weighted average after regional differences was 1.461 kg.</li> </ol> <p>The aforementioned data is also disclosed on the</p>		2024 years (parent company))	2025 (merged)	CO2 emissions (tCO2e)	198.41	6,367.26	Water consumption (metric tons)	1997.3	28428.14	Water consumption (tCO2e)	0.47	6.2247	Total weight of waste (metric tons)	22.21	157.83	Total weight of waste (tCO2e)	16.37	99.70	
	2024 years (parent company))	2025 (merged)																				
CO2 emissions (tCO2e)	198.41	6,367.26																				
Water consumption (metric tons)	1997.3	28428.14																				
Water consumption (tCO2e)	0.47	6.2247																				
Total weight of waste (metric tons)	22.21	157.83																				
Total weight of waste (tCO2e)	16.37	99.70																				


Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			<p>company's website, reflecting the company's commitment to fulfilling its corporate social responsibility in the goal of mitigating global warming.</p> <p>The total CO2 emissions in 2025 amounted to 6,367.26 metric tons , an increase of 6,168.85 metric tons compared to 198.41 metric tons in 2024. This increase was primarily due to the inclusion of subsidiaries such as Smart Healthcare (hotel industry) in the audit scope in 2025. The increase in waste and water consumption was due to the same reason. The consolidation audit and external verification have now been completed. In addition, in conjunction with the commencement of the warming operation, we are continuously committed to energy-saving measures based on the data and sources of the warming operation to reduce carbon dioxide emissions, water consumption, and total waste weight.</p> <p>2. The various reduction policies and specific measures are as follows :</p> <p>(1) Energy conservation and carbon reduction</p> <ul style="list-style-type: none"> <li>· Continuously seek and replace office equipment with more energy-efficient ones (backup).</li> <li>· Implement energy-saving plans from three main aspects: air conditioning systems, power lighting, and other electricity consumption, and regularly inspect energy-consuming equipment and replace it as necessary.</li> <li>· Organize energy conservation and carbon reduction education and training courses and</li> </ul>	

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			<p>promote awareness.</p> <ul style="list-style-type: none"> <li>· Irregularly inspect individuals' efforts in energy conservation and carbon reduction at their workplaces.</li> </ul> <p>(2) Water management</p> <ul style="list-style-type: none"> <li>· The company is required to implement a water conservation plan internally.</li> <li>· Regularly check the water supply system to ensure it is functioning properly and avoid unnecessary water consumption.</li> <li>· Conduct water management education and training courses and promote awareness.</li> </ul> <p>(3) Waste reduction</p> <ul style="list-style-type: none"> <li>· Implement stricter waste recycling and sorting operations.</li> <li>· Accelerate the implementation of fully paperless processes.</li> <li>· Conduct educational and training courses and promote waste reduction.</li> <li>· We conduct unscheduled audits of the implementation of waste sorting (including kitchen waste) at various units and report the implementation status to the company meetings.</li> </ul> <p>3. Furthermore, according to the "Roadmap for Sustainable Development of Listed Companies" issued by the Financial Supervisory Commission in March 2022, our company is a company with paid-in capital of less than NT\$5 billion. The subsidiary (i.e.,</p>	

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			<p>the parent company) should be subject to the greenhouse gas inventory in the third stage (i.e., the inventory should be completed in 2026, and the verification in 2028). According to regulations, only greenhouse gas emissions in Categories I and II need to be disclosed ; verification of the aforementioned information is not required in 2023. Going forward, our company will continue to monitor the completion of the greenhouse gas inventory and verification disclosure schedule in accordance with the reference guidelines and relevant regulations issued by the competent authority .</p> <p>Our company's current reduction targets are to further reduce greenhouse gas emissions, water consumption, and waste production by 5% by the end of 2025 (compared to 2020). We have also made adjustments based on more precise data obtained from the 2024 greenhouse gas inventory results. Although our company is only required to disclose greenhouse gas emissions in Categories I and II according to regulations, as our company operates in the healthcare services industry, many of our business operations' greenhouse gas emissions fall under Category III. Therefore, in the 2025 consolidated parent and subsidiary inventory, significant indirect emission sources were included in the inventory in accordance with ISO 14064-1:2018.</p> <p>4. Our company's current reduction targets for greenhouse gas emissions, water consumption, and waste production are based on our 2020 CO2</p>	

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			emissions (kg/ping), with the target being the total emissions (kg) (kg/ping * usable ping), aiming for a further 5% reduction by 2030. We will adjust these targets based on more precise data obtained from the 2025 greenhouse gas inventory results. Our company has completed external verification work for the 2025 greenhouse gas inventory and will continue to expand the scope of the inventory of major indirect emission sources to obtain more complete data for developing a more comprehensive reduction plan.	
<p>4. Social Issues</p> <p>(1) Has the company formulated relevant management policies and procedures in accordance with relevant laws and regulations and international human rights conventions?</p>	✓		<p>1. Our company's human rights policy supports and adheres to internationally recognized human rights norms and principles, including the Universal Declaration of Human Rights, international labor conventions , and, but not limited to, the elimination of all forms of forced or compulsive labor , the elimination of employment and occupational discrimination, and Taiwan's Labor Standards Act . Our Human Resources Department is responsible for formulating this human rights policy. In addition to applying the company's established human rights standards to all employees, we actively extend this policy to our suppliers and investigate human rights concerns, striving to promote workplace diversity and equality. For example, in our compensation and recruitment processes, we uphold the principle of gender equality, awarding salaries based on professional skills, expertise, experience, and the scope of responsibilities. Promotions and transfers</p>	Comply with the Code of Practice for Sustainable Development of Listed Companies

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes																																				
	yes	no	Summary																																					
			<p>are conducted with fairness, without gender discrimination .</p> <p>(1) Percentage of female employees:</p> <table border="1"> <thead> <tr> <th>Female employee count</th> <th>percentage(%)</th> </tr> </thead> <tbody> <tr> <td>Women make up (%) of total employees</td> <td>76.6%</td> </tr> <tr> <td>Female managers account for (%) of all managers</td> <td>60.0%</td> </tr> <tr> <td>Female managers account for (%) of all managers</td> <td>54.5%</td> </tr> </tbody> </table> <p>(2) The ratio of female employees' salaries to male employees:</p> <table border="1"> <thead> <tr> <th>Salary Indicators</th> <th>percentage of male salaries</th> </tr> </thead> <tbody> <tr> <td>Average salary of female employees</td> <td>95.9%</td> </tr> <tr> <td>Median salary of female employees</td> <td>96.3%</td> </tr> </tbody> </table> <p>(3) Statistical table of gender and age structure by job title: (unit%)</p> <table border="1"> <thead> <tr> <th rowspan="2">Job title</th> <th colspan="2">Manager</th> <th colspan="2">Supervisory position</th> <th colspan="2">Non-management position</th> <th rowspan="2">total</th> </tr> <tr> <th>male</th> <th>female</th> <th>male</th> <th>female</th> <th>male</th> <th>female</th> </tr> </thead> <tbody> <tr> <td>&lt; 30 years old</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>twenty three</td> <td>9.7</td> <td>12.0</td> </tr> </tbody> </table>	Female employee count	percentage(%)	Women make up (%) of total employees	76.6%	Female managers account for (%) of all managers	60.0%	Female managers account for (%) of all managers	54.5%	Salary Indicators	percentage of male salaries	Average salary of female employees	95.9%	Median salary of female employees	96.3%	Job title	Manager		Supervisory position		Non-management position		total	male	female	male	female	male	female	< 30 years old	0	0	0	0	twenty three	9.7	12.0	
Female employee count	percentage(%)																																							
Women make up (%) of total employees	76.6%																																							
Female managers account for (%) of all managers	60.0%																																							
Female managers account for (%) of all managers	54.5%																																							
Salary Indicators	percentage of male salaries																																							
Average salary of female employees	95.9%																																							
Median salary of female employees	96.3%																																							
Job title	Manager		Supervisory position		Non-management position		total																																	
	male	female	male	female	male	female																																		
< 30 years old	0	0	0	0	twenty three	9.7	12.0																																	

Promote the project	Implementation status (Note 1)								Sustainable development with listed companies Differences in codes of practice and their causes	
	yes	no	Summary							
			30-49 years old	0	0.6	twenty three	4.6	6.9	3 6.0	5 0.3
			50-64 years old	twenty three	2.9	twenty three	8.6	1.7	1 3.1	3 0.9
			≥65 years old	0.6	0	4.0	0.6	1.1	0.6	6.9
			Data source: Employee statistics for November 4th and December.							
			<p>2. In line with policies, formulate various regulations, such as "Work Rules," "Sexual Harassment Prevention," and "Recruitment and Employment Management," to eliminate gender discrimination; clearly define employee rights regarding employment age, working hours, leave and attendance, etc., to ensure that colleagues are properly cared for, and design a "Human Rights Due Diligence Process" to address human rights issues and take appropriate measures to protect employee rights.</p> <p>(1) Human Rights Due Diligence Process (This study focuses on employees) :</p>  <pre> graph LR     A[Policy Commitment] --&gt; B[Identification and Assessment]     B --&gt; C[Stop/Slow Down]     C --&gt; D[Tracking Results]     D --&gt; E[Communication and Reporting] </pre> <p>(a) Policy Commitment: The Board of Directors reaches a consensus and publicly declares its</p>							

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes				
	yes	no	Summary					
			<p>respect for human rights and the establishment of a human rights policy.</p> <p>(b) Identification and assessment: Identification of potential human rights risks and assessment of human rights impacts.</p> <p>(c) Stop / mitigate: Summarize the assessment results and take appropriate measures and actions.</p> <p>(d) Tracking effectiveness: Regularly review and monitor the effectiveness of improvement measures.</p> <p>(e) Communication and Reporting: Establish clear appeal channels and disclose management practices in sustainability reports.</p> <p>(2) Human rights concerns in 2025 :</p> <p>(a) Creating a safe and healthy working environment</p> <p>( b ) Maintaining work-health balance for employees</p> <p>( c ) Eliminate illegal discrimination</p> <p>(d) Comply with labor laws</p> <p>(3) The specific measures and results are verified as follows:</p> <table border="1"> <thead> <tr> <th>Implementation policy</th> <th>Specific implementation measures</th> </tr> </thead> <tbody> <tr> <td>Create a safe and healthy working environment</td> <td>Office drinking water testing Work environment disinfection operation Workplace environment monitoring (such as CO2 , lighting) Fire safety awareness courses Provide masks for colleagues during the COVID-19 pandemic.</td> </tr> </tbody> </table>	Implementation policy	Specific implementation measures	Create a safe and healthy working environment	Office drinking water testing Work environment disinfection operation Workplace environment monitoring (such as CO2 , lighting) Fire safety awareness courses Provide masks for colleagues during the COVID-19 pandemic.	
Implementation policy	Specific implementation measures							
Create a safe and healthy working environment	Office drinking water testing Work environment disinfection operation Workplace environment monitoring (such as CO2 , lighting) Fire safety awareness courses Provide masks for colleagues during the COVID-19 pandemic.							

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes								
	yes	no	Summary									
			<table border="1"> <tr> <td>Maintaining work-health balance for employees</td> <td> <p>In accordance with the law, all employees, regardless of age, undergo routine medical examinations.</p> <p>With on-site nursing planning and timely adjustment of physical examination items</p> <p>Increase out-of-pocket medical examination items and strive for preferential prices</p> <p>Remind unit supervisors of employee special leave arrangements</p> </td> </tr> <tr> <td>Eliminate illegal discrimination</td> <td> <p>Develop sexual harassment prevention guidelines and compile statistics on the number of complaints.</p> <p>Conduct human rights education and training to promote awareness of human rights.</p> <p>( In 2025, we conducted awareness courses on preventing workplace misconduct, with a satisfaction rate of 94 % . )</p> </td> </tr> <tr> <td rowspan="3">Strictly abide by labor laws</td> <td> <p>The employment of child laborers under the age of 16 is prohibited.</p> <p>Prepare a compliant annual calendar and submit it to the labor-management meeting for review.</p> <p>Overtime work should be based on employees' voluntary applications.</p> </td> </tr> <tr> <td> <p>Elect representatives from both labor and management sides in accordance with the law and execute the meeting.</p> </td> </tr> <tr> <td> <p>In accordance with laws and regulations and employee needs, assist in handling childcare leave operations.</p> </td> </tr> </table> <p>Please refer to our company's official website for the execution results.</p>	Maintaining work-health balance for employees	<p>In accordance with the law, all employees, regardless of age, undergo routine medical examinations.</p> <p>With on-site nursing planning and timely adjustment of physical examination items</p> <p>Increase out-of-pocket medical examination items and strive for preferential prices</p> <p>Remind unit supervisors of employee special leave arrangements</p>	Eliminate illegal discrimination	<p>Develop sexual harassment prevention guidelines and compile statistics on the number of complaints.</p> <p>Conduct human rights education and training to promote awareness of human rights.</p> <p>( In 2025, we conducted awareness courses on preventing workplace misconduct, with a satisfaction rate of 94 % . )</p>	Strictly abide by labor laws	<p>The employment of child laborers under the age of 16 is prohibited.</p> <p>Prepare a compliant annual calendar and submit it to the labor-management meeting for review.</p> <p>Overtime work should be based on employees' voluntary applications.</p>	<p>Elect representatives from both labor and management sides in accordance with the law and execute the meeting.</p>	<p>In accordance with laws and regulations and employee needs, assist in handling childcare leave operations.</p>	
Maintaining work-health balance for employees	<p>In accordance with the law, all employees, regardless of age, undergo routine medical examinations.</p> <p>With on-site nursing planning and timely adjustment of physical examination items</p> <p>Increase out-of-pocket medical examination items and strive for preferential prices</p> <p>Remind unit supervisors of employee special leave arrangements</p>											
Eliminate illegal discrimination	<p>Develop sexual harassment prevention guidelines and compile statistics on the number of complaints.</p> <p>Conduct human rights education and training to promote awareness of human rights.</p> <p>( In 2025, we conducted awareness courses on preventing workplace misconduct, with a satisfaction rate of 94 % . )</p>											
Strictly abide by labor laws	<p>The employment of child laborers under the age of 16 is prohibited.</p> <p>Prepare a compliant annual calendar and submit it to the labor-management meeting for review.</p> <p>Overtime work should be based on employees' voluntary applications.</p>											
	<p>Elect representatives from both labor and management sides in accordance with the law and execute the meeting.</p>											
	<p>In accordance with laws and regulations and employee needs, assist in handling childcare leave operations.</p>											

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
(2) Does the company formulate and implement reasonable employee welfare measures (including salary, vacation and other benefits) and appropriately reflect operating performance or results in employee remuneration?	✓		<p>1. System regulations: The company has established work rules and relevant personnel management regulations, which cover the basic wages, working hours, vacations, pension benefits, labor and health insurance benefits, occupational accident compensation, etc. of the workers employed by the company, all of which comply with the relevant provisions of the Labor Standards Act.</p> <p>2. Employee Compensation: Salary: The Company has established a salary assessment method for employees. The assessment principle is based on the employee's job category and manager level and takes into account the market salary level, including monthly salary and performance bonus. Bonus: There is an employee appraisal method, and performance appraisals are conducted twice a year. Managers are also subject to this performance appraisal system. Evaluation factors include the unique value of an individual's overall performance to the organization, the ability to work with others and team spirit, the risk of harming customers or the team, and whether there is potential for promotion. Employee remuneration is reflected based on performance results, such as the issuance of year-end bonuses.</p> <p>3. Welfare measures: The company promotes labor-management harmony and improves labor welfare through employee welfare committees and labor-management meetings. The</p>	Comply with the Code of Practice for Sustainable Development of Listed Companies

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			<p>above two organizations elect labor representatives through employee elections to propose, coordinate, communicate and supervise labor-management related issues on behalf of employees, including but not limited to labor-management relations, labor conditions, labor welfare, workplace sexual harassment and bullying, employee diversity and equality issues. Employees are ex-officio members and have the right to raise the above issues to the labor committee for discussion and negotiation. Labor-management meetings are held once a quarter, four times a year; the employee welfare committee meets once a quarter, four times a year. The company allocates 0.08% of its revenue each month as employee welfare funds to handle various welfare matters, including but not limited to wedding and funeral allowances, birthday gifts, scholarships, travel allowances, etc.; annual employee health examinations are provided in accordance with the law, and annual employee influenza vaccinations are provided.</p> <p>4. Employee retirement system: Our company has established an employee retirement policy. Employees who meet one of the following conditions may request retirement. Employees who have served in the company or its affiliated companies for more than 25 years. Employees who have worked continuously for the company or its affiliated companies for more than 15 years and are 55 years of age or older.</p>	

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			<p>Employees who have worked continuously for the company or its affiliated companies for more than 10 years and are 60 years of age or older.</p> <p>Our company has established an application procedure for the old labor retirement system and allocates retirement reserves monthly within the statutory range of 2 %-15%; in addition, we make contributions under the new labor retirement system in accordance with the Labor Retirement Act, with a monthly contribution rate of 6 % for employees under the new labor retirement system.</p> <p>There is also a former Labor Retirement Reserve Oversight Committee, which meets quarterly to monitor the number of retirees and the management of retirement reserve funds.</p> <p>5. Reflection of operating performance:</p> <p>Performance bonus: Budget review and performance target setting are conducted annually, and performance bonuses are issued based on the achievement of performance targets.</p> <p>Employee Compensation: In addition, 6% to 10% of the company's profits should be allocated to employee compensation (the amount of this employee compensation shall be no less than 10% of the compensation for junior employees). The amount of compensation paid shall be submitted to the Remuneration Committee for review and approval by the Board of Directors, and shall be determined based on employee performance and job contribution. The company is committed to providing employees with a</p>	

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			salary and level that is above the industry average .	
(3) Does the company provide employees with a safe and healthy working environment and provide regular safety and health education to employees?	✓		<ol style="list-style-type: none"> <li>1. Our company complies with the relevant regulations of the Occupational Safety and Health Act, and stipulates that smoking is prohibited in all office premises. We also require annual safety inspections of office equipment and facilities in accordance with government fire safety regulations. We have also been conducting comprehensive work environment monitoring since 2019 to provide employees with a safe working environment. 2025 projects implemented: 2 times of work environment monitoring, 4 times of drinking water equipment related inspections, and 4 times of workplace environment disinfection.</li> <li>2. The Company will cooperate with the requirements of the office space management unit and regularly participate in actual drills on fire escape and the use of fire extinguishing equipment.</li> <li>3. The company regularly conducts health checks on employees and provides safety and health education to employees every year. It also provides on-site labor health services (the implementation situation in 2025 is: 24 times/year by nurses and 2 times/year by doctors).</li> <li>4. To promote employee health, our company conducts related health promotion activities. In 2025, we held an internal health promotion incentive program, the results of which are as follows:</li> </ol>	Comply with the Code of Practice for Sustainable Development of Listed Companies

Promote the project	Implementation status (Note 1)		Sustainable development with listed companies Differences in codes of practice and their causes																
	yes	no																	
			<table border="1"> <thead> <tr> <th>project</th> <th>Relevant statistics</th> </tr> </thead> <tbody> <tr> <td>Nutrition guidance lecture</td> <td>1 session/18 participants</td> </tr> <tr> <td>Exercise guidance lecture</td> <td>1 session / 20 participants</td> </tr> <tr> <td>Weight loss</td> <td>6 people</td> </tr> <tr> <td>Waist circumference reduction</td> <td>10 people</td> </tr> <tr> <td>BMI decrease</td> <td>10 people</td> </tr> <tr> <td>Body fat reduction</td> <td>3 people</td> </tr> <tr> <td>Increased skeletal muscle weight</td> <td>2 people</td> </tr> </tbody> </table> <p>In addition to organizing health promotion activities, annual employee health checkups are conducted, and on-site nurses assist in following up on abnormal results for follow-up examinations, health management, and health education. Through health education, health lectures, and participation in health promotion incentive activities , we are committed to maintaining employee health, actively preventing cardiovascular and metabolic chronic diseases that are common in modern people , creating a healthy workplace, and achieving mutual benefit for our employees.</p> <p>5. There were a total of 2 occupational injury cases involving employees in 2025 , accounting for 1.14 % of the total number of employees at the end of 2025 .</p> <p>6. To strengthen employees' awareness of human rights ,</p>	project	Relevant statistics	Nutrition guidance lecture	1 session/18 participants	Exercise guidance lecture	1 session / 20 participants	Weight loss	6 people	Waist circumference reduction	10 people	BMI decrease	10 people	Body fat reduction	3 people	Increased skeletal muscle weight	2 people
project	Relevant statistics																		
Nutrition guidance lecture	1 session/18 participants																		
Exercise guidance lecture	1 session / 20 participants																		
Weight loss	6 people																		
Waist circumference reduction	10 people																		
BMI decrease	10 people																		
Body fat reduction	3 people																		
Increased skeletal muscle weight	2 people																		

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			including but not limited to workplace bullying , workplace sexual harassment, gender discrimination, and labor relations, a complaint hotline and dedicated complaint mailbox have been set up; 1. In 2025, an awareness campaign on workplace illegal infringements was launched, with a total of 44 % of employees participating, totaling 77 hours.	
(4) Does the company establish an effective career development training program for its employees?	✓		<p>1. In order to implement lifelong learning and improve work skills and quality, the company has established the "Employee Continuing Education and Training Measures", provided training subsidies, and encouraged employees to study on the job . There are also scholarships to provide substantial rewards to employees and their children with excellent learning results.</p> <p>2. The company reviews and evaluates the skills, expertise and management capabilities of employees through the supervisors of each unit. When a higher-level supervisor is vacant, employees with outstanding performance will be promoted first. There is also a job transfer mechanism to give outstanding employees the opportunity to develop a second expertise.</p> <p>3. The results of relevant employee training conducted in 2025 are as follows:</p> <p>(1) Training of senior executives of the group: 294 training sessions , satisfaction rate of 95.6 % .</p> <p>(2) Training of mid-level managers in the group: 253 training sessions , satisfaction rate 93.7 % .</p> <p>(3) Information Security Management System ( ISMS) -</p>	Comply with the Code of Practice for Sustainable Development of Listed Companies

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			<p>Auditor /Lead Auditor Training : 1 person  (4) Carbon reduction training course for commercial sector personnel: 3 people completed the training.  (5) Specialized training: 2 people / 212 hours.</p>	
(5) Regarding issues such as customer health and safety, customer privacy, marketing and labeling of products and services, does the company comply with relevant laws and regulations and international standards, and has established relevant policies and complaint procedures to protect the rights and interests of consumers or customers?	✓		<p>1. The Company's main operating activities are the sale of medicines and medical consumables, the leasing of medical equipment and the provision of hospital health examination and laboratory management services. Among them, medicines, medical consumables and medical equipment are closely related to the life safety of the general public. During the process of research and development, manufacturing, importation, sales, transportation, storage and use, international and domestic regulations impose higher verification standards than those for general products . Our company also complies with the domestic Good Distribution Practice (GDP) for Western Medicines in terms of drug sales .</p> <p>2. When selecting products for operational purposes, our company will comply with international and domestic laws and regulations. The company has good communication channels and dedicated personnel who are responsible for listening to the needs of various stakeholders and responding to and tracking the feedback information collected through different communication channels according to the status of the issue . For detailed communication channels, please refer to the company's official website.</p> <p>3. The laboratory managed by our company has been</p>	Comply with the Code of Practice for Sustainable Development of Listed Companies

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			approved for ISO 9001 2015 revision certification, and the scope of accreditation includes: clinical testing services, teaching training and academic research.	
(6) Does the company have a supplier management policy that requires suppliers to comply with relevant regulations on issues such as environmental protection, occupational safety and health, or labor human rights, and its implementation?	✓		<p>1. In order to implement the company's commitment to fair, honest, trustworthy and transparent business activities, the "Supplier Management Policy" was formulated in accordance with the company's integrity management operating procedures and behavioral guidelines , requiring cooperation with suppliers to follow relevant standards on issues such as quality, environmental protection, safety and hygiene, and jointly strive to improve and perfect the relevant standards for corporate sustainable development ; and the content enhancement was completed in July 2020. The Company also formulated a new "Supplier Integrity Management Commitment" in November 2021, and added new supplier (organization or individual) assessments. All suppliers are required to sign the aforementioned Integrity Management Commitment in stages to commit to operating in an honest and ethical manner, fulfilling corporate social responsibility, promoting environmental sustainability, and safeguarding basic human rights.</p> <p>2. Before dealing with suppliers and customers, our company will follow the established "Supplier Management and Price Inquiry and Bargaining Operation Methods" and "Credit Management Methods" to investigate and confirm the integrity of</p>	Comply with the Code of Practice for Sustainable Development of Listed Companies

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			<p>suppliers and customers, such as whether they have obtained drug or medical device licenses, whether they have obtained drug dealer licenses, whether they have any tax arrears or debts, etc. We must confirm that their products have obtained national standard certification and that the company's operations are in line with integrity before transactions can be conducted.</p> <p>3. The contracts signed between our company and suppliers stipulate that "both parties shall comply with ○○industry-related laws and ethical standards and act in good faith", or "if the contracting party commits any dishonest behavior or its products have a significant impact on the environment and society, resulting in a breach of contract or damage, we may terminate the contract at any time and demand compensation in accordance with the contract or damage situation" to ensure the company's rights and interests.</p>	
5. Does the company prepare perpetual reports and other reports that disclose the company's non-financial information by referring to internationally accepted reporting standards or guidelines? Has the above-mentioned report obtained confirmation or assurance from a third-party verification agency?		✓	<p>the framework of the disclosure principles of the Global Reporting Initiative (GRI ) GRI Sustainability Reporting Standards ( GRI Standards : 2021 ) of the Global Sustainability Standards Board ( GSSB ) , the UK Accountability Organization ( AA ) AA1000 Stakeholder Engagement Standards ( SES ), and the Taiwan Stock Exchange Foundation. The "Operational Guidelines for the Preparation and Filing of Sustainability Reports by Listed Companies", the "Sustainability Development Action Plan for Listed Companies ( 2023 )" and the "Guidelines for the Establishment of Internal Control Systems by Publicly Offered Companies" have been</p>	The company plans to start preparing a sustainability report in 2014

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			implemented, and the " 2024 Sustainability Report" has been completed. The main purpose is to provide stakeholders with a public corporate operating policy and to present the company's strategy and vision for sustainable development goals. The content covers specific matters in five major areas: sustainable development, corporate governance, economic performance, environmental protection and social inclusion.	
<p>6. If the company has its own sustainable development code based on the "Sustainable Development Best Practices Code for Listed and OTC Companies", please describe the differences between its operation and the established code:</p> <p>The Company has formulated its own Code of Practice for Sustainable Development with reference to the "Code of Practice for Sustainable Development of Listed Companies " and is actively moving in the direction set out in the Code. There is no difference in the implementation content.</p>				
<p>7. Other important information that helps to understand the implementation of sustainable development :</p> <p>Sheng Hung Pharmaceutical's suppliers must comply with all relevant laws and regulations of the company and the government regarding E (Environmental Protection), S (Occupational Safety and Health, Labor Rights), and G (Data Security and Privacy). Core suppliers are required to have relevant international certifications (such as ISO14001, ISO27001, ISO45001, etc.) and be included as one of the supplier evaluation items in 2026. When providing services, pharmaceuticals, medical consumables, medical equipment and facilities, or other products, they must work together to fulfill the company's commitment to the core values of fairness, honesty, integrity, and transparency in conducting business activities .</p> <p>1. Supplier Management</p> <p>To establish a sustainable supply chain, in addition to establishing an internal supply chain management platform for supply chain management assessment and supervision, our company also conducts necessary audits annually on supplier partnerships, product quality, and product prices. In 2025, we had a total of 802 suppliers, with cooperation projects covering pharmaceuticals, medical supplies, equipment, engineering, reagents, administrative services, and labor procurement. All procurement was conducted in Taiwan, with 609 suppliers . The relevant statistics are shown in the table below.</p>				

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	

Table: 2025 Supplier Statistics

year	2025			
Types of Contracts	Procurement Area	Main supplier	Number of purchasing companies in 2025 years	Number of audited entities in 2025 years
Labor procurement	Taiwan	14	15	2
Drug procurement	Taiwan	196	155	196
Medical supplies procurement	Taiwan	335	335	334
Procurement of testing reagents	Taiwan	37	37	37
Equipment Procurement	Taiwan	169	twenty four	twenty four
Engineering Procurement	Taiwan	17	16	16
Procurement	Taiwan	34	27	27
total		802	609	636

Our company primarily handles supplier procurement locally; auditing work follows various procurement regulations and requirements. For example, for pharmaceutical and medical supplies procurement, supplier audits must be conducted for all categories regardless of whether any procurement transactions occurred in the current year; for other procurement categories, supplier audits are primarily based on whether procurement transactions occurred in the current year. The relevant supplier audit statistics are as follows:

- Drug and medical supplies procurement categories: A total of 196 drug suppliers and 334 medical supply suppliers were audited, representing an audit rate of 92%.
- Equipment procurement: audit ratio is 100%;
- For the procurement of testing reagents: the audit rate is 100%.
- For engineering procurement: the audit rate is 100%;
- For procurement-related items: the audit rate is 100%.
- Labor procurement: Audit rate is 13.3 %.

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes											
	yes	no	Summary												
<p>2. Supplier's Commitment to Honest Business Practices</p> <p>Our company continues to require newly added suppliers to sign integrity commitment letters, jointly abide by Shenghong's supplier integrity responsibility, and work together to realize our company's commitment to fair, honest, trustworthy, and transparent business activities .</p> <p>Table: Statistics on Signatures in 2025</p> <table border="1"> <thead> <tr> <th>year</th> <th>Signed content</th> <th>area</th> <th>Number of signatures (copies )</th> </tr> </thead> <tbody> <tr> <td rowspan="2">2025</td> <td>Commitment to Honest Business Practices</td> <td>Taiwan</td> <td>44</td> </tr> <tr> <td>Good faith business terms (as stipulated in the contract)</td> <td>-</td> <td>-</td> </tr> </tbody> </table>					year	Signed content	area	Number of signatures (copies )	2025	Commitment to Honest Business Practices	Taiwan	44	Good faith business terms (as stipulated in the contract)	-	-
year	Signed content	area	Number of signatures (copies )												
2025	Commitment to Honest Business Practices	Taiwan	44												
	Good faith business terms (as stipulated in the contract)	-	-												

Note 1: If you select “Yes” for implementation, please specify the important policies, strategies, measures and implementation status adopted; if you select “No” for implementation, please explain the differences and reasons in the column “Differences and reasons from the Code of Best Practice on Sustainable Development of Listed and OTC Companies” and explain the plans for the adoption of relevant policies, strategies and measures in the future.

Note 2: The materiality principle refers to environmental, social and corporate governance issues that have a significant impact on the company's investors and other stakeholders.

Note 3: For disclosure methods, please refer to the best practice reference examples on the Taiwan Stock Exchange Corporate Governance Center website.

( VI ) Implementation of climate-related information

- 一、 According to the "Sustainable Development Roadmap for OTC Companies" issued by the Financial Supervisory Commission in March 2022, our company is a company with paid-in capital of less than NT\$5 billion. The individual company (i.e., the parent company) should apply for greenhouse gas inventory in the third phase (i.e., complete the inventory in 2026 and complete the verification in 2028). We will continue to control the completion of the greenhouse gas inventory and verification disclosure schedule in accordance with the reference guidelines and relevant regulations issued by the competent authority.
- 二、 The Board of Directors and management have implemented some of the following in terms of their oversight and governance of climate-related risks and opportunities :
  1. According to the Financial Supervisory Commission's regulations, the greenhouse gas inventory and verification schedule for the parent company and the group (including subsidiaries) must be completed by the end of the second quarter of 2022 and the end of the first quarter of 2023, respectively, and submitted to the board of directors for approval.
  2. The aforementioned implementation progress was reported to the Board of Directors quarterly as required, and this was done in fiscal year 2022, with reports submitted quarterly from then until 2025. The completion of the greenhouse gas inventory and verification disclosure schedule is continuously monitored. The company's Specialist Services Department serves as the part-time unit for greenhouse gas inventory and verification .
  3. of consolidated subsidiaries was submitted to the Board of Directors in accordance with regulations for the first quarter of 2023. Submissions were made quarterly to the Board of Directors from 2023 to 2025 .
  4. The company continues to enhance the sustainability governance knowledge of its directors and supervisors, planning and participating in courses covering topics such as "Net-Zero Emissions and Carbon Neutrality," "Carbon Pricing Mechanisms," "TCFD Climate Risk Assessment," "Net-Zero Carbon Emissions and Corporate Governance," and "Taiwan Sustainability Classification Standards," thereby continuously improving the board's understanding of climate issues and regulatory trends. For related information, please refer to the Public Information Observation Station at: <https://mops.twse.com.tw/mops/web/t100sb07>
  5. The chairman and general manager participated in the company's greenhouse gas inventory launch meeting and training course held on December 29, 2023 .
  6. In conjunction with the company's ESG 2024, in June, we began the process of establishing the "ESG Corporate Sustainability Report" and simultaneously initiated related climate risk assessments and development opportunities.
- 三、 Greenhouse gas emission information, greenhouse gas inventory and confirmation :
  1. Currently, the company collects statistics on greenhouse gases, water use, waste weight, etc. every year and discloses them on its official website.

2. our company's 2025 fiscal year audit includes both parent and subsidiary companies. Greenhouse gas emissions are explained in the table below :

Greenhouse gas emissions	Total emissions (metric tons of CO <sub>2</sub> e)	density (Metric tonnes of CO <sub>2</sub> e/million yuan)	Confirmation Agency	Statement of Confirmation	Scope of data
illustrate	6367.26	$6367.26/4357.867 = 1.461$	FREC International Certification Co., Ltd.	on May 7, 2016 , by FABI International Certification Co., Ltd.	The greenhouse gas emissions data for 2011-2014 represent significant indirect emissions from Categories I and II and Category III .

On December 29, 2023, Sheng Hung Company, together with Hua Yu Management Company and Ding Hsin Computer Company, held a kick-off meeting for the company's greenhouse gas inventory and verification work. The scope of the greenhouse gas inventory for 2025 was expanded to include both parent and subsidiary companies, and based on the different operating models of each subsidiary, the scope was expanded to include more comprehensive significant indirect emission sources in accordance with the ISO 14064-1 : 2018 identification process. The company completed the external verification work with FASI Certification Co., Ltd. on May 7, 2026 .

( VII ) Implementation of good faith management and differences from the good faith management rules of listed and OTC companies and their reasons

Evaluation Project	Implementation status (Note 1)			Differences and reasons from the Integrity Management Code of the listed companies
	yes	no	Summary (Note 2)	
<p>1. Formulate integrity management policies and plans</p> <p>(1) Has the company formulated a business integrity policy approved by the board of directors, and has it clearly stated its business integrity policy and practices in its bylaws and external documents, as well as the board of directors and senior management's commitment to actively implement the business integrity policy?</p>	✓		<p>1. "Integrity" is the primary core value of the Company. In order to ensure that all members of the Company and its subsidiaries implement the commitment to integrity management in their work, the Company has formulated the "Integrity Management Operating Procedures and Behavior Guidelines" with reference to the "Integrity Management Code for Listed Companies". It was approved by the 19th meeting of the 4th Board of Directors on March 18, 2015 ; and was amended by the 12th meeting of the 6th Board of Directors on March 20, 2020.</p> <p>2. The Company's " Integrity Management Operating Procedures and Behavior Guidelines" are disclosed in the Company's annual report, website and public information observatory. Investors can download them from the Company's website\ Corporate Governance \Corporate Governance Regulations .</p> <p>3. The Company has established a "Code of Ethical Conduct" to regulate the Company's directors , supervisors , and managers to strictly prevent conflicts of interest , avoid opportunities for personal gain , maintain confidentiality , fair trade , protect and properly use company assets , and comply</p>	<p>Comply with the Integrity Management Code of Conduct for Listed Companies</p>

Evaluation Project	Implementation status (Note 1)			Differences and reasons from the Integrity Management Code of the listed companies
	yes	no	Summary (Note 2)	
			<p>with laws and regulations when engaging in operational activities for the Company based on their authority. They should set an example and shape the company's corporate culture of honest management.</p> <p>4. The company has established "employee work rules" to regulate the service code of all staff at work, including: not taking advantage of the position to engage in malpractice, accept gifts, seek benefits for others or yourself, strictly abide by the principle of integrity in handling official business, and not engage in breach of trust, fraud, or behavior that damages the company's rights and interests, etc., to implement the policy of honest management in work.</p>	
(2) Has the company established a mechanism to assess the risk of dishonest behavior, regularly analyze and assess business activities within its business scope that carry a higher risk of dishonest behavior, and formulate a plan to prevent dishonest behavior based on the risk, and at least cover the preventive measures for each of the behaviors in Article 7, Paragraph 2 of the "Code of Conduct for Listed and OTC Companies"?	✓		The "Integrity Management Operating Procedures and Behavior Guidelines" established by our company have detailed regulations prohibiting the company's directors , managers and all employees from engaging in any business activities that are in violation of the provisions of Article 7, Paragraph 2 of the "Integrity Management Code for Listed Companies" or other business activities that have a higher risk of dishonest behavior within the scope of other business.	Comply with the Integrity Management Code of Conduct for Listed Companies
(III) Does the company clearly define	✓		1. The company has established "Integrity	Comply with the Integrity

Evaluation Project	Implementation status (Note 1)			Differences and reasons from the Integrity Management Code of the listed companies
	yes	no	Summary (Note 2)	
operating procedures, behavioral guidelines, disciplinary measures for violations, and complaint systems in its plan to prevent dishonest behavior, implement them, and regularly review and revise the plan?			<p>Management Operating Procedures and Behavior Guidelines" to regulate specific integrity management practices and prevent dishonest behavior plans, including operating procedures, behavioral guidelines, and the establishment of a promotion , punishment, complaint system and disciplinary sanctions, etc., to regulate matters that personnel should pay attention to when performing business, prohibit the provision or acceptance of improper benefits, in order to implement the prevention of dishonest behavior. The company will also continue to review and revise it.</p> <p>2. The company has also established "Procedures for Handling Reports of Illegal, Immoral or Dishonest Behavior Cases" to establish internal and external reporting channels and handling systems to implement the " Code of Ethical Conduct " and " Integrity Management Operating Procedures and Behavior Guidelines " formulated by the company to ensure the sustainable development of the company's foundation and to ensure the legitimate rights and interests of reporters and related persons. Reporting of any illegal, immoral, and dishonest behavior is encouraged, and the standards for punishment are set in the "Employee Work Rules" and "Employee</p>	Management Code of Conduct for Listed Companies

Evaluation Project	Implementation status (Note 1)			Differences and reasons from the Integrity Management Code of the listed companies
	yes	no	Summary (Note 2)	
			Reward and Punishment Methods".	
<p>2. Implementing Integrity Management</p> <p>1. Does the company evaluate the integrity records of its trading partners and clearly stipulate good faith behavior clauses in the contracts signed between it and its trading partners ?</p>	✓		<p>1. Before dealing with suppliers and customers, our company will follow the established "Supplier Management and Price Inquiry and Negotiation Operation Methods" and "Credit Management Methods" to investigate and confirm the integrity of suppliers and customers, such as whether they have obtained drug or medical device licenses, whether they have obtained drug dealer licenses, whether they have any tax arrears, etc. We must confirm that their products have obtained national standard certification and that the company's operations are in line with integrity before transactions can be conducted.</p> <p>2. The contracts signed between our company and suppliers stipulate that "both parties shall comply with ○○industry-related laws and ethical standards and act in good faith", or "if the contracting party commits any dishonest behavior or its products have a significant impact on the environment and society, resulting in a breach of contract or damage, we may terminate the contract at any time and demand compensation in accordance with the contract or damage situation" to ensure the company's rights and interests.</p>	Comply with the Integrity Management Code of Conduct for Listed Companies

Evaluation Project	Implementation status (Note 1)			Differences and reasons from the Integrity Management Code of the listed companies
	yes	no	Summary (Note 2)	
			<p>3. Our company states in its procurement regulations that suppliers who comply with environmental, safety and health regulations will be given priority, meaning that we will not cooperate with suppliers who have concerns about environmental , safety or health issues, thereby encouraging suppliers to comply with relevant regulations and work together to enhance corporate social responsibility.</p> <p>4. In accordance with the implementation of the company's supplier management policy, the official contract (agreement) and the revision of relevant methods and forms of each department were completed in 2021. New suppliers will sign a letter of commitment to honest management in accordance with the company's regulations.</p>	
(II) Does the company have a dedicated unit under the board of directors to promote corporate integrity management, and does it regularly (at least once a year) report to the board of directors on its integrity management policy and plan for preventing dishonest behavior and the status of its supervision of implementation?	✓		<p>1. Regarding the promotion of the company's integrity management, in addition to having an independent internal auditing unit to audit and internalize and explain the relevant systems and regulations for dissemination, the company has designated the Chairman's Office as the responsible unit for promoting integrity management matters in the "Integrity Management Operating Procedures and Code of Conduct". The Chairman's Office is</p>	Comply with the Integrity Management Code of Conduct for Listed Companies

Evaluation Project	Implementation status (Note 1)			Differences and reasons from the Integrity Management Code of the listed companies
	yes	no	Summary (Note 2)	
			<p>responsible for revising , implementing , interpreting , providing consultation services for the operating procedures and code of conduct, as well as logging and filing the notification content and supervising the implementation of the operating procedures and code of conduct .</p> <p>2. In 2019, the Chairman appointed the "Information Planning Office" to assist in the integration of various internal functional organizations and the implementation of related policies, and to report to the Board of Directors regularly. On December 19 , 2025 , the 8th Board of Directors reported on the annual implementation. No major incidents of violating integrity management occurred in 2025 .</p> <p>3. The Company has implemented the integrity management policy. The relevant implementation status in 2025 is as follows: (1) The Company has established internal and external reporting channels and handling systems, and has set up a dedicated unit and contact information for reporting; no relevant reports were received in 2025. (2) "Supplier Integrity Management Commitment Letter": Starting from November 2021, the Company has required all suppliers to sign the Supplier Integrity Management Commitment Letter in stages (or to stipulate it in the contract in the form</p>	

Evaluation Project	Implementation status (Note 1)			Differences and reasons from the Integrity Management Code of the listed companies
	yes	no	Summary (Note 2)	
			of integrity management terms), to commit to operating with integrity and ethics, fulfilling corporate social responsibility, promoting environmental sustainability and protecting basic human rights ; a total of 44 commitment letters were signed in 2025 .	
(3) Has the company formulated a policy to prevent conflicts of interest, provided appropriate channels for representation, and implemented it?	✓		<ol style="list-style-type: none"> <li>1. Our company's "Integrity Management Operating Procedures and Behavior Guidelines" have clear instructions on the prohibition of providing or accepting improper benefits , prohibition of facilitation payments , conflict of interest policies , handling procedures, and handling of reported cases, and require all personnel to implement them.</li> <li>2. The Company regularly confirms the competitive situations of directors and managers for use in business operation review and approval to grasp the potential risks of conflicts of interest.</li> <li>3. If the board of directors of our company encounters a case of conflict of interest, it shall strictly follow Article 15 of the company's "Board of Directors' Meeting Rules". If a director has a conflict of interest with himself or the legal person he represents in the meeting matters, he shall explain the important details of his conflict of interest at the current board meeting. If there is a possibility of harming the interests</li> </ol>	Comply with the Integrity Management Code of Conduct for Listed Companies

Evaluation Project	Implementation status (Note 1)			Differences and reasons from the Integrity Management Code of the listed companies
	yes	no	Summary (Note 2)	
			of the company, he shall not participate in the discussion and voting, and shall recuse himself from the discussion and voting, and shall not exercise the voting rights on behalf of other directors; and detailed records shall be made in the meeting minutes.	
(IV) Has the company established an effective accounting system and internal control system to implement honest business operations? Has the internal audit unit formulated relevant audit plans based on the results of the assessment of dishonest behavior risks and used them to verify compliance with the plan to prevent dishonest behavior, or has it entrusted a certified public accountant to perform the audit?	✓		<p>1. The accounting system and internal control system of the Company are designed under the framework for the purpose of implementing honest business operations. The internal audit unit conducts regular audits and reports the audit results and implementation status to the board of directors every quarter.</p> <p>2. The Company appoints an accountant to conduct annual audits and certifications to conduct random confirmation of the implementation of internal controls in order to reasonably ensure that the Company's accounting system and internal control system are operating effectively.</p>	Comply with the Integrity Management Code of Conduct for Listed Companies
(V) Does the company regularly hold internal and external education and training on integrity management?	✓		<p>1. Our company encourages employees to participate in various educational and training courses, and regularly promotes relevant measures such as "Honest Business Operation Procedures and Code of Conduct" and "Code of Ethical Conduct" in internal meetings to make employees understand their importance.</p> <p>2. Our company regularly conducts annual</p>	Comply with the Integrity Management Code of Conduct for Listed Companies

Evaluation Project	Implementation status (Note 1)			Differences and reasons from the Integrity Management Code of the listed companies
	yes	no	Summary (Note 2)	
			<p>training sessions on integrity in business and related laws and regulations. Course topics include: guidelines for honest business practices and prevention of insider trading, to prevent dishonest behavior. The implementation of internal training courses in 2025 was as follows: a) On December 12th, an external lecturer , Attorney Yu - Ting Yu from Ambow Law Firm , was invited to conduct a 3- hour online course for all employees on two topics: "Internal Honest Business Practices" and "Prevention of Insider Trading ," with 60 participants . b) Other external training received by employees in 2025 is disclosed on pages 179-181 of the annual report .</p> <p>3. The Company also provides information on courses related to director responsibilities, integrity in business operations, and new legal knowledge from time to time for the directors' reference. The continuing education status of directors and independent directors in 2025 is disclosed on pages 48-50 of the Annual Report .</p>	
<p>3. Operation of the company's whistleblower system</p> <p>1. Has the company established a specific reporting and reward system, established convenient reporting channels, and</p>	✓		<p>1. Our company has established "Regulations for Handling Cases of Reporting Illegal, Unethical or Dishonest Conduct", which assigns appropriate personnel to handle the reported cases and</p>	<p>Comply with the Integrity Management Code of Conduct for Listed Companies</p>

Evaluation Project	Implementation status (Note 1)			Differences and reasons from the Integrity Management Code of the listed companies
	yes	no	Summary (Note 2)	
assigned appropriate personnel to handle reports?			<p>specifies the reporting channels, categories of reported matters, reporting procedures, protection policies, and rewards and obligations for whistleblowers.</p> <p>2. Specific reporting and reward systems, including: establishing confidential and direct reporting channels, designating dedicated personnel to handle reports, standard operating procedures for investigating reported matters and related confidentiality mechanisms, measures to protect whistleblowers from improper treatment due to their reports, and measures to reward those who report dishonest behavior.</p> <p>3. The company has established the following specialized units based on the type of whistleblower:</p> <p>a) Spokesperson and proxy spokesperson: handling inquiries from shareholders, investors, etc. Reports from interested parties. Email address for inquiries : spokesperson@share-hope.com</p> <p>b) Chairman's Office and Audit Office: Handling reports from company colleagues, customers, suppliers, etc. Email address for inquiries: convener@share-hope.com</p>	
(II) Does the company have established	✓		Our company's "Procedures for Handling	Comply with the Integrity

Evaluation Project	Implementation status (Note 1)			Differences and reasons from the Integrity Management Code of the listed companies
	yes	no	Summary (Note 2)	
standard operating procedures for investigating reported matters, follow-up measures to be taken after the investigation is completed, and related confidentiality mechanisms?			Reports of Illegal, Immoral or Dishonest Behavior" clearly stipulates the reporting procedures, including what should be recorded in the report , the handling procedures for reports, and improvement measures.	Management Code of Conduct for Listed Companies
(3) Has the company taken measures to protect whistleblowers from being improperly punished for reporting?	✓		Our company's "Procedures for Handling Reports of Illegal, Immoral or Dishonest Behavior" clearly stipulates a protection policy: the identity of the reporter and the content of the report should be kept completely confidential and verified through independent channels. The Company will maintain confidentiality and protect whistleblowers or persons involved in the investigation from unfair treatment or retaliation. Let the whistleblower feel at ease and reassured, and maintain a positive and kind corporate culture and atmosphere.	Comply with the Integrity Management Code of Conduct for Listed Companies
4. Strengthening Information Disclosure established integrity management code and the effectiveness of its promotion on its website and public information observatory ?	✓		<p>1. The Company's "Integrity Management Operating Procedures and Behavior Guidelines" have been disclosed in the Company's annual report, website and public information observatory. Investors can check the Company's website \ Corporate Governance \ Corporate Governance Regulations.</p> <p>2. The Company discloses the Company's integrity management policies, activities and implementation status for the current year in the Corporate Governance and</p>	Comply with the Integrity Management Code of Conduct for Listed Companies

Evaluation Project	Implementation status (Note 1)			Differences and reasons from the Integrity Management Code of the listed companies
	yes	no	Summary (Note 2)	
			Integrity Management area of the Company's website.	
<p>5. If the company has its own integrity management code based on the "Integrity Management Code for Listed and OTC Companies" , please describe the differences between its operation and the established code:  The Company has established the "Integrity Management Operating Procedures and Behavior Guidelines" in accordance with the "Integrity Management Code for Listed Companies". Currently, there is no significant difference between the relevant operations and the established code, and the implementation is normal.</p>				
<p>6. Other important information that helps to understand the company's integrity management operations: (such as the company's review and revision of its established integrity management code, etc.)  If the Company amends the "Integrity Management Operating Procedures and Behavior Guidelines", it will first submit the proposal to the Board of Directors for approval , send it to each independent director and submit a report to the shareholders' meeting, and then announce it for implementation.</p>				

Note: Regardless of whether you tick “Yes” or “No”, the operating status should be stated in the summary column.

( 8 ) Other important information that is sufficient to enhance understanding of the company's governance operations may also be disclosed :None.

1. In order to strengthen the prevention of insider trading, the Company has established a mechanism for handling and disclosing important information within the Company to avoid improper information leakage, ensure the security of the Company's important information and the consistency and accuracy of external information. The Company has formulated the "Management Measures for Preventing Insider Trading" for insiders to follow.

2. Public Information Observation Station: <http://mops.twse.com.tw/mops/web/index>  
( Stock Code: 8403 )

( 9 ) The implementation status of the internal control system should disclose the following matters :

1. Internal Control Statement, website:

URL: <https://mops.twse.com.tw/mops/#/web/t06sg20>

2. Those who entrust an accountant to conduct a special audit of the internal control system shall disclose the accountant's audit report: Not applicable.

( X ) Important resolutions of the shareholders' meeting and the board of directors in the most recent year and up to the date of publication of the annual report

1. Board of Directors

Meeting Date	Major resolutions
<p>2025.03.14 The 8th Session 6th Board of Directors</p>	<p>( I ) Matters to be reported:</p> <ol style="list-style-type: none"> <li>1. Resolutions of the previous meeting and their implementation status.</li> <li>2. Business report.</li> <li>3. Audit business report.</li> <li>4. Report on the distribution of year-end bonuses and annual salary review for our company's managers in 2024.</li> <li>5. Greenhouse gas inventory and verification implementation status.</li> <li>6. 2024 Annual Performance Evaluation Report of the Board of Directors and Functional Committees.</li> </ol> <p>( II ) Items for Discussion:</p> <ol style="list-style-type: none"> <li>1. The 2024 Annual Report and Financial Statements are submitted for discussion.</li> <li>2. The proposal regarding the proportion and amount of directors' remuneration and employee remuneration for 2024 is submitted for discussion.</li> <li>3. The proposed distribution of profits for fiscal year 2024 is submitted for discussion.</li> <li>4. The proposal to transfer surplus to capital and issue new shares is submitted for discussion.</li> <li>5. The company's definition of frontline employees and the proposed ratio for profit allocation to frontline employees are submitted for discussion.</li> <li>6. The proposal to replace outdated bidirectional cardiac catheters at Min Sheng General Hospital is submitted for discussion.</li> <li>7. The 2025 assessment of the independence and competence of certified public accountants is submitted for discussion.</li> <li>8. The appointment of visa accountants for fiscal year 2025 is hereby submitted for discussion.</li> <li>9. The internal control system declaration proposal is submitted for review and discussion.</li> <li>10. We hereby submit our proposed amendments to the Company's "Internal Control System" and "Internal Audit Implementation Rules" for discussion.</li> <li>11. We hereby submit a proposal to amend the Company's "Operational Guidelines for Financial Transactions Between Related Parties" for discussion.</li> <li>12. The proposed amendments to the Company's Articles of Association are submitted for discussion.</li> <li>13. New (extended) short-term comprehensive credit lines for financial institutions are proposed for discussion.</li> <li>14. The proposal to convene the 2025 Annual General Meeting of Shareholders is hereby submitted for discussion.</li> <li>15. The proposed salary for the Deputy General Manager of our Smart Healthcare City Business Unit is submitted for discussion.</li> </ol>

Meeting Date	Major resolutions
<p>2025.05.09 8th Session of the 7th Board of Directors</p>	<p>( I ) Matters to be reported:  3. Resolutions of the previous meeting and their implementation status.  4. Business report.  5. Audit business report.  6. This explains Article 10-1 of our company's "Operational Guidelines for Financial Transactions Between Related Parties".  7. Corporate Governance Assessment Report.  8. Greenhouse gas inventory and verification implementation status.  9. Report on liability insurance coverage for directors, supervisors and key personnel.</p> <p>( II ) Items for Discussion:  1. The proposed consolidated financial statements for the first quarter of 2025 are submitted for discussion.  2. The proposed adjustment to the attendance fees for the company's board meetings (including independent directors) is submitted for discussion.  3. We hereby submit our proposed policy linking senior management compensation with ESG performance evaluation for discussion.  4. The proposal to develop a health checkup information system for Taiwanese citizens is submitted for discussion.</p>
<p>2025.08.08 The 8th Session Board of Directors</p>	<p>( I ) Matters to be reported:  1. Resolutions of the previous meeting and their implementation status.  2. Business report.  3. Audit business report.  4. Greenhouse gas inventory and verification implementation status.</p> <p>( II ) Items for Discussion:  1. The proposed consolidated financial statements for the second quarter of 2025 are submitted for discussion.  2. We propose to submit our "2024 Sustainability Report" for discussion.  3. We propose to set the ex-dividend date and other related matters for the 2024 earnings distribution, and submit them for discussion.  4. The case of financial institutions applying for credit lines is submitted for discussion.  5. The proposed loan of NTD 70 million to Precision Health (stock) Co., Ltd. is submitted for discussion.</p>
<p>2025.10.17 The 8th and 9th Board of Directors</p>	<p>( I ) Matters to be reported:  1. Resolutions of the previous meeting and their implementation status.</p> <p>( II ) Items for Discussion:  1. We hereby submit a proposal to discuss adjustments to the operating security deposit for medical institutions managed by our company.  2. The appointment of the company's chief financial officer is hereby submitted for discussion.</p>

Meeting Date	Major resolutions
<p>2025.11.07 The 8th Session 10th Board of Directors</p>	<p>( I ) Matters to be reported:</p> <ol style="list-style-type: none"> <li>1. Resolutions of the previous meeting and their implementation status.</li> <li>2. Business report.</li> <li>3. Audit business report.</li> <li>4. Greenhouse gas inventory and verification implementation status.</li> </ol> <p>( II ) Items for Discussion:</p> <ol style="list-style-type: none"> <li>1. The proposed consolidated financial statements for the third quarter of 2025 are submitted for discussion .</li> <li>2. We propose to formulate the "Nomination Committee Organization Regulations" and establish a Nomination Committee, and submit them for discussion.</li> <li>3. The appointment of members of the company's first Nomination Committee is hereby submitted for discussion.</li> <li>4. The case of financial institutions applying for credit lines is submitted for discussion.</li> <li>5. We hereby submit our proposed amendments to the Company's "Internal Control System" and "Internal Audit Implementation Rules" for discussion.</li> <li>6. We would like to submit the proposed compensation for our Chief Financial Officer for discussion.</li> </ol>
<p>2025.12.19 The 8th Session 11th Board of Directors</p>	<p>( I ) Matters to be reported:</p> <ol style="list-style-type: none"> <li>1. Resolutions of the previous meeting and their implementation status.</li> <li>2. Business report.</li> <li>3. Track the progress of internal audit findings and improvements made by the subsidiary, Mincheng Health Technology Co., Ltd., in the third quarter of 2025.</li> <li>4. Investment report on the newly established company "Hehehe Healthy Life Co., Ltd".</li> <li>5. Report on the operation of the Risk Management Working Group in 2025.</li> <li>6. Report on the progress and implementation of sustainable business in 2025.</li> <li>7. Information Security Committee's Business Promotion and Implementation Status in 2025.</li> <li>8. Implementation status of the 2025 Intellectual Property Management Plan.</li> <li>9. Report on the results of communication with various stakeholders in 2025.</li> <li>10. Year 2025 Corporate Integrity Management Implementation Report.</li> </ol> <p>( II ) Items for Discussion:</p> <ol style="list-style-type: none"> <li>1. The 2026 budget and operating plan are submitted for discussion.</li> <li>2. audit plan for 2026 has been prepared and is submitted for discussion.</li> <li>3. The proposed donation of NT\$1 million to the Taiwan United Medical Foundation is submitted for discussion.</li> <li>4. The proposed cash capital increase and share subscription plan for the investment company Precision Health (stock) in 2025 is submitted for discussion.</li> </ol>

Meeting Date	Major resolutions
	<p>5. The company's year-end bonus plan and manager year-end bonus distribution proposal are submitted for discussion.</p>
<p>2026.03.13 The 8th Session 12th Board of Directors</p>	<p>( I ) Matters to be reported:</p> <ol style="list-style-type: none"> <li>1. Resolutions of the previous meeting and their implementation status.</li> <li>2. Report on the actual amount of year-end bonuses paid to the company's managers in 2025 and the annual salary review report for 2025.</li> <li>3. Business report.</li> <li>4. Audit business report.</li> <li>5. The report on the marketable securities of Guoguang Biotechnology Co., Ltd. was obtained from the centralized market.</li> <li>6. This is the resignation report of the Deputy General Manager, Spokesperson, and Chief Cybersecurity Officer of the Company's Information Planning Department.</li> <li>7. Report on the implementation of greenhouse gas inventory and verification.</li> <li>8. 2025 Annual Performance Evaluation Report of the Board of Directors and Functional Committees.</li> </ol> <p>( II ) Items for Discussion:</p> <ol style="list-style-type: none"> <li>1. The 2025 Business Report and Financial Statements are submitted for discussion.</li> <li>2. The proposal regarding the proportion and amount of directors' remuneration and employee remuneration for 2025 is submitted for discussion.</li> <li>3. The employee compensation distribution plan for 2025 is hereby submitted for discussion.</li> <li>4. The proposal regarding the replacement of certified public accountants and the assessment and appointment of certified public accountants for the year 2026 is submitted for discussion.</li> <li>5. The internal control system declaration proposal is submitted for review and discussion.</li> <li>6. We would like to request discussion of the proposed change of our company spokesperson.</li> <li>7. We hereby submit the proposed change of our cybersecurity chief for discussion.</li> <li>8. The proposed appointment of the General Manager of our Smart Healthcare City Business Unit is submitted for discussion.</li> <li>9. The proposal to extend short-term comprehensive credit lines by financial institutions is submitted for discussion.</li> <li>10. The proposal for year 2026 board member training course is submitted for discussion.</li> <li>11. The proposal to convene the 2026 Annual General Meeting of Shareholders is hereby submitted for discussion.</li> <li>12. We hereby submit for discussion the proposed disposal of our shares in BenQ BM Holding Cayman Corporation (BBHC).</li> </ol>

## 2. Regular shareholders meeting

Meeting Date	Major resolutions	Implementation
2025.6.16 Shareholders' Meeting	1. Approval of the 2024 Annual Report, Financial Statements and Consolidated Financial Statements	Execution completed.
	2. 2024 Profit Distribution Plan	On March 14, 2025, the Board of Directors approved and authorized the Chairman on August 8, 2025, to set September 1, 2025 as the ex-dividend date ( a cash dividend of NTD 0.50 and a stock dividend of NTD 0.49999999 per share ).
	3. Case of transferring surplus to capital increase and issuing new shares	1. Number of shares issued: 6,554,302 shares. 2. Paid - in capital after capital increase NTD 1,376,403,430. 3. Use of the increased capital: To strengthen the financial structure.
	4. Amendment to the Company 's Articles of Association	The revised procedure has been followed and announced on the company's website.

( XI ) In the most recent year and up to the date of publication of the annual report, the directors or supervisors had different opinions on important resolutions passed by the board of directors and the main contents of the records or written statements are : None.

## 2.3 Information on public fees for accountants

( 1 ) Information on the public fees for visa-based accountants:

### Visa Accountant Public Fund Information

Amount Unit: NT\$ thousand

Name of accounting firm	Accountant's Name	During the period of audit by accountants	Audit public expenses	Non-audit public expenses	total	Remark
KPMG in Taiwan	Kou Huizhi	2025/01/01	3,256	736	3,991	1. Non-audit publicly funded services include: Tax visa fee: NT\$256,000; transfer pricing report fee: NT\$180,000; business registration fee: NT\$300,000.
	Guo Xinyi	- 2025/12/31				

( 2 ) If the accounting firm is changed and the audit fees paid in the year of change are less than the audit fees paid in the year before the change, the amount of audit fees before and after the change and the reason should be disclosed: Not applicable.

( 3 ) If the audit expenses are reduced by more than 10% compared with the previous year, the amount, proportion and reason of the reduction in audit expenses shall be disclosed: Not applicable.

## 2.4 Information on change of accountant: None

**2.5 The company's chairman, general manager, or manager in charge of financial or accounting affairs who has worked for the firm to which the certifying CPA belongs or its affiliated companies within the past year: None.**

**2.6 Changes in equity transfers and equity pledges by directors, supervisors, managers, and shareholders holding more than 10% of the shares in the most recent year and up to the date of publication of the annual report:**

## (1) Changes in the equity of directors, supervisors, managers and major shareholders

Unit: Share

Job title ( Note 1)	N a m e	2025		April 20, 2026	
		Number of shares held Increase (decrease) number	Number of pledged shares Increase (decrease) number	Number of shares held Increase (decrease) number	Number of pledged shares Increase (decrease) number
Corporate Director ( Major Shareholder )	Minsheng Medical Control Co. , Ltd.	1,887,931	1,500,000	0	0
Chairman	Minsheng Medical Control Co. , Ltd. Representative: Yang Hongren	61,757	0	0	0
Vice Chairman	Minsheng Medical Control Co. , Ltd. Representative: Xu Shengxin	0	0	0	0
Director and President	Minsheng Medical Control Co. , Ltd. Representative: Liu Qingwen	2,955	0	0	0
director	Minsheng Medical Control Co. , Ltd. Representative: Sun Zhili	0	0	0	0
director	Minsheng Medical Control Co. , Ltd. Representative: Chen Wenzhong	0	0	0	0
Corporate Director	Rong Yang Management Consultants Limited	6,964	0	0	0
director	Rong Yang Management Consultants Limited Representative: Zhang Changrong	0	0	0	0
director	Yang Chen Caibi	73,672	0	0	0
Independent Director	Wu Genzai	0	0	0	0
Independent Director	Li Shuxing	0	0	0	0
Independent Director	Chen Houming	0	0	0	0

Job title (Note 1)	Name	2025		April 20, 2026	
		Number of shares held Increase (decrease) number	Number of pledged shares Increase (decrease) number	Number of shares held Increase (decrease) number	Number of pledged shares Increase (decrease) number
Independent Director	Yao Xiubi	0	0	0	0
Deputy General Manager	Chen Pengxuan	7	0	0	0
Deputy General Manager	Wu Mingxun	22,243	0	0	0
Deputy General Manager	Kovison	9	0	0	0
Deputy General Manager	Cai Yufang	0	0	0	0
Deputy General Manager	He Weiguang	0	0	0	0
Deputy General Manager	Zhong Yiting	0	0	0	0
Chief Financial Officer	Lin Fangyu	0	0	0	0
Accounting Assistant	Huang Yamei	633	0	0	0

(2) In the most recent year and up to the date of publication of the annual report, the directors, supervisors, managers and shareholders holding more than 10% of the shares to whom the shareholders transferred their shares were related persons: None.

(3) In the most recent year and up to the date of publication of the annual report, the directors, supervisors, managers and shareholders holding more than 10% of their shares whose counterparties are pledged are related parties: None.

**2.7 Information on whether the top ten shareholders in terms of shareholding ratio are related persons or spouses or relatives within the second degree of kinship.**

April 25 , 2026/ Unit: Shares; %

NAME (NOTE1)	MYSELF SHAREHOLDING		SHARES HELD BY SPOUSE AND MINOR CHILDREN		SHARES HELD IN THE NAMES OF OTHERS		FOR THE TOP TEN SHAREHOLDERS WHO ARE RELATED TO EACH OTHER OR ARE SPOUSES OR RELATIVES WITHIN THE SECOND DEGREE OF KINSHIP , PLEASE PROVIDE THEIR NAMES OR SURNAMES AND RELATIONSHIPS. (NOTE 3)		REMARK
	Number of shares	Share holding ratio	Number of shares	Share holding ratio	Number of shares	Share holding ratio	name	relation	
Minsheng Medical Control Co., Ltd. Representative: Yang Hongren	39,637,732	28.80	0	0	0	0	none	none	none
	1,029,687	0.75	0	0	0	0	Yang Chen Caibi	Mother and child	none
Yang Chen Caibi	154,713	1.12	1,324	0	0	0	Yang Hongren	Mother and child	none
Huang Hui	1,128,999	0.82	0	0	0	0	none	none	none
Yang Hongren	1,029,687	0.75	0	0	0	0	Yang Chen Caibi	Mother and child	none
Fu Fengcheng	875,000	0.64	0	0	0	0	none	none	none
Yangzheng Investment Co., Ltd. Representative: Yang Chen Caibi	776,936	0.56	0	0	0	0	none	none	none
Tian Yulong	754 , 408	0.61	0	0	0	0	none	none	none
Zhang Chaotang	720,000	0.52	0	0	0	0	none	none	none
Xu Rongyuan	658,513	0.48	0	0	0	0	none	none	none

NAME (NOTE1)	MYSELF SHAREHOLDING		SHARES HELD BY SPOUSE AND MINOR CHILDREN		SHARES HELD IN THE NAMES OF OTHERS		FOR THE TOP TEN SHAREHOLDERS WHO ARE RELATED TO EACH OTHER OR ARE SPOUSES OR RELATIVES WITHIN THE SECOND DEGREE OF KINSHIP, PLEASE PROVIDE THEIR NAMES OR SURNAMES AND RELATIONSHIPS. (NOTE 3)		REMARK
	Number of shares	Share holding ratio	Number of shares	Share holding ratio	Number of shares	Share holding ratio	name	relation	
Min Sheng Asset Management Co., Ltd. Representative: Zhang Changrong	649,951	0.47	0	0	0	0	none	none	none
	0	0	0	0	0	0	none	none	none

Note 1 : The top ten shareholders should all be listed. If they are legal person shareholders, the names of the legal person shareholders and the names of their representatives should be listed separately.

Note 2 : The calculation of shareholding ratio refers to the calculation of shareholding ratio in one's own name, spouse, minor children or in the name of another person.

Note 3 : The shareholders listed above include both legal persons and natural persons, and the relationship between them should be disclosed .

**2.8 The number of shares held by the company, its directors, supervisors, managers and enterprises directly or indirectly controlled by the company in the same invested enterprise, and the calculation of the comprehensive shareholding ratio**

March 31, 2026 ; Unit: 1,000 shares ; %

Investee businesses (Note)	Our company's investment		Directors, supervisors, managers, and investments in businesses directly or indirectly controlled by them.		Comprehensive Investment	
	Number of shares	Shareholding ratio	Number of shares	Shareholding ratio	Number of shares	Shareholding ratio
Mincheng Health (stock) Co., Ltd.	22,454	61.46%	0	0	22,454	61.46%
Shenghong Pharmaceutical (Hong Kong) Co., Ltd.	1,500	100 %	0	0	1,500	100%
Zhongyuan Medical Management (Stock) Company	1,000	100 %	0	0	1,000	100%
Precision Health (stock) company	12,601	38.19%	0	0	12,601	38.19%
Shengshi Digital Health Co., Ltd. (formerly known as Shengshi Technology Co., Ltd.)	100	100%	0	0	100	100%
Medical Electronics Digital Transformation (Stock) Company	600	60%	200	20%	800	80%
Fangding Information Technology Co., Ltd.	1	51%	0	0	1	51%
Global Biotech Investment ( Stock ) Company	500	23.98%	0	0	500	23.98%
Shengyu Health Technology Co., Ltd.	200	40%	0	0	200	40%
Hehehe Healthy Living Co., Ltd.	2,000	20%	0	0	2,000	20%
Minsheng Asia Pacific (Beijing) Enterprise Management Co., Ltd.	0	100%	0	0	0	100%
Mincheng (stock) Co., Ltd.	0	0	6,000	100%	6,000	100%
First Long-Term Care Platform (Stock) Company	0	0	867	29.09%	867	29.08%

Investee businesses (Note)	Our company's investment		Directors, supervisors, managers, and investments in businesses directly or indirectly controlled by them.		Comprehensive Investment	
	Number of shares	Shareholding ratio	Number of shares	Shareholding ratio	Number of shares	Shareholding ratio
Leap Lion Health (stock) Co., Ltd.	0	0	6,035	100%	6,035	100%
Shengyun Pharmaceutical Co., Ltd.	0	0	6,460	100%	6,460	100%
Shangjia Health Business ( Stock ) Company	0	0	3,390	28.18%	3,390	28.18%
Anzhun Technology Co., Ltd.	0	0	2,000	40%	2,000	40%

### 3. Participation and Fund Raising

#### 3.1 Capital and Shares

##### 1. Source of equity

Unit: 1,000 shares; 1,000 yuan

years	issued price	Authorized share capital		Paid-in capital		Remark		
		Number of shares	Amount	Number of shares	Amount	Source of equity	Using property other than cash to pay for shares	other
Oct. 2003	10	1,000	10,000	1,000	10,000	Establishment capital	none	Note 1
Nov. 2007	10	21,000	210,000	21,000	210,000	Cash capital increase	none	Note 2
May 2008	15	50,000	500,000	23,100	231,000	Cash capital increase	none	Note 3
Aug. 2008	10	50,000	500,000	25,000	250,000	Surplus transfer to capital increase	none	Note 4
Sep. 2009	10	50,000	500,000	27,000	270,000	Surplus transfer to capital increase	none	Note 5
	13.25			27,150	271,500	Employee bonus transfer to capital increase		
Oct. 2009	27	50,000	500,000	30,150	301,500	Cash capital increase	none	Note 6
Feb. 2010	31	50,000	500,000	35,148	351,480	Cash capital increase	none	Note 7
Jul. 2010	10	50,000	500,000	37,960	379,598	Surplus transfer to capital increase	none	Note 8
	15.16			38,110	381,098	Employee bonus transfer to capital increase		
Mar. 2011	36	50,000	500,000	42,192	421,918	Cash capital increase	none	Note 9
Sep. 2011	10	50,000	500,000	43,458	434,576	Surplus transfer to capital increase	none	Note 10
Oct. 2012	18.8	100,000	1,000,000	43,708	437,076	Employee Stock Purchase	none	Note 11
	10			45,881	458,805	Surplus transfer to capital increase		
	22.98			51,297	512,971	Convertible bonds convertible into common stock		
Mar. 2013	22.98	100,000	1,000,000	51,850	518,497	Convertible bonds convertible into common stock	none	Note 12
May 2013	18	100,000	1,000,000	51,854	518,537	Employee Stock Purchase	none	Note 13
	22.98			52,398	523,977	Convertible bonds convertible into common stock		
Oct. 2013	18	100,000	1,000,000	52,467	524,672	Employee Stock Purchase	none	Note 14
	10			55,087	550,870	Surplus transfer to capital increase		

years	issued price	Authorized share capital		Paid-in capital		Remark		
		Number of shares	Amount	Number of shares	Amount	Source of equity	Using property other than cash to pay for shares	other
	22.98			55,152	551,523	Convertible bonds convertible into common stock		
Dec. 2013	17.1	100,000	1,000,000	55,428	554,283	Employee Stock Purchase	none	Note 15
	18							
Apr. 2014	17.1	100,000	1,000,000	55,452	554,523	Employee Stock Purchase	none	Note 16
	21.89			55,589	555,894	Convertible bonds convertible into common stock		
Jun. 2014	17.1	100,000	1,000,000	55,600	556,003	Employee Stock Purchase	none	Note 17
Oct. 2014	17.1	100,000	1,000,000	55,630	556,303	Employee Stock Purchase	none	Note 18
	10			58,410	584,104	Surplus transfer to capital increase		
	21.89			58,734	587,347	Convertible bonds convertible into common stock		
Jan. 2015	16.3	100,000	1,000,000	58,745	587,457	Employee Stock Purchase	none	Note 19
	21.89			58,823	588,234	Convertible bonds convertible into common stock		
Jun. 2015	16.3	100,000	1,000,000	59,021	590,214	Employee Stock Purchase	none	Note 20
	20.86			59,093	590,933	Convertible bonds convertible into common stock		
	37.85			59,318	593,179	Convertible bonds convertible into common stock		
Oct. 2015	37.85	100,000	1,000,000	59,492	594,923	Convertible bonds convertible into common stock	none	Note 21
	10			62,372	623,722	Surplus transfer to capital increase		
Dec. 2015	37.85	100,000	1,000,000	63,548	635,479	Convertible bonds convertible into common stock	none	Note 22
	36.09			64,684	646,839	Convertible bonds convertible into common stock		
Apr. 2016	36.09	100,000	1,000,000	74,287	742,874	Convertible bonds convertible into common stock	none	Note 23
Jun. 2016	36.09	100,000	1,000,000	74,971	749,718	Convertible bonds convertible into common stock	none	Note 24
Oct. 2016	36.09	100,000	1,000,000	75,584	755,842	Convertible bonds convertible into common stock	none	Note 25

years	issued price	Authorized share capital		Paid-in capital		Remark		
		Number of shares	Amount	Number of shares	Amount	Source of equity	Using property other than cash to pay for shares	other
Sep. 2017	10	100,000	1,000,000	79,288	792,888	Surplus transfer to capital increase	none	Note 26
Feb. 2018	10	100,000	1,000,000	77,797	777,978	Cancellation of Treasury Stock	none	Note 27
Apr. 2018	30	100,000	1,000,000	92,797	927,978	Cash capital increase	none	Note 28
Oct. 2018	10	100,000	1,000,000	97,437	974,378	Surplus transfer to capital increase	none	Note 29
Oct. 2019	10	150,000	1,500,000	102,309	1,023,096	Surplus transfer to capital increase	none	Note 30
Oct. 2020	34.6	150,000	1,500,000	103,425	1,034,252	Convertible bonds convertible into common stock	none	Note 31
Oct. 2020	10			108,541	1,085,407	Surplus transfer to capital increase	none	
Jan. 2021	33	150,000	1,500,000	108,697	1,086,969	Convertible bonds convertible into common stock	none	Note 32
Apr. 2021	33	150,000	1,500,000	108,882	1,088,818	Convertible bonds convertible into common stock	none	Note 33
Oct. 2021	10	150,000	1,500,000	114,326	1,143,259	Surplus transfer to capital increase	none	Note 34
Sep. 2022	10	150,000	1,500,000	120,042	1,200,422	Surplus transfer to capital increase	none	Note 35
Sep. 2023	10	150,000	1,500,000	126,044	1,260,442	Surplus transfer to capital increase	none	Note 36
Sep. 2024	10	200,000	2,000,000	131,086	1,310,860	Surplus transfer to capital increase	none	Note 37
Sep. 2025	10	200,000	2,000,000	137,640	1,376,403	Earnings transferred to capital increase	none	Note 38

Note 1 : Issued on October 13, 2003 , under document number 09232793980.

Note 2 : Issued on November 20, 2007 , under the document number 09633073780.

Note 3 : Issued on May 19, 2008 , under the approval number 09732260910.

Note 4 : Issued on August 4, 2008 , under the name of the State Administration of Letters and Documents No. 09732765220 .

Note 5 : Financial Institutional Qualification Certificate No. 0980034558 issued on July 14, 2009 and Certificate No. 09833057760 issued on September 15 , 2009 .

Note 6 : Financial Institutional Qualification Certificate No. 0980037987 issued on July 29, 2009 and Certificate No. 09833206110 issued on October 8 , 2009 .

Note 7 : Financial Institutional Registry Certificate No. 0980066075 issued on December 11, 2009 , and Certificate No. 09931671870 issued on February 10, 2010 .

Note 8 : Financial Institutional Qualification Certificate No. 0990039571 issued on July 28, 2010 and Certificate No. 09932762350 issued on November 1, 2010 .

Note 9 : Financial Institutional Registry Certificate No. 0990073963 issued on January 17 , 2011 , and Certificate No. 10031753080 issued on March 14 , 2011 .

Note 10 : Financial Authority Certificate No. 1000031409 issued on July 7 , 2011 and Certificate No. 10032489230 issued on September 14 , 2011 .

Note 11 : Financial Supervisory Commission Certificate No. 1010035228 issued on August 10 , 2012 and Business License No. 10101224560 issued on October 30 , 2012 .

Note 12 : Business License No. 10201044170 issued on March 12 , 2013

Note 13 : Business License No. 10201091590 issued on May 17 , 2013

- Note 14 : Financial Supervisory Commission Certificate No. 1020030545 issued on August 6 , 2013 and Business License No. 10201202410 issued on October 1 , 2013
- Note 15 : Business License No. 10201256970 issued on December 20 , 2013
- Note 16 : Business License No. 10301070200 issued on April 22 , 2014
- Note 17 : Business License No. 10301114790 issued on June 17 , 2014 .
- Note 18 : Business License No. 10301204740 issued on October 3 , 2014
- Note 19 : Business License No. 10301262300 issued on January 13 , 2015
- Note 20 : Business License No. 10401117580 issued on June 17 , 2015
- Note 21 : Business License No. 10401201570 issued on October 5 , 2015 .
- Note 22 : Business License No. 10401268730 issued on December 15 , 2015 .
- Note 23 : Business License No. 10501077020 issued on April 20 , 2016
- Note 24 : Business License No. 10501130760 issued on June 28 , 2016
- Note 25 : Business License No. 10501236380 issued on October 3 , 2016
- Note 26 : Business License No. 10601134570 issued on September 27 , 2017
- Note 27 : Business License No. 10701017630 issued on February 14 , 2018
- Note 28 : Business License No. 10701037200 issued on April 11 , 2018
- Note 29 : Business License No. 10701128970 issued on October 9 , 2018
- Note 30 : Business License No. 10801134510 issued on October 4 , 2019
- Note 31 : Business License No. 10901186610 issued on October 13 , 2020
- Note 32 : Business License No. 11001007520 issued on January 19 , 2021
- Note 33 : Business License No. 11001063430 issued on April 20 , 2021
- Note 34 : Business License No. 11001184020 issued on October 18 , 2021
- Note 35 : Business License No. 11101178780 issued on September 28 , 2022.
- Note 36 : Approved by the State Administration for Industry and Commerce on September 20, 2023, under license number 11230178490 .
- Note 37 : Approved by the State Administration for Industry and Commerce on September 23, 2024, under license number 11330167330 .
- Note 38: Commercial Permit No. 11430146030 issued on September 24, 2025 .

Types of Shares		April 25 , 2026 / Unit : Shares		
Shares type	Authorized share capital			Remark
	Outstanding shares (Note)	Unissued shares	total	
Common Stock	137,640,343 shares	62,359,657 shares	200,000,000 shares	none

Note: 1. Issued shares are OTC stocks.

2. Information related to the summary declaration system: None.

( II ) List of major shareholders: names of shareholders with a shareholding ratio of 5% or more or the top ten shareholders, and the amount and ratio of their shares  
April 25 , 2026 ; Unit : Shares

Name of major shareholder	Shares	
	Number of shares held	Shareholding ratio
Minsheng Medical Control Co., Ltd.	39,637,732	28.80
Yang Chen Caibi	1,547,113	1.12
Huang Hui	1,128,999	0.82
Yang Hongren	1,029,687	0.75

Fu Fengcheng	875,000	0.64
Yangzheng Investment Co., Ltd.	776,936	0.56
Tian Yulong	754,408	0.55
Zhang Chaotang	720,000	0.52
Xu Rongyuan	658 , 513	0.48
Min Sheng Asset Management Co., Ltd.	649,951	0.47

( III ) The company's dividend policy and implementation status

1. Dividend policy as stipulated in the company's articles of association

If the company's annual financial statements show a surplus, after paying taxes in accordance with the law and making up for accumulated losses, another 10% will be set aside as a statutory surplus reserve. However, if the statutory surplus reserve has reached the company's paid-in capital, no further setting aside may be made; the remainder will be set aside or transferred as a special surplus reserve in accordance with laws and regulations; if there is any balance, together with the accumulated undistributed surplus, the board of directors shall prepare a surplus distribution proposal and submit it to the shareholders' meeting for resolution on the distribution of dividends to shareholders.

The Company's shareholder dividend policy is based on consideration of the Company's current and future investment environment, funding needs, profitability, capital structure and future operating needs, while taking into account shareholder interests, balancing dividends and the Company's long-term financial planning. Dividends are distributed in cash or stock. The proportion of cash dividends distributed in the current year shall not be less than 20% of the total dividends for the current year , and the rest shall be distributed in the form of stock dividends. However, the actual distribution ratio may be adjusted based on the actual profit and operating conditions of the current year.

2. Proposed (already) dividend distribution for this year :

The proposed dividend distribution at the Company's 2026 Annual General Meeting of Shareholders (approved by the Board of Directors on May 8, 2026)

Dividend Types	Distribution per share ( yuan )	source
Cash dividends	0.60000000	Undistributed surplus
Stock dividends	0	

( IV ) The impact of the proposed free rights issue at this shareholders' meeting on the company's operating performance and earnings per share: None.

( V ) Remuneration of employees , directors and supervisors

1. The percentage or range of employee dividends and directors' and supervisors' remuneration as specified in the company's articles of association :

If the Company makes a profit in a given year, it shall allocate 6% to 10% as employee compensation (with no less than 10% allocated to lower-level employees), to be distributed in the form of shares or cash by resolution of the Board of Directors. The distribution shall be made to employees of subsidiaries who meet certain conditions. Based on the aforementioned profit, the Board of Directors shall allocate no more than 3% as director compensation. The distribution of employee and director compensation shall be reported to the shareholders' meeting. However, if the Company has accumulated losses, a reserve shall be set aside in advance to cover them before allocating employee and director compensation according to the aforementioned proportions .

2. The basis for estimating the remuneration of employees , directors and supervisors in this period, the basis for calculating the number of shares for employee remuneration distributed in the form of stocks, and the accounting treatment when the actual distribution amount differs from the estimated amount :

directors and supervisors of the Company for this period is calculated based on the Company's internal estimated full-year operating results and the contribution ratio stipulated in the Company's Articles of Association. If the subsequent distribution amount determined by the board of directors differs from the estimated amount, it will be considered a change in accounting estimate and the annual profit or loss will be adjusted to increase or decrease the distribution amount .

3. The board of directors approves the distribution of remuneration :

- (1) Amount of employee compensation and director and supervisor compensation distributed in cash or stock. If there is a difference with the estimated amount of the recognized expense in the year, the difference, reason and treatment should be disclosed :

Unit: Yuan

Assign Project	Amount proposed by the Board of Directors to be allotted (A)	Annual estimated amount of expense recognition (B)	Difference Amount (AB)	Causes of differences and solutions
Employee Remuneration	11,339,647	11,339,647	0	No difference
Remuneration of Directors and Supervisors	1,889,941	1,889,941	0	

- (2) Amount of employee compensation distributed in the form of stock and its proportion to the total net profit after tax and total employee compensation of the current period or individual financial statements:  
Not applicable .

4. The actual distribution of employee, director and supervisor remuneration in the previous year (including the number of shares distributed, amount and share price); if there is a difference between the employee, director and supervisor remuneration recognized, the difference, reason and handling status shall be stated :

Unit: Yuan

Project allocation	The Board proposes to distribute (A)	Actual disbursement amount (B)	Difference Amount (AB)	Reasons for and handling of differences
Employee compensation	16,014,437	0	16,014,437	The discrepancy in our employee compensation is mainly due to the practice of distributing compensation in installments, which results in some amounts still not being paid.
Directors' remuneration	2,669,073	2,669,073	0	

( VI ) The company repurchased its own shares: None

**3.2 Corporate bond handling status: None .**

**3.3 Special shares handling situation: None.**

**3.4 Overseas depositary receipts: None.**

**3.5 Employee stock option certificates: None.**

**3.6 Issuance of new shares in the event of a merger or acquisition or transfer of shares of another company: None .**

**3.7 Fund utilization plan and implementation status: None .**

## 4. Operation Overview

### 4.1 Business Content

#### 1. Business scope

The main business operations and product offerings of our company :

Shenghong Pharmaceutical Co., Ltd. is a professional health management and pharmaceutical distribution organization. Its main business scope includes drug and medical supply supply, medical equipment leasing, health management, medical personnel dispatch, medical management consulting and entrusted operation services, telemedicine, and hospital management .

The main business items registered with the Ministry of Economic Affairs by our company are as follows:

- 01.F108021 Wholesale of Western medicine.
- 02.F108011 Wholesale of Traditional Chinese Medicine.
- 03.F208050 Retail of Class B pharmaceutical products.
- 04.F108031 Wholesale of medical equipment.
- 05.F108040 Cosmetics wholesale industry.
- 06.F208040 Cosmetics retail industry.
- 07.F118010 Information software wholesale business.
- 08.F401010 International trade.
09. I 103060 Management Consulting.
10. I 301010 Information software services industry.
11. I C01010 Pharmaceutical inspection industry.
12. I Z12010 Human resource dispatch industry.
- 13.JE01010 Leasing industry.
- 14.JZ99050 Intermediary services.
- 15.ZZ99999 may engage in businesses other than those permitted by law.
- 16.F102170 Wholesale of food and miscellaneous goods
- 17.F203010 Retail of food and beverages
- 18.F208031 Medical device retail industry.
- 19.J901020 General hotel industry .

## 2. Business proportion

Unit: NT\$ thousand

Business Category \ year	2025	
	Business income	Proportion of turnover
Supply of medicines, medical materials and scientific materials	3,530,744	81.02
Health and Medical Management	734,562	16.86
Equipment rental service	92,561	2.12
total	4,357,867	100

## 3. The company's current products ( services )

### (1) Pharmaceutical Distribution Department

- A. Joint Procurement Platform for Pharmaceuticals : including medicines, medical supplies, home care products, etc.
- B. Pharmaceutical and Medical Supplies Warehousing and Logistics Management
- C. Professional information consulting and services for pharmaceuticals and medical supplies
- D. Distribution and agency of pharmaceuticals, health foods and cosmeceuticals

### (2) Health Management Department

- A. Medical and Health Checkup Management Consulting and Outsourced Operation Services
- B. Medical testing laboratory management consulting and outsourced operation services
- C. Integrated marketing of medical testing instruments, reagents, and consumables
- D. Medical and nursing staff planning and dispatch services
- E. Planning and Establishment of Medical Clinics
- F. Workplace health management consulting services
- G. Acquisition and management of hospital operating rights.

### (3) Specialist Services Department

- A. Medical equipment leasing : including the sale and leasing of medical equipment, engineering, surgical instruments, information hardware and software, and other specific equipment :
  - a. Instruments: including medical imaging equipment, ultrasound, exercise electrocardiogram, hearing test equipment, respirators, bedside physiological monitors, defibrillators, electrocautery machines, surgical air drills, electric drills, anesthesia machines, ECMO, aortic balloon pumps, operating tables, microcomputer autoclaves, electronic gastroscopes, etc.,

and other instruments and auxiliary equipment and facilities required for treating or prolonging the patient's life.

- b. Instruments: surgical instruments, soft and hard endoscopes, etc.
- c. Information: information hardware and software related to medical operations, etc.
- B. Subsequent services for leased medical equipment: including maintenance ( original or aftermarket ) , repair and related maintenance consultation, and assistance in handling second-hand equipment.
- C. Project leasing: We tailor-make products and services according to customer needs and provide customers with complete and appropriate leasing projects.
- D. Professional Consulting: Provide evaluation related to the establishment, procurement and updating of medical equipment, software and hardware consulting related to the establishment of medical institutions, establishment and cooperation consulting of large medical equipment; floor plan planning, engineering design and cooperation consulting of medical specialties.
- E. Specialized operation: Cooperate with medical specialists in medical institutions to provide high-end medical equipment for specialized operation, combine medical expertise with the equipment supply chain, and provide more advanced and professional medical services to the public.

#### (4) Dialysis Division

- A. General dialysis : hemodialysis, peritoneal dialysis, maintaining high-quality dialysis medical services.
- B. Specialized Dialysis : Intensive Dialysis, Ascites Dialysis, Specialized Blood Purification - Supporting Critical Care Medicine, Blood Purification DFPP-Double plasma filtration .
- C. Case management of chronic kidney disease, nutritional counseling, and guidance on kidney disease nursing.

#### 4. ( services ) to be developed

- (1) Domestic and foreign pharmaceutical and medical supplies agency and development.
- (2) Expand clinic and pharmacy business through joint retail channels.
- (3) We provide customers with a complete range of leasing services through human resource dispatch and professional human resource training, which have been expanded to include long-term care and hemodialysis.
- (4) Agency and distribution of medical instruments and equipment and distribution of special medical materials.
- (5) Establish cooperative business for specialized operation of medical instruments and equipment.
- (6) Provide better long-term chronic medical services through expansion of high-quality hemodialysis centers.

## ( II ) Industry Overview

### (1) Pharmaceutical Market

#### A. Global Pharmaceutical Market

According to IQVIA's latest survey report, the global pharmaceutical market size in 2024 was approximately US\$1.74 trillion, an increase of about 8.90% from US\$1.60 trillion in 2023. Developed countries accounted for US\$1,421.5 billion, or 81.23% of the global pharmaceutical market. The top ten developed countries—the United States, Germany, France, the United Kingdom, Italy, Spain, Japan, Canada, Australia, and South Korea—accounted for US\$1,194.5 billion in 2024, representing 68.26% of the global pharmaceutical market, up from 67.31% in 2023, and continuing to increase. Emerging pharmaceutical markets, mainly composed of China, Brazil, India, and Russia, had a market size of US\$312.2 billion in 2024, with their share of the global pharmaceutical market decreasing to 17.84%. The pharmaceutical market size in low-income countries was US\$16.1 billion, accounting for only 0.92%, as shown in the table below.

### Global pharmaceutical sales by region in 2024

Unit: US\$ billion, %

Geographical distinction	2024 Year Sales	2020~2024 Year CAGR	2029 Year Estimated sales	2025~2029 Year CAGR
advanced countries	14,215	8.2	19,450~19,750	5.5~8.5
-Top 10 Advanced Countries	11,945	8.2	16,350~16,650	5~8
Emerging pharmaceutical countries	3,122	6.0	3,750~4,050	3.5~6.5
Low-income countries	161	1.0	180~220	2~5
total	17,498	7.7	23,550~23,850	5~8

**Note:** CAGR: Compound Annual Growth Rate Annual Growth Rate) .

**Source:** Global Use of Medicines Outlook through 2029 , IQVIA , 2025 June.

In 2024, the top three global therapeutic areas were cancer drugs, metabolic disease drugs, and immune disease drugs, each with sales exceeding US\$100 billion. Cancer drug sales reached US\$232.388 billion, and are projected to reach US\$426.839 billion by 2030, with a CAGR of 11.1% from 2023 to 2030, indicating that cancer remains a major global disease category, as shown in the table below. Next were metabolic disease drugs, including those for diabetes, hyperglycemia, and obesity, with global sales reaching US\$125.036 billion and projected to reach US\$224.548 billion by 2030, boasting a CAGR of 14.1% from 2023 to 2030—the highest CAGR among the top ten therapeutic areas. Additionally, drugs for the gastrointestinal system, ophthalmology, central nervous system, and hematology also generally had CAGRs exceeding 10%.

## Top 10 global therapeutic drug categories in 2024

Unit: US\$ billion, %

Ranking	Pharmaceutical field	2024 Year Sales	2030 Year Forecasted sales	2023~2030 Year CAGR
1	Oncologics (Cancer Drugs )	2,323.88	4,268.39	11.1
2	Metabolic Disorders ( medications for metabolic diseases )	1,250.36	2,245.48	14.1
3	Immunology (Medications for Immune Diseases )	1,000.56	1,472.22	5.5
4	Infectious Diseases (Medications for Infectious Diseases )	863.26	1,073.85	1.9
5	Central Nervous System (Central Nervous System Drugs )	811.61	1,543.56	10.4
6	Cardiovascular medication	608.73	579.26	0.3
7	Respiratory medications	499.48	650.53	4.9
8	Hematological Disorders (medications for blood disorders )	304.95	563.32	10.4
9	Ophthalmology ( medications for eye diseases )	213.37	406.12	11.6
10	Gastrointestinal medication	182.66	388.57	13.2

**Source:** GlobalData , 2025 May.

According to a survey of pharmaceutical industry experts by GlobalData, the development of immuno-oncology drugs, anti-obesity drugs, the increasing complexity and cost of clinical trials, real-world evidence (RWE), cell and gene therapy (CGT), and personalized/precision medicine will be the most influential industry trends in 2025. Among these, the rapid growth in sales of GLP-1 anti-obesity drugs not only provides solutions for global health but also creates enormous market opportunities for pharmaceutical companies. The complexity and increasing costs of clinical trials directly impact drug development and timelines to market. Cell and gene therapy is opening up new models for disease treatment and healthcare payment, and its influence on the industry will continue to grow. The development of personalized medicine, providing customized disease prevention and treatment, will also drive the development of global healthcare.

According to GlobalData's statistics, the top ten best-selling drugs globally in 2031 are predicted in the table below. Eli Lilly's diabetes drug Mounjaro® and weight-loss drug Zepbound® occupy the top two spots in 2031 sales, with projected CAGRs of 17.5% and 28.3%, respectively, reaching \$35.63 billion and \$28.2 billion in sales. Novo Nordisk's weight-loss drug Wegovy® also sees a CAGR of 17.4%, with projected sales reaching \$26.093 billion in 2031, up from \$8.449 billion in 2024. As for Merck's melanoma treatment Keytruda®, while it maintained rapid growth in 2024,

its future growth is limited due to the development of many of its indications; projected sales will decline to \$18.113 billion in 2031, a decrease in CAGR of approximately 6.7%.

### Forecast of the top ten global pharmaceutical sales in 2031

Unit: US\$ billion

Row name	product	Manufacturer Name	2024 Year Sales	2031 Year Forecasted sales	2024~2031 CAGR (%)
1	Mounjaro®	Eli Lilly	115.40	356.30	17.5
2	Zepbound®	Eli Lilly	49.26	282.00	28.3
3	Wegovy®	Novo Nordisk	84.49	260.93	17.4
4	Dupixent®	Sanofi	141.36	250.28	8.5
5	Skyrizi®	AbbVie Inc	117.18	244.88	11.1
6	Ozempic®	Novo Nordisk	174.68	238.11	4.5
7	Keytruda®	Merck & Co	294.82	181.13	- 6.7
8	Biktarvy®	Gilead Sciences Inc	134.23	168.59	3.3
9	Orforglipron Calcium®	Eli Lilly	-	143.65	-
10	Rinvoq®	AbbVie Inc	59.71	143.51	13.4

**Source:** GlobalData 2025 March.

#### B. Domestic pharmaceutical market

China's pharmaceutical industry is divided into Western medicine preparations, active pharmaceutical ingredients (APIs), biological preparations, and traditional Chinese medicine preparations, as shown in the table below. Western medicine preparations, including small molecule new drugs and generic drugs past their patent expiration date, are currently the main source of revenue for China's pharmaceutical industry. APIs are the active ingredients in Western medicine preparations; after adding excipients, they are made into finished products. Domestic APIs are mostly supplied to foreign pharmaceutical companies, and their revenue is second only to Western medicine preparations, but the proportion of exports is higher. As for biological preparations and traditional Chinese medicine preparations, their industry scale is relatively small, and they account for a low percentage of the overall pharmaceutical industry revenue.

#### Scope of my country's pharmaceutical industry and its main products

Sub-sectors of the industry	Main product items
API (Active Pharmaceutical Ingredient) Industry	Active pharmaceutical ingredient, active pharmaceutical ingredient intermediates, excipients
Western medicine preparation industry	Small molecule drugs (new drugs or generic drugs )

Biopharmaceutical Industry	Biological drugs, blood products, vaccines and toxoids, allergen drugs
Traditional Chinese Medicine Preparation Industry	herbal/ plant-based drugs, concentrated Chinese herbal medicines, traditional Chinese medicines, and Western medicine preparations of Chinese herbal medicines

**Source:** Industry Information Group, Center for Biotechnology Development, 2025 Year.

The pharmaceutical industry has seen a continuous increase in the number of new drug launches in recent years, coupled with domestic generic drug manufacturers obtaining marketing authorizations for their products from foreign generic drug markets, contributing to the industry's revenue. In 2024, the pharmaceutical industry's revenue was NT\$119.6 billion, a decrease of approximately 7.36% compared to 2023. This decrease was mainly due to the surge in orders in 2023, which resulted in a growth rate of 34.34%, creating a higher base and leading to a decrease in revenue growth in 2024, as shown in the table below.

### 2020~2024 Overview of my country's Pharmaceutical Industry

Unit: New Taiwan Dollar

Year (CE)	2020	2021	2022	2023	2024
Revenue (in 100 million yuan )	890	917	961	1,291	1,196
Number of manufacturers (number of companies )	375	378	372	366	368
Employees (persons )	19,500	19,800	20,380	27,500	27,600
Export value (100 million yuan )	322	333	403	608	502
Import value (100 million yuan )	1,681	1,818	2,176	1,749	1,859
Domestic sales: Export sales (%)	62:38	64:36	58:42	53:47	58:42
Domestic market demand (in 100 million yuan )	2,249	2,402	2,734	2,432	2,553

**Source:** Pharmaceutical Industry Technology Development Center, 2025 .


Taiwan's pharmaceutical industry primarily relies on generic drugs and active pharmaceutical ingredients (APIs) for revenue. However, with the increasing number of new drugs launched, their contribution to revenue is also growing year by year. As of June 2025, Taiwan had 16 new drugs listed internationally, encompassing small molecule drugs, biological products (including vaccines), biosimilars, and botanical drugs. In 2024, new drug sales and royalty income totaled approximately NT\$15 billion, contributing to the growth of the pharmaceutical industry's revenue.

Domestic pharmaceutical companies continue to expand their operations. Among

them, Meishi Chemical Pharmaceutical Co., Ltd. has seen a continuous increase in both domestic and international sales, and Baorui Pharmaceutical Co., Ltd. has acquired equity in a US pharmaceutical plant and manufacturing base through mergers and acquisitions. Both companies have exceeded NT\$10 billion in revenue. China Chemical Pharmaceutical Co., Ltd., Yung-Shin Pharmaceutical Industrial Co., Ltd., Shengda Pharmaceutical Co., Ltd., Taiwan Tungyang Pharmaceutical Co., Ltd., and PharmaEssential Pharmaceutical Co., Ltd. have also exceeded NT\$5 billion in revenue. Among them, PharmaEssential Pharmaceutical Co., Ltd., which is engaged in new drug development, has benefited from the sales driven by the domestic and international launch of new drugs, and its revenue has increased significantly, reaching NT\$9.7 billion.

In 2024, the overall revenue of Taiwan's biotechnology industry reached NT\$775.4 billion, a 2.32% increase from NT\$757.8 billion in 2023, as shown in the chart below. The pharmaceutical industry benefited from a surge in orders, achieving a growth rate of 34.34% in 2023. However, in 2024, the industry returned to normal, resulting in a decline in revenue to NT\$119.6 billion, a decrease of approximately 7.36%, as shown in the table below.

**Growth trend of revenue in my country's biotechnology industry**



Note: 1. Based on the Ministry of Economic Affairs' classification of the medical device industry and the unified calculation of the medical device industry's turnover, starting from January 2024, the turnover of the medical device and health care industry will be adjusted to the turnover of the medical device industry. The original equipment and supplies for disease prevention and health promotion will be moved to the health and welfare industry for calculation.

Note: 2. Regenerative medicine revenue has been separated from applied biotechnology revenue into a single industry item since 2024.

**Source:** Biotechnology and Pharmaceutical Industry Development Promotion Group, Ministry of Economic Affairs; Pharmaceutical Industry Development Center, Pharmaceutical Industry Development Center; Industrial Technology Research Institute, International Strategy Development Center, 2025.

## (2) Medical Laboratory

According to industry research data, Taiwan's healthcare market size was approximately US\$4.3 billion in 2024 and is projected to continue growing. Taiwan's medical testing market was approximately NT\$60 billion in 2024 and is estimated to reach NT\$90 billion by 2030. Considering changes in medical technology and market demand, the future of Taiwan's medical testing industry will focus on: "integration of precision medicine and gene testing," "development of molecular diagnostic technology," "AI and smart healthcare applications," "big data and biomedical database applications," and "preventive medicine and health management." However, it also faces challenges such as "medical regulations and testing certification standards," "high investment costs for high-end testing equipment," "genetic data privacy and ethical issues," and "increasing demand for professional medical testing personnel."

Overall, medical testing plays a crucial role in Taiwan's healthcare system and is gradually moving towards the era of molecular diagnostics and precision medicine with advancements in medical technology. In the future, medical testing will combine gene testing, big data analysis, and artificial intelligence technologies to create a more precise and personalized healthcare model. With an aging population, increased health awareness, and the development of the biotechnology industry, the medical testing market will continue to grow and become one of the important development areas of Taiwan's biotechnology and medical industry. If Taiwan can integrate medical resources, technological research and development, and industrial applications, it will have a significant competitive advantage in the global precision medicine and biomedical technology industry.

## ( 3 ) Health check

With rising national income and increased health awareness, the demand for health checkups continues to grow, driving rapid growth in the overall health management market. Taiwan will officially enter a "super-aged society" in 2025, with the proportion of the population aged 65 and over continuing to increase, leading to a rise in demand for health management and chronic disease prevention. This has caused health checkup services to gradually shift from "disease diagnosis" to "health prevention and management," prompting medical institutions and health management centers to actively develop integrated health services. Current health management center services, in addition to health checkups, also include post-checkup medical advice, health tracking, health consultation, and disease risk assessment. They also provide

lifestyle improvement and preventative healthcare recommendations for sub-healthy individuals, aligning with the development of preventative medicine. The Taiwan health checkup market is estimated to be worth approximately NT\$18-30 billion in 2024, with a projected compound annual growth rate (CAGR) of 6.0-7.0% over the next five years. Large hospital-affiliated health checkup centers will hold approximately 60% of the market share, specialized health checkup clinics approximately 30%, and general clinics approximately 10%. Currently, the domestic health management market is highly competitive, with various types of medical institutions and health management organizations developing diversified service models based on their business strategies to meet the diverse health management needs of different groups. It is projected to grow to NT\$28-42 billion by 2030. For hospitals, clinics, and medical testing institutions, this represents a crucial foundational market with high volume, stable cash flow, and the potential for extending health management services.

In recent years, precision medicine and related technologies such as gene testing have continued to develop. Some countries have promoted the collection and analysis of gene data through policies and research projects to support medical research and clinical applications. With advancements in gene sequencing technology and the gradual reduction in testing costs, the application scope of next-generation sequencing (NGS) is also gradually expanding. Taiwan's precision health market is projected to reach approximately NT\$14.2 billion by 2025. To make health management services more comprehensive, some companies are gradually incorporating gene testing into the application scope of health management. In the future, health checkups will combine gene testing, health data, and medical imaging to provide personalized disease prediction and health management solutions.

Overall, with an aging population, advancements in medical technology, and increased health awareness, the health checkup industry is gradually transforming from traditional medical examinations into integrated health management services. In the future, health checkups will not only be disease screening tools but also a crucial foundation for personal health management. Driven by precision medicine and gene testing technologies, health checkups will become more personalized and precise, integrating with artificial intelligence, big data analytics, and digital health platforms to form a complete health management ecosystem. If Taiwan can fully leverage its advantages in its medical system, technology industry, and biotechnology research and development, and strengthen the integration of gene databases and industrial applications, it will possess considerable competitiveness and development potential in the global precision medicine and health management industry.

#### ( 4 ) Medical equipment rental

According to the latest statistics from the Department of Statistics, Ministry of Economic Affairs, the total revenue of the rental industry in 2025 was NT \$ 180.41 billion, an increase of NT\$10.86 billion compared to NT \$169.54 billion in 2024 , representing an annual growth rate of 6.4%. Among this, transportation equipment rental increased by 5.03%, mainly due to the stable

growth of long-term rental business from corporate users and the increased demand from diversified operations of car rental companies (such as mobile rentals). Personal and household goods rental saw a negative growth of 0.53%, mainly due to a decline in demand for some bicycle and sporting goods rentals. Machinery and equipment rental, however, experienced a significant growth of 11.03%, primarily due to increased demand for industrial and medical machinery and equipment, especially semiconductor equipment. Overall, the global economy slowed slightly in 2025, affected by weak global end-user demand and inventory reduction in the supply chain. Furthermore, geopolitical conflicts such as those involving Russia and Ukraine, the Middle East, and US tariff policies led to a decline in exports. However, the booming development of AI-related industries was an indispensable factor. Most leasing businesses adopt financial leasing, where the leasing company purchases the equipment needed by the lessee and then leases it back to the lessee, collecting the purchase price and interest in installments. Upon lease expiration, the lessee has the option to purchase the asset outright. Regarding our company's leasing revenue, total leasing revenue in 2016 increased by 12.77% compared to 2017. In 2019, leasing revenue increased by 1.49% compared to 2018. However, in 2020, leasing revenue decreased by 9.7% compared to 2019 due to the impact of the pandemic and increased equipment maintenance. Including other specialty businesses within the division (ophthalmology and weight loss), although ophthalmology revenue increased significantly by 74.4% in 2020 compared to 2018, the weight loss business suffered from shortages and production stoppages of original equipment manufacturer (OEM) consumables due to the pandemic, resulting in a 11.71% decrease in total revenue for the division in 2020 compared to 2018. In 2021, the department's total revenue decreased by 2.55% compared to 2020, mainly due to the two-month suspension of ophthalmology services caused by the pandemic and the transfer of weight loss consumables to the pharmaceutical distribution department. In 2022, the department's total revenue decreased by 26.09% compared to 2021, primarily due to the sale of leased assets from the Tzu Chi system's testing equipment leasing case. In 2023, the department's total revenue increased by 2.61% compared to 2021, mainly due to a 29.3% increase in revenue from ophthalmology services. In 2024, the department's total revenue increased by 20.34% compared to 2022, with both leasing and ophthalmology businesses showing growth. In 2025, the department's total revenue decreased by 14.96% compared to 2023, with both leasing and ophthalmology businesses declining. Excluding regional geopolitical and war factors, the leasing business plays an increasingly important role in domestic economic development. Affected by the COVID-19 pandemic, the rental business model has demonstrated its flexibility and resilience in business operations; for example, the rental of transportation equipment and personal and household goods has grown, reflecting the accelerating trend of the stay-at-home economy. With the advancement of technology, new and more advanced medical instruments and equipment are constantly being introduced. In addition, the medical instruments currently used by various medical

institutions are entering their replacement period. Furthermore, factors such as rising personnel costs and prices, as well as the rapid maturation and application of AI in various fields , make it even more necessary for hospitals to use their operating funds effectively. Therefore, by adopting the flexible model of medical instrument and equipment leasing, it is hoped that medical institutions at all levels can reduce one-time capital expenditures, maintain good operations, improve the quality of medical care, and achieve sustainable operation, creating a win-win situation for patients, medical institutions, and leasing service industries.

( 5 ) Dialysis business

Our company has shifted from a self-operated to a cooperative business model for dialysis operations, primarily providing logistical services such as equipment leasing and medical supplies for dialysis centers. We are redirecting working capital towards building a comprehensive health ecosystem and smart healthcare services.

1. The interconnectedness of upstream, midstream, and downstream industries :

The triangular relationship between the company, pharmaceutical manufacturers, and logistics providers represents Sheng Hong's collaborative model with upstream industries and is an innovative trend in the domestic pharmaceutical industry, resulting in a significant transformation of the supply and demand ecosystem of the drug procurement supply chain. Under this new triangular relationship, the negotiating partner for drug unit prices remains the pharmaceutical manufacturer, but the payment recipient shifts to the logistics provider. This means that many pharmaceutical manufacturers ( especially international ones ) transfer inventory pressure and accounts receivable risks to their partner logistics providers. Therefore, the logistics provider's role is no longer simply as a distributor entrusted by pharmaceutical manufacturers, but as a direct dealer transacting with the company and signing contracts. Our company collaborates with downstream industries through "innovative integrated medical services," leveraging superior pharmaceutical expertise combined with joint procurement and resource integration to effectively integrate existing channels, achieving optimal cost management to meet clients' needs for drug and equipment items and quality management. We also provide professional management consulting and entrusted operation services for health checkups and medical testing.

Upstream	Midstream	Downstream
Medical instrument and equipment supplier Drug suppliers sanitary supplies supplier logistics provider	Healthcare management consulting firm Medical technology service company Joint Procurement Center for	Medical institutions chain pharmacies healthcare system

	Pharmaceuticals	
--	-----------------	--

Source : Compiled by this company

## 2. Various development trends of the product

### (1) Supply of medicinal materials

Currently, medical institutions and pharmacies not only face financial pressures from the National Health Insurance system but also need to maintain the quality of medical services. The procurement costs and supply quality of essential medical supplies such as pharmaceuticals and medical supplies are particularly crucial to their operations. Medical institutions and pharmacies have begun to address their logistical management needs, adopting collaborative procurement and pharmaceutical logistics systems to effectively reduce procurement costs and ensure supply quality. To achieve this, the following development conditions and priorities are necessary:

- A. A large-scale joint procurement platform.
- B. Fast, timely, professional, and secure pharmaceutical logistics and supply chain information systems.
- C. Know-how support from a professional medical team.

Given the continued growth of the global and Taiwanese pharmaceutical markets in recent years, and the fact that pharmacy channels are one of the main drivers of growth, strategic cooperation with community pharmacies is also a key area for continued development.

### (2) Entrusted operation of health management

#### A. Health check

With changes in population structure and increased health awareness, health check-up services have gradually evolved from single-test items to integrated health management services, encompassing examination, assessment, follow-up, and health consultation. Our company's related services are planned in accordance with medical regulations and market demands, providing diversified health check-up solutions.

As the global population ages, governments and the public are placing increasing emphasis on health checkups. Health checkup services have evolved from primarily medical examinations and tests to integrated health management services encompassing health assessments, follow-up monitoring, and health consultations. Health checkups are no longer just a basic service provided by medical institutions, but have gradually evolved into an integrated health management system that includes diverse services such as health assessments, disease prevention, medical consultations, follow-up monitoring, and health promotion. Based on industry estimates, the domestic health care and management industry has a considerable economic scale and has been listed by the government as one of its key development industries.

Taiwan's health checkup market, while large, is characterized by stable and

sustainable growth due to its regulatory compliance and essential demand. The market is evolving from "one-off checkups" to "long-term health management services," with a potential model combining health checkups, AI analysis, genetic testing, health coaching, and ongoing monitoring. The health checkup industry is no longer just a medical service but a crucial core market within Taiwan's broader health industry.

## B. Medical Laboratory Technology

With the development of biotechnology, medical testing technology has evolved from early manual operations to automated and high-throughput analysis, playing an increasingly important role in clinical medicine. In recent years, the healthcare industry has combined information technology and data applications, and medical testing is also gradually moving towards big data analysis and precision medicine.

In response to emerging infectious diseases, advancements in molecular testing technologies, and related regulations, the application of medical testing services has gradually expanded from traditional disease diagnosis to preventative healthcare and health risk assessment. In the future, there is still room for continued deepening of interdisciplinary collaboration and the development of gene testing and precision medicine.

Advances in medical technology and changes in population structure have made medical testing increasingly important in the modern healthcare system. Medical testing is a crucial foundation for clinical diagnosis. Through the analysis of samples such as blood, urine, tissues, and genes, it assists physicians in disease diagnosis, treatment monitoring, and health assessment. In recent years, due to an aging population, the increase in chronic diseases, and heightened health awareness, the demand for medical testing has continued to grow, making it an indispensable part of the healthcare industry. Furthermore, the development of precision medicine and gene technology has led to the expansion of traditional medical testing into the fields of molecular diagnostics and gene testing, propelling the medical testing industry towards a high-tech and high-value-added development direction.

Based on changes in medical technology and market demand, Taiwan's medical testing industry will focus on "integration of precision medicine and genetic testing," "automation and smart laboratories," "centralized large-scale testing laboratories," "digital health and telemedicine," and "preventive medicine and health management." However, it also faces challenges such as "medical regulations and testing certification standards," "high investment costs for high-end testing equipment," "genetic data privacy and ethical issues," and "increasing demand for professional medical testing personnel."

Overall, medical testing laboratories in Taiwan primarily operate under three models: hospital-affiliated laboratories, independent medical testing centers, and biotechnology molecular diagnostic laboratories. With an aging population, increased health awareness, and the development of precision medicine technologies, the demand for medical testing will continue to grow. In

the future, the medical testing industry will gradually transform into an integrated healthcare service industry combining gene testing, artificial intelligence, and health management platforms. It is estimated that the Taiwanese medical testing market will continue to expand over the next decade, becoming a highly promising and important sector within the biotechnology and medical industry.

### (3) Equipment leasing

As domestic medical institutions increasingly accept asset leasing, leasing companies are expanding their operations and diversifying their services. Meanwhile, the demand for medical equipment from medical institutions is increasing year by year, leading to a wider range of medical equipment and related services offered by leasing companies. To continuously enhance the market competitiveness of medical equipment leasing and effectively meet customer needs, several key objectives have been initiated and are being pursued continuously:

- A. Expand business scale and explore new leasing areas, such as assisting primary clinics with equipment leasing and leasing business consulting, and providing equipment leasing and other medical equipment professional service providers to offer more diversified and comprehensive leasing services, including project planning services, dispatch of professional management and technical personnel and management assistance.
- B. The establishment of professional training facilities will enhance the quality of various professional personnel, strengthen industry cooperation, and enable the company to provide support and dispatch to various medical institutions at any time, thereby expanding its competitive advantage.
- C. Strengthen professional talent education and training, actively cultivate personnel with expertise in both medical business management and leasing, and be able to execute project plans. Form alliances with original equipment manufacturer (OEM) technicians or industry professionals to collaboratively develop the repair market.
- D. Collaborate with medical institutions to provide specialized equipment and jointly operate specialized departments. For example , since September 2015, a collaboration has been established with the Ophthalmology Department of Min-Sheng General Hospital, providing the latest generation of femtosecond cataract and laser correction equipment. This allows patients in need to access faster, safer, and more precise medical equipment for eye treatment, improving service standards and patient satisfaction. Statistics show that from 2015 to 2025, a total of 7,351 cataract surgeries were performed, of which 1,281 were femtosecond laser cataract surgeries, accounting for 17.43% of the total, benefiting many patients .

### (4) Dialysis services

In response to improved efficacy of medications for treating kidney disease and their ability to effectively slow the decline of kidney function, the dialysis business has transformed into providing logistical support to dialysis centers, such as equipment leasing and supply of medical consumables.

### 3. Product competition situation

#### (1) Supply of medicinal materials

##### A. Competitors

Currently, there are not many companies in the pharmaceutical industry that conduct joint procurement, mainly because there are not enough medical institutions as a basis for the scale of joint procurement.

##### B. Potential entrants

Large medical institutions, such as medical centers, are large in scale, but because most of them are public institutions or foundations rather than corporations, they are less likely to enter the formal commercial transaction market.

##### C. Supplier

In addition to the advantage of pooling resources to negotiate prices, joint procurement will also give you more control over the selection of brands and products in the future.

##### D. Buyer

The focus is primarily on the procurement needs of small and medium-sized medical institutions and pharmacies, with the aim of reducing costs through a joint procurement platform.

##### E. Substitute goods

Large distribution and logistics companies typically offer a limited range of products, which cannot fully meet the needs of medical institutions and pharmacies.

#### (2) Entrusted operation of health management

##### A. Health check

###### a. Competitors in the same industry

Some medical institutions have established their own health checkup service systems, while others operate their health checkup businesses through outsourcing partnerships. These different business models vary in service content, quality control, and pricing strategies, resulting in a high level of market competition.

###### b. Potential entrants

Small medical institutions, limited by equipment, resources, and regulatory qualifications, can offer relatively limited services and pose little competitive threat to our company. Larger medical institutions, on the other hand, are gradually developing health check-up-related businesses and have established a certain brand influence.

###### c. Supplier

Currently, all suppliers of health check-up equipment and services are able to provide corresponding products and support in line with the company's service location layout and operational planning .

d. Buyer

The demand for health check-up services comes from both group and individual clients. Group clients primarily consist of foreign migrant workers and domestic employees. For foreign migrant workers, the service is provided through labor agencies, while for domestic employees, we offer both in-person and mobile check-up services. Individual clients choose customized check-up plans based on their health management needs.

e. Alternative goods

The health checkup service process provided by our company is relatively unlikely to be replaced by other products, but the examination items may be replaced. Some advanced imaging examinations (MRI, 64-slice CT, PET-CT, etc.) may affect the selection of general health checkup items, but due to the limitations of investment costs and introduction conditions, their substitutability for the overall health checkup service is still limited.

B. Medical Laboratory Technology

a. Competitors in the same industry

The main competitors are third-party medical testing laboratories, each developing related services based on their professional fields. Currently, some suppliers, leveraging their product distribution resources and government-business connections, are rapidly gaining market share, making them a force to be reckoned with .

b. Potential entrants

The development of the biotechnology industry has led some non-clinical laboratories to pay attention to the medical testing market; however, actual entry still requires compliance with regulations and professional qualifications.

c. Supplier

There are many brands of testing reagents and equipment, with varying quality, prices, and service conditions. Our company has several managers with both professional expertise and operational management experience who can assist customers in communicating with suppliers and making integrated selections based on actual needs.

d. Buyer

The demand for clinical testing services comes from the medical end and the examinees. Indirect purchasers include examinees who receive health check services. Therefore, it is necessary to continuously provide new testing items and services in line with clinical needs to meet the needs of all purchasers at different levels .

e. Alternative goods

The development of medical testing services is showing a diversified trend, including small-volume, rapid point-of-care testing (POCT) services and

low-cost, high-volume batch processing models. However, it is necessary to seize the opportunity for change. In addition to mastering both POCT services and batch processing, it is also necessary to develop specialized and advanced testing technologies (such as trace element detection technology and molecular testing technology). The related substitution effects still need to be continuously observed .

### (3) Equipment leasing

Large leasing companies often have a financial holding company background, operating primarily through lending, and their leasing projects include factory equipment, aviation equipment, and general automobiles. However, there are relatively few professional companies specializing in medical equipment leasing. While companies like ORIX, Chailease, and Taiwan Life Insurance are currently larger in the market, their leasing projects are diversified and not specifically focused on medical equipment leasing, lacking professional integrated medical equipment services. Our specialized service department integrates various medical equipment suppliers and connects with medical institutions to form an economy of scale procurement model, creating a bargaining advantage. Our company has sound financial operations and good relationships with banks, enabling us to provide leasing services of various terms and types. Furthermore, we cater to the needs of medical institutions, providing not only equipment but also original manufacturer service support, offering comprehensive maintenance services to ensure the accurate and normal use of the leased medical equipment. In addition, our company can also provide medical institution medical needs project planning, with a professional service team covering everything from site design and operational practices to management advice.

### (4) Dialysis services

The dialysis business has transformed into a supplier model, encompassing pharmaceuticals, medical consumables, and equipment. We continue to integrate the upstream and downstream of the dialysis industry chain to provide more competitive products and expand our cooperation scope .

## ( III ) Overview of Technology and R&D

Our company operates in the medical logistics services industry, and our main focus is on business and channel expansion. We are not a research and development-oriented company , and therefore we have no future research and development plans.

## ( IV ) Long-term and short-term business development plans

### 1.Short-term plan :

- (1) Strategic alliances with medical institutions with large purchasing scale enable the pharmaceutical joint procurement framework to be expanded to a larger scale and the scope of pharmaceutical supply services to meet more of the customer's needs.
- (2) Collaborate with clinics and pharmacies to establish a pharmaceutical procurement platform, and further obtain procurement authorization based on the pharmaceutical supply of the platform.
- (3) Actively develop the health care market in the Taipei area.
- (4) Integrate external resources to establish inpatient medical examination centers in the Hsinchu area.
- (5) Actively seek out outsourced health check business from hospitals in Taichung and expand Share-hope Medicine Co., Ltd's health management services to the Taichung market.
- (6) Actively develop the medical and nursing staff dispatch market in northern Taiwan and develop diversified health promotion activities.
- (7) Plan and build a physical examination space in the hospital to serve the employees of enterprises who need to go to the hospital for health check-up services.
- (8) Develop management consulting and single-supplier services for medical laboratories.
- (9) Integrate original manufacturers of testing instruments, reagents and consumables to supply customers with competitive and high-quality testing products.
- (10) Integrate community medical resources and expand the medical equipment rental service in Taoyuan, Hsinchu and Miaoli areas.
- (11) Education and training project labor outsourcing services and other support services.
- (12) Strengthen hospital management and suggest key operational directions.
- (13) Assist the growth of the system's hemodialysis and peritoneal dialysis business.

## 2. Long-term plan :

- (1) Develop clinical trials in the field of biotechnology.
- (2) Actively develop health check-up and inspection management consulting and entrusted operation services in southern Taiwan.
- (3) Develop precision medical gene testing to provide customers with personalized precision health check services.
- (4) By attracting a wide range of pharmaceutical procurement clients, we create a more powerful procurement platform and provide new value to our clients' pharmaceutical supply.
- (5) Operate its own brand of pharmaceuticals, medical supplies, health products and cosmetics to develop market niche.

- (6) Expand equipment leasing and joint procurement items, build an information-based second-hand instrument platform, and develop specialized business operations.
- (7) Go west to the mainland and introduce Taiwan's medical management experience into the mainland market.
- (8) Enhance the image of the health and wellness sector within the system.
- (9) Each service point should have a centralized procurement or supply chain integration mechanism to reduce costs.

## 4.2 Market and Production and Sales Overview

### 1. Market Analysis

#### 1. Sales (provided) regions of the company's main products (services)

Unit: NT\$ thousand

year project	2024		2025	
	Amount	%	Amount	%
Domestic sales	4,297,675	99.01	4,297,675	99.01
Export	28,156	0.99	28,156	0.99
total	4,325,831	100	4,325,831	100

### 2. Market share

- (1) The main service areas of the pharmaceutical distribution department are currently the Greater Taoyuan area, Hsinchu, Miaoli and the Greater Taipei area. The customer base is mainly regional hospitals, primary healthcare clinics and pharmacies. The total turnover in 2024 was approximately NT \$ 1.65 billion . According to the statistics of the current status table of Taiwan's biotechnology industry, the total value of pharmaceuticals and medical devices in 2024 was NT\$ 273.1 billion, accounting for 0.60% of the total Taiwan market .
- (2) The total revenue of the health checkup market in Taiwan is estimated to be between NT\$18 billion and NT\$30 billion. The total revenue of the medical checkup management or entrusted operation services provided by our company is about NT\$1.1 billion, accounting for about 6.2 % of the health checkup market in Taiwan .

### 3. Future market supply and demand and growth

#### (1) Supply of medicinal materials

The primary clients of our pharmaceutical procurement services are small and medium-sized medical institutions and pharmacies. The current healthcare environment necessitates structural changes in the entire pharmaceutical supply chain. Through joint procurement, we can not only reliably ensure the quality of supplies but also enable these institutions to achieve lower procurement costs. Currently, no other pharmaceutical service provider in the domestic market offers a complete range of products and warehousing services to medical institutions and other clients like our company. Very few pharmaceutical companies can currently meet the needs of medical institutions for single-point procurement of a full range of products. Leveraging our existing joint procurement advantages, combined with our pharmaceutical expertise, procurement advantages, and diversified new services, we are actively pursuing market share. This allows us to build customer loyalty and dependence on our products and services early on, making it difficult for competitors to penetrate our comprehensive service network even if more enter the market in the future. The value of our pharmaceutical procurement services lies in establishing product and service channels, which will contribute to the development of future new products and services.

#### (2) Health Management

With increased health awareness and the widespread availability of medical information, health management services are gradually becoming an important direction for the development of medical services. Market observations indicate that the domestic health checkup market is quite large, with various types of medical institutions and health management organizations continuously developing related services according to their positioning. Changes in overall market demand will still depend on population structure, policy environment, and consumer needs. Even larger health checkup business opportunities will undoubtedly emerge in the future. This phenomenon has also attracted the attention of many technology companies and conglomerates, who are investing in health checkup businesses, demonstrating their strong ambition to seize the health management and care market .

#### (3) Equipment leasing

With an aging population, people are increasingly reliant on healthcare, leading to a growing demand for medical equipment from medical institutions. The development of AI (Artificial Intelligence) is further enhancing the interaction and dependence of doctors and patients on medical devices. Major medical brands are developing AI - assisted medical and diagnostic technologies to make medical decisions more accurate and rapid. The advantages of equipment leasing are foreseeable, including tax management, financial planning, preventing equipment obsolescence, and accelerating equipment replacement to maintain professional competitiveness. In recent years, more and more hospitals, clinics, and home care facilities have chosen to partner

with medical equipment leasing companies instead of direct procurement or bank financing, increasing the utilization and circulation of medical equipment and making the medical equipment leasing market a promising sector. Expanding company logistics channels can also create more leasing opportunities. The healthcare industry is shifting from a disease-centered approach to a people-centered approach, and the deep integration of big data and AI into all aspects of the pharmaceutical industry is a fiercely competitive battleground. Currently, there is a persistent global shortage of healthcare personnel, and the use of equipment (such as wearable health monitoring devices) and technology-assisted healthcare is a future trend. The company continues to develop and integrate the big health ecosystem model, strengthens upstream and downstream integrated support and makes comprehensive progress, seeking further development breakthroughs.

#### 4. Competitive Niche

The operating model of SHAREHOPE MEDICINE CO., LTD. is "providing innovative integrated medical services." It pioneered an integrated medical logistics service platform, leveraging its extensive medical experience and pharmaceutical expertise to implement flexible corporate management, effectively integrating existing channels and actively developing potential markets to create optimal profits and value. In addition to providing professional management consulting and outsourced management services for health checkups and medical testing, it utilizes joint procurement, information integration, and channel management to offer optimized cost management, meeting clients' needs for pharmaceuticals, medical supplies, and equipment in terms of both quantity and quality. The company aims to become a leading brand in the national pharmaceutical service channel.

In terms of pharmaceutical supply, the company leverages existing medical institutions and chain pharmacies as the foundation for its joint procurement scale, expanding outwards to pharmaceutical chain channels. Excellent supply chain management, cost advantages in procurement, and a suitable market integration mechanism create sufficient conditions for integrated joint procurement, fostering a new profit-sharing model and establishing its own brand products to further enhance company profitability. Furthermore, the joint procurement platform has a first-mover advantage; once a joint procurement cooperation model is established with clients, switching to other competitors in the future will incur considerable switching costs. Therefore, a well-established joint procurement platform also strengthens customer loyalty and dependence.

Our company has accumulated extensive professional experience in management consulting and outsourced operation services for health checkups and medical testing. We continuously develop medical testing technologies and operational management systems, successfully guiding medical institutions to expand their business and improve service quality. In addition to receiving numerous quality certifications, we have earned the recognition and trust of our clients. Regarding healthcare personnel support, we integrate the human resources of the healthcare

system as a strong backup, providing medical professional dispatch and management services through professional training and human resource management mechanisms to enhance overall service stability .

In terms of equipment leasing, our professional medical management, medical equipment background, and biomedical engineering expertise represent our best resources and advantages in medical equipment procurement. Furthermore, we integrate equipment to achieve optimal utilization, avoiding waste in medical equipment procurement and providing added value through subsequent maintenance and repair services, thus creating favorable conditions for expanding joint procurement channels. We further integrate medical equipment leasing and professional personnel dispatch through professional services, enabling specialized operations; this not only ensures excellent management of medical institution logistics services but also allows us to participate in and assist medical institutions in their operations, increasing company revenue.

In terms of hospital management, we rely on the medical management, medical, and nursing personnel of the medical system as a strong support, and we attach great importance to both quality and quantity. We not only have a rich and comprehensive talent pool, but also continuously improve the quality of our personnel through professional training, so as to provide our clients with the highest quality medical professional dispatch and management services.

In the dialysis business, we leverage the system's strong advantages in pharmaceutical distribution, equipment leasing, information technology, and hospital channels to provide dialysis centers with high-quality and safe medical logistical support.

## 5. Advantages and disadvantages of development prospects and corresponding countermeasures

### (1) Favorable factors for development prospects :

- A. Current health insurance policies put pressure on medical institutions regarding total health insurance reimbursement and downward adjustments to drug prices, making cost control a top priority. Establishing an integrated procurement mechanism can effectively reduce the procurement costs of medical drugs, consumables, and equipment, which aligns with market demand. Furthermore, the single-point procurement business model provides medical institutions with fast and convenient integrated medical services, bringing more stable and substantial revenue to the company.
- B. Our company has a stable existing distribution channels and a loyal customer base, forming a basic scale for joint procurement. In the future, whether it is the integration of upstream and downstream or the development of our own brand products, we have laid a foundation of customers and established smooth operating channels. With the advantage of an increasingly complete operating network, we can effectively expand our business and generate revenue.

C. Located in the center of northern Taiwan, it is close to Taipei City, where the headquarters of the top 100 companies are concentrated, and to Hsinchu Science Park, where listed technology companies are located, in the south. It has an excellent geographical location for the development of domestic health examinations, inspections and medical manpower dispatching businesses . On the international front, our company is located at the country's gateway, close to Taoyuan International Airport. Whether it is the three links across the Taiwan Straits or international routes in the future, we will have great geographical advantages.

(2) Unfavorable factors and countermeasures for development prospects :

A. Changes in drug health insurance prices and related subsidy policies affect the company's profitability .

Every year, the prices of drugs covered by health insurance are adjusted. Existing contract customers will also request the company to adjust the prices in order to reduce hospital losses, which will affect the company's profits.

Countermeasures:

When National Health Insurance drug prices are adjusted, we will immediately renegotiate supply prices with suppliers for the affected items to mitigate the impact of the price adjustment. Furthermore, the impact of National Health Insurance drug price adjustments is shared by hospitals and suppliers. Since hospitals typically have weaker bargaining power than our company, especially small and medium-sized hospitals with smaller market sizes, they often seek joint procurement channels. Therefore, when National Health Insurance drug prices are adjusted, our company will offer outsourced pharmacy services to medical institutions to enhance their competitive advantage.

B. There are many brands represented by distributors, leading to fierce price competition .

Taiwan's biotechnology industry is highly developed, and there are numerous foreign distributors and brands. The mature pharmaceutical market has led to a vicious cycle of price competition in pharmaceutical-related products. In addition, although the scale of joint procurement is gradually expanding, it is also facing pressure from customers to lower prices.

Countermeasures:

By leveraging market price information, we strive to achieve economies of scale to secure the lowest possible supply prices. We integrate upstream to obtain ample and reasonably priced supplies. Our goal is to provide clients with excellent inventory and warehousing management and zero inventory, helping them minimize pharmaceutical and medical supply stock and enhance their competitiveness.

C. Changes in national health check regulations and restrictions on health insurance payments often affect company policies and operations, leading to reduced profits .

In the pharmaceutical sector, besides the pressure from declining prices from end-users, the demand side also faces the potential for new competitors to enter the market, leading to price wars and customer loss. On the supply side, some manufacturers are unwilling to cooperate with the joint procurement platform, and may be unwilling to lower prices or supply certain items to the company. As the company's joint procurement platform grows larger, manufacturers' profits may decrease, thus some manufacturers may be unable to agree to the company's negotiating terms.

In terms of health checkups, the business environment for health checkup-related services is highly competitive due to factors such as the total amount controlled by the National Health Insurance payment system and competition from self-funded health checkups in the market. In addition, due to corporate restructuring and changes in relevant regulations, the growth trend of demand for certain regulatory health checkups may slow down .

In the field of medical equipment leasing, there is pressure from clients to lower their leasing interest rates, or there is an accumulation of equipment due to lease expiration or non-renewal, resulting in increased costs.

Countermeasures:

In the pharmaceutical sector, we will establish a regional integration mechanism to achieve economies of scale in joint procurement, enabling our company to maintain a favorable negotiating position on both the supply and demand sides in order to secure higher profits.

In terms of health check-ups, the company will assess and expand its service sources and market share through strategic alliances and cooperative operations in accordance with market changes, and adjust relevant service content in accordance with regulations. At the same time, the company will continue to cultivate professional talents in health management and medical care, establish a health check-up management talent pool, and further consolidate the company's health check-up footprint to support medium- and long-term operational development .

In the medical equipment leasing sector, we are guided by the professional needs of our clients regarding medical instruments, strengthening our medical engineering expertise to not only reduce their operating costs but also provide professional assessments. Furthermore, we are continuously planning and building an e-commerce platform for medical instruments to assess and lease/sell used equipment, increasing turnover and reducing inventory backlog. Additionally, we are acquiring distributors or agents to obtain exclusive rights and technologies for original equipment sales and maintenance, thereby expanding our market share.

#### D. Potential competitors entering the market

After our company went public, our business model became more transparent, which made it easier for potential competitors to imitate and enter the market, thus creating competition for our business.

Countermeasures:

Actively seize market share in joint procurement, leverage the advantages of being a first mover, strengthen connections and services with clients, and become an important partner of hospitals to create barriers to entry for competitors, raise the entry threshold for competitors, and increase customer switching costs.

#### Important uses and production processes of main products

Main Products	Important uses
medicinal herb supply	Joint procurement of pharmaceuticals, warehousing and logistics management, professional consulting services, and agency and distribution of health products.
Entrusted health management	Management consulting and entrusted operation of medical testing laboratories and medical health examinations, and workplace health management and planning.
Equipment rental	Medical equipment leasing, joint procurement of medical equipment, medical engineering professional services, and specialized business cooperation services

\*Our company is not a manufacturing company, so there are no production-related issues.

#### (III) Supply status of main raw materials

Main raw materials	Main Suppliers	Availability
medicinal materials	Yu-Li Co., Ltd., DKSH Co., Ltd., Joyce Enterprises Co., Ltd., Yung-Shin Pharmaceutical Industrial Co., Ltd., Chicony International Co., Ltd., Vision Optical Co., Ltd., Hsin-Tung Biotechnology Co., Ltd., Toyo Pharmaceutical Industrial Co., Ltd., Yu-Hua Biotechnology Co., Ltd., Jordan Biotechnology Co., Ltd.	good

( IV ) Explanation of significant changes in gross profit margins of major products or departments in the most recent two years

Unit: %

Main products	year	2024 gross profit margin	2025 gross profit margin	Increase/decrease
Supply of medicines, medical materials and scientific materials		12.38	11.80	-4.68%
Health and Medical Management		41.30	38.32	-7.22%
Equipment rental service		0.92	11.91	1194.57%
Description of major changes	Equipment and building rental: Gross profit from housing rentals declined in 2024.			

( V ) List of major purchasing and sales customers

1. Names of suppliers who accounted for more than 10% of the total purchases in any of the last two years, purchase amounts, proportions and reasons for changes

Unit: NT\$ thousand

pr oj ec t	2024				2025				2026 years ended the previous quarter			
	name	Amount	Percenta ge of net purchas es for the whole year [ % ]	proje ct	name	Amount	Percenta ge of net purchas es for the whole year [ % ]	proje ct	nam e	Amount	Percentag e of net purchas es for the whole year [ % ]	proj ect
1	Yuli	831,236	27.17	none	Yuli	844,337	27.08	none	Yuli	226,203	27.06	non e
2	other	2,227,679	72.83		other	2,273,417	72.92		othe r	609,665	72.94	
	Net purch ases	3,058,915	100.00		Net purch ases	3,117,754	100.00		Net purch ases	835,868	100.00	

Reasons for the increase/decrease: The amount owed to suppliers may have changed due to business needs.

2. Names of customers who have accounted for more than 10% of total sales in any of the last two years , sales amount, proportion and reasons for change:

Unit: NT\$ thousand

pr oj ec t	2024				2025				2026 years ended the previous quarter			
	name	Amount	Percent age of net sales for the year [ % ]	Relat ionsh ip with the Issue r	name	Amount	Percent age of net sales for the year [ % ]	Relat ionsh ip with the Issue r	name	Amount	Percentag e of net sales for the year [ % ]	Relat ionsh ip with the Issue r
1	Min Shin g Gene ral Hos pital	1,655,672	38.27	Its head is the same perso n as the pare nt comp any's chair man	Min Shin g Gene ral Hos pital	1,616,425	37.09	Its head is the same perso n as the pare nt comp any's chair man	Min Shin g Gene ral Hos pital	366,637	34.04	Its hea d is the chair man of the boar d of direc tors of the com pany
2	othe r	2,670,159	61.73		other	2,741,442	62.91		other	710,435	65.96	
	Net sale s	4,325,831	100		Net sales	4,357,867	100		Net sales	1,077,072	100.00	

Reasons for increase/decrease: In 2025, revenue from medical management and health checkup services increased compared to 2024.

### 4.3 Information about employees

(l) Information on employees in the last two years and up to the date of publication of the annual report

year		2024	2025	As of the end of the current year March 31, 2026
staff Num ber of peop le	Number of employees at the beginning of the period	141	147	175
	Number of people leaving this period	28	49	4
	Number of new employees	34	77	13
	total	147	175	184
Average age		43.58	44.19	45.16
Average years of service		6.06	6.23	5.76
stud y cale ndar point cloth Com pare Rate	PhD	3.4%	3.4%	3.3%
	master	14.3%	13.1%	13.0%
	College	76.9%	72.6%	73.4%
	high school	4.0%	9.1%	8.7%
	Below high school	1.4%	1.7%	1.6%

## (II) Employees obtaining certificates and licenses

job title	Employee code	Certificate Name	Issuing authority	Date of acquisition
Deputy Manager	A003976	1. CIA Certified International Auditor 2. Internal Auditor Certification	1. IIA (Institute of Auditors) 2. Internal Audit Association of the Republic of China	1. 2006/05 2. 2007/05/22
manager	A000362	1. Class A Occupational Safety Technician Certificate 2. Class B Safety and Health Technician Certificate	1. Council of Labor Affairs, Executive Yuan 2. Council of Labor Affairs, Executive Yuan	1. 2004/07/18 2. 1997/12/21
manager	A000851	1. Class B Waste Disposal Technician 2. Operators of specific high-pressure gas equipment 3. First type of pressure vessel operator 4. Supervisor of oxygen-deficient work areas . 5. Fire safety manager	1. Environmental Protection Administration Environmental Protection Personnel Training Institute 2. Taiwan Provincial Industrial and Commercial Safety and Health Association 3. Taiwan Provincial Industrial and Mining Safety and Health Technicians Association 4. Taiwan Provincial Industrial and Commercial Safety and Health Association 5. Fire Safety Education and Research Foundation	1. 2003/03/11 2. 2001/06/15 3. 2001/01/18 4. 2002/03/29 5. 2009/07/09
manager	A 000865	1. Class A Occupational Safety and Health Supervisor	1. China Occupational Safety and Health Management Association	1. 2026/01/26
manager	P000018	1. ISO 15189 Medical Laboratory Accreditation Staff training qualification certificate	1. Nationally Certified Foundation	1. 2011/06/15
Team leader	P001452	1. ISO 15189 Medical Laboratory Supervisor Training Certificate	1. Nationally Certified Foundation	1. 2016/12/18
Team leader	P00167 8	1. ISO 15189 Medical Laboratory Supervisor Staff training qualification certificate	1. Nationally Certified Foundation	1. 2016/12/18

Commissioner	P000763	1. ISO 15189 Medical Laboratory Supervisor Staff training qualification certificate	1. Nationally Certified Foundation	1. 2010/07/19
Higher Vocational College	A002878	1. Certified ESG Sustainability Manager (CESGA)	1. Taiwan Management Association	1. 2024/03
Commissioner	A000724	1. Information Security Engineer - Basic Competency Assessment	1. Ministry of Economic Affairs Industrial Talent Competency Assessment	1. 2023/12/31
Manager	A002883	1. Information Security Engineer - Basic Competency Assessment	1. Ministry of Economic Affairs Industrial Talent Competency Assessment	1. 2023/12/31

### (III) Employee Code of Conduct and Reward and Punishment Measures

#### 1. Employee Service Code

In order to establish systems, improve organization and management, our company formulates employee work rules in accordance with the Labor Standards Act and relevant government regulations.

All personnel management regulations or personnel operation regulations shall be handled in accordance with the employee work rules. The service code is summarized as follows:

- (1) Employees shall comply with government laws and company regulations, obey the reasonable supervision of their supervisors, pay attention to work safety, cherish the company's reputation, demonstrate team spirit, and work hard to perform their duties.
- (2) Employees should behave appropriately, be loyal and responsible, and have honest conduct. One must not use his or her position to engage in corruption, accept gifts, or seek benefits for others or oneself. When handling official business, the principle of honesty and integrity must be strictly followed, and no actions that damage the company's rights and interests should be taken.
- (3) Employees shall not disclose information related to the company's business, technology, salary, customer information, etc., and shall not use the company's name to conduct any external affairs without approval.
- (4) Employees who manage the money, assets, documents, etc. of the company or its affiliated companies must register them clearly and complete the procedures. If there is any loss, the company may request compensation in accordance with the law.

#### 2. Employee Reward and Punishment Measures

In order to regulate employee rewards and punishments, establish fair and reasonable reward and punishment standards to motivate employees and strengthen group discipline, the company has formulated the "Employee Reward and Punishment Methods". This includes the proposal, review, decision-making and related operations of reward and punishment cases. Reward and punishment cases are reported by supervisors to the general manager for approval, and then transferred to the personnel department for follow-up work.

(1) The Company's rewards are divided into three levels:

Reward: A bonus of 500 yuan will be awarded, and a reward and punishment order will be issued.

Minor Merit: Award a bonus of 1,500 yuan and issue a reward and punishment order.

Great Merit: A bonus of 3,000 yuan will be awarded, and a reward and punishment order will be issued.

(2) The Company's penalties are divided into four levels:

Admonition: A fine of 500 yuan and the issuance of a reward and punishment order.

Minor offense: A fine of RMB 1,500 and the issuance of a reward or punishment order.

Serious offense: A fine of RMB 3,000 and the issuance of a reward or punishment order.

Dismissal: To terminate an employee's job and remove him from his position.

#### **4.4 Environmental Protection Expenditure Information**

(1) The total amount of losses (including compensation) and penalties incurred by the company due to environmental pollution in the most recent year and up to the date of publication of the annual report, and disclosure of its future response measures and possible expenditures: None.

(II) Future response measures and possible expenditures: This situation has not yet occurred .

(III) Protection measures for the working environment and personal safety of employees:

In order to improve the health of our employees and maintain workplace safety, our company conducts regular employee physical examinations every year in accordance with the relevant provisions of the "Occupational Safety and Health Law" and the "Labor Health Protection Rules", which go beyond the regulations. In addition, in order to protect the workplace safety of employees, prevent sexual harassment in the workplace, and maintain gender equality and personal dignity, the Company has established sexual harassment prevention measures,

complaints and disciplinary procedures in accordance with gender equality work regulations. In addition to the above, our company purchases labor and health insurance and arranges group insurance for employees in accordance with labor-related laws to ensure workplace safety for colleagues and protect the rights and interests of employed employees.

1. Workplace safety:

- (1) Sexual harassment prevention and control work: The company has a complaint committee and relevant methods to conduct investigations and penalties.
- (2) Provide necessary health and first aid facilities, strive to reduce hazards to employee safety and health, and prevent occupational hazards.
- (3) Drinking water equipment that meets drinking water standards shall be installed in the workplace and shall be inspected, cleaned and maintained every quarter.
- (4) The environmental hygiene and cleaning management of the workplace shall be entrusted to a professional cleaning company to carry out cleaning and disinfection at least once every quarter to ensure the maintenance of the hygienic quality of the working environment.
- (5) The workplace conducts working environment monitoring (such as carbon dioxide, noise, etc.) twice a year to ensure the safety and health of employees.
- (6) Implement a comprehensive smoking ban in accordance with the Tobacco Control Act.
- (7) Workplace safety is entrusted to a professional security company to conduct daily patrols and install cameras to ensure the personal safety of employees.
- (8) In order to protect the safety of our employees, in addition to purchasing labor and health insurance in accordance with the law, we also provide insurance programs such as business trip travel insurance.
- (9) In accordance with the "Labor Health Protection Rules", special medical staff are deployed to handle labor health management, occupational disease prevention, health promotion and other labor health protection matters, and occupational safety nurses are arranged to provide on-site services twice a month.

2. Fire safety:

- (1) A complete fire protection system shall be installed in accordance with laws and regulations, including alarm system, fire protection system, escape system, etc.
- (2) The fire protection equipment in our building is commissioned to a qualified professional testing consulting company to conduct system unit function testing every month.
- (3) Promotional activities and professional courses are held at least once a year to enable colleagues to understand escape routes and become proficient in the use of facilities, etc.

3. Health management:

- (1) We arrange employee health checks every year to ensure that our colleagues are in good health.
- (2) The company has a first aid kit and medicines.

- (3) The company cooperates with hospitals every year to provide employees with influenza vaccinations.
- (4) Cooperate with hospitals to encourage employees to participate in health lectures and first aid training held by hospitals, so as to establish health awareness from a daily basis and prevent accidents.

## 4.5 Labor-Capital Relations

( 1 ) The Company's employee welfare measures, continuing education and training, retirement system and implementation status, as well as labor-management agreements and employee rights protection measures.

### 1. Employee welfare measures:

- (1) Pursue labor insurance and health insurance for employees in accordance with the Labor Insurance Act and the National Health Insurance Act, and allocate labor pensions in accordance with the law.
- (2) Establish an employee welfare committee to provide benefits including marriage, childbirth, funeral subsidies, scholarships, hospitalization condolence money, birthday gifts, employee travel, year-end parties, celebration activities, three festival gifts , clubs, books, newspapers and magazines, etc.
- (3) After being calculated by the Human Resources Department and approved by the responsible supervisor, the employee's salary will be remitted to the employee's account via bank transfer on the payday of each month.
- (4) Performance bonus: The business unit shall submit the performance bonus calculation method, which shall be implemented after approval.
- (5) Year-end bonus: The year-end bonus is allocated based on the company's annual operating conditions. The payment method and related contents are handled in accordance with the year-end bonus application submitted for that year.

### 2. Further study and training measures:

#### (1) Education and training of new employees :

On the day new employees report to work, the human resources department will be responsible for explaining the personnel regulations and company profile, and each department will then be responsible for introducing their supervisors and colleagues, work environment, work processes, and job descriptions .

#### (2) On-the-job employee education and training :

In order to implement lifelong learning, promote the growth of colleagues' professional knowledge, skills and humanistic qualities, thereby improving service quality and performance and driving the overall development of the company, the "Employee Continuing Education and Training Measures" have been specially formulated. Continuing education training is divided into "on-the-job education" and "advanced education". "On-the-job education" includes

internal on-the-job training, professional courses, special lectures, etc.  
"Continuing education" includes personal study or participation in external seminars, conferences, annual meetings, courses, etc.

## 2025 Annual Employee Education and Training Statistics

Department	Job title	Name	Class Dates	Hours	Course Name	Course organizer
Human Resources Department	manager	Li Xiaoping	20250328	1.5	Management Trainee Program (MA)	Human Resources Weekend Community Co., Ltd.
Administration Department	Deputy General Manager	Cai Yufang	20250425	3	Senior Management Compensation and ESG Performance System Design	China Corporate Governance Association
Information Planning Office	engineer	Wei Kailun	20250217-20250218	16	ISO/IEC 27001:2022 Information Security, Cybersecurity and Privacy Protection - Information Security Management System (ISMS) - Auditor/Lead Auditor Training Course	SGS Taichung Management Institute
Information Planning Office	engineer	Wei Kailun	20250224-20250226	twenty four	ISO/IEC 27001:2022 Information Security, Cybersecurity and Privacy Protection - Information Security Management System (ISMS) - Auditor/Lead Auditor Training Course	SGS Taichung Management Institute
Human Resources Department	manager	Li Xiaoping	20250617	4	Seminar on the Acceptance, Investigation, and Evaluation of Complaints Regarding Workplace Violations (Bullying, Sexual Harassment, Discrimination) and Sharing of Practical Experiences	Asian Chinese Health Industry Human Resource Management Association
Human Resources Department	manager	Li Xiaoping	20250710	6	2025 Hospital Human Resources Management Seminar - Making Change Visible, Creating Happy Healthcare Institutions	Taiwan Hospital Association
Accounting Office	Deputy Manager	Deng Yurong	20250724-20250725	12	Continuing Education Program for Accounting Supervisors of Securities Firms and Stock Exchanges	Accounting Research and Development Foundation
Audit Office	Commissioner	Chen Yongchun	20250901	6	It is essential to understand the key considerations and impacts of IFRS S1/S2 on internal control and internal audit.	Internal Audit Association of the Republic of China

Human Resources Department	manager	Li Xiaoping	20250823	2	Performance Management Solutions	Not just human resources company
Human Resources Department	manager	Li Xiaoping	20250829	1.5	Annual Education and Training Planning Practices - Starting from Survey Techniques	HR Weekend
Health Management Department	Deputy Manager	Huang Rujun	20250902-20250903 20250910-20250911 20250916	40	Biosafety Management Personnel Training Course	Taoyuan Vocational Training Center, affiliated with the China Association of Occupational Safety and Health Management
Audit Office	Commissioner	Chen Yongchun	20250917	6	Advanced Data Editing Workshop on Financial and Audit Excel Functions (Hidden Techniques)	Internal Audit Association of the Republic of China
Audit Office	Deputy Manager	Ye Peiyu	20251017	6	It is essential to understand the key considerations and impacts of IFRS S1/S2 on internal control and internal audit.	Internal Audit Association of the Republic of China
Accounting Office	Commissioner	Hsiao Peiling	20251017	6	2015 Uniform Invoice Implementation and Tax Law Seminar	Northern District State Taxation Bureau
Human Resources Department	manager	Li Xiaoping	20251017	2	Talent Training Course: Mastering ESG and Net Zero vs. AI Implementation Guide for Small and Medium-Sized Teams	Yuanzhi Enterprise Management and Development Industry-Academia Alliance
Specialist Service Department	manager	Chen Shouhui	20251017	2	Talent Training Course: Mastering ESG and Net Zero vs. AI Implementation Guide for Small and Medium-Sized Teams	Yuanzhi Enterprise Management and Development Industry-Academia Alliance
Accounting Office	Commissioner	Hsiao Peiling	20251105	6	Analysis of IFRS 18 "Presentation and Disclosure in Financial Statements" Standard and Practice	Accounting Research and Development Foundation
Legal Affairs Office	Senior Specialist	Lin Lifan	20251120	8	Related-Party Transaction Legal Risk Workshop	Taiwan Academy of Banking and Finance
Accounting Office	Associate	Huang Yamei	20251127-20251128	12	Continuing Education Program for Accounting Supervisors of Securities Firms and Stock Exchanges	Accounting Research and Development Foundation

Audit Office	Deputy Manager	Ye Peiyu	20251117	6	Analysis of IFRS 18 "Presentation and Disclosure in Financial Statements" Standard and Practice	Accounting Research and Development Foundation
Human Resources Department	manager	Li Xiaoping	20251207-20251228	42	Class A Occupational Safety and Health Supervisor	China Occupational Safety and Health Management Association

3. The company's retirement, pension, layoff and resignation system :

(1) Retirement, layoffs, occupational accident benefits, and pensions :

In order to regulate employee retirement, layoffs, occupational accident compensation, and pensions, the Company has formulated the "Employee Retirement, Layoff, and Occupational Accident Compensation Regulations". All matters related to employee retirement, layoffs, occupational accident subsidies, and compensation, such as identification, application, and payment, are spelled out in the regulations. The summary is as follows:

A. Retirement:

Employees of our company who meet any of the following conditions may voluntarily retire.

Continuously worked for the company or its affiliated companies for more than 25 years.

Those who have worked for the Company or its affiliated companies for more than 15 consecutive years and are 55 years of age or older.

Those who have worked for the Company or its affiliated companies for more than 10 consecutive years and are 60 years of age or older.

The Company has established a Labor Retirement Reserve Supervisory Committee and formulated the Labor Retirement Reserve Supervisory Committee's organizational charter. Representatives are elected from among the old system employees to serve as committee members to manage the old system retirement funds. In accordance with Article 56 of the Labor Standards Act, 2% -15% of the total monthly salary of old system employees is set aside as a retirement reserve fund. The pension payment shall be made from the retirement reserve account set aside by the company, and the shortfall shall be made up by the company.

The Labor Retirement Reserve Fund Supervisory Committee holds meetings quarterly to review the retirement reserve fund allocation and balance, review the retirement fund applications of old-system employees, and obtain information on employees who have chosen the old retirement system. In addition, for new employees, in accordance with the Labor Pension Regulations, 6% of the labor retirement grade will be contributed to the employee's personal pension account at the Labor Insurance Bureau every month; for those who voluntarily contribute to their pensions, the voluntary

contribution rate will be deducted from the employee's salary and transferred to the employee's personal pension account at the Labor Insurance Bureau.

**B. Layoffs:**

If the Company encounters any of the circumstances specified in Article 11 of the Labor Standards Act, it may terminate the labor contract with the employee by giving advance notice and pay severance pay in accordance with the law. Those who are laid off must provide advance notice in accordance with Article 16 of the Labor Standards Act. When a company lays off an employee, it should list the name, gender, age, address, telephone number, job, reason for layoff, and whether or not job counseling is required of the laid-off employee 10 days before the employee leaves the company, and report the list to the competent authority and public employment service agency for notification.

**C. Occupational accident benefits:**

When an employee becomes disabled, injured, becomes ill, or dies due to an occupational accident, the company will provide compensation in accordance with the Labor Standards Act. However, if the company has already paid compensation for the same accident in accordance with the Labor Insurance Act and other laws and regulations, such compensation may be offset. When an employee is injured or suffers from an occupational disease, the company will compensate for the necessary medical expenses. The types of occupational diseases and the scope of medical treatment shall be in accordance with the relevant provisions of the Labor Insurance Act.

**D. Compensation:**

If an employee of our company dies of illness, accident, danger encountered in the performance of duties or death caused by illness during his/her employment, the company will pay a pension.

**(2) Resignation system:**

In order to enable employees to resign under reasonable and legal circumstances and ensure smooth business handover, we have formulated the "Employee Resignation Management Measures". The resignation of all full-time or part-time employees of the Company shall be managed in accordance with these regulations. Employees should submit resignation applications in accordance with regulations and complete relevant resignation procedures .

**4. Collective Agreement :**

The Company promotes labor-management harmony and improves labor welfare through employee welfare committees and labor-management meetings. Both of the above organizations elect labor representatives through employee elections to propose, coordinate, communicate and supervise labor-management related issues on behalf of employees, including but not limited to labor-management relations, working conditions, labor welfare, workplace sexual harassment and bullying, employee diversity and equality issues. Employees are

ex-officio members and have the right to raise the above issues to the labor committee for discussion and negotiation.

In accordance with the "Labor-Management Meeting Implementation Regulations" and Article 83 of the Labor Standards Act, relevant regulations are formulated to hold labor-management meetings regularly. Meetings are held quarterly, four times a year.

In accordance with Article 5 of the Employee Welfare Fund Regulations, public institutions and employees jointly contribute to the employee welfare fund and establish an employee welfare committee. The employee welfare committee meets once a quarter and four times a year.

The company, with representatives from both labor and management, will discuss and properly handle matters through meetings, and track progress and results at the next labor-management or employee welfare meeting.

Cooperate with the government's labor law amendments, implement various labor leave management spirits, and remind employees of the importance of balancing work and vacation.

5. Measures to protect employees' rights and interests:


In order to protect the rights and interests of employees, the Company has clearly stipulated relevant measures for employee benefits in accordance with the law, including various subsidy measures and a mechanism for distributing bonuses during the three festivals. A Labor Retirement Reserve Fund Supervisory Committee will be established to be responsible for the preparation, allocation, custody, use and related legal and regulatory matters of the retirement fund. In order to deal with possible sexual harassment between employees and safeguard gender equality and personal dignity at work, we have formulated "Sexual Harassment Prevention Measures, Complaints and Disciplinary Measures" in accordance with the Gender Equality Work Regulations .

( 2 ) A description of the losses incurred by the Company due to labor-management disputes in the most recent two years and up to the date of publication of the prospectus, and the estimated amounts and response measures that may occur currently and in the future. If no reasonable estimate is available, the facts that cannot be reasonably estimated shall be explained: The Company has established a complete communication channel and is committed to creating a good and harmonious labor-management relationship. To date, it has not suffered significant losses due to labor-management disputes. In the future, we will continue to improve communication and coordination between labor and management so that all employees can grow in a safe and enjoyable working environment.

## 4.6 Information and communication security management

### 1. Information Security Risk Management Framework

To strengthen information operation security and management, our company has established an interdepartmental Information Security Committee. This committee is responsible for formulating information security management policies, promoting "Information Operation Procedures," coordinating interdepartmental information processing workflows, reviewing the company's information security policies and their implementation results, and regularly reporting to the Board of Directors on the company's information security governance overview. The organizational structure of the Information Security Committee is as follows:



The Information Security Committee consists of: one chairperson, one director-general, one executive secretary, and six members. Information security team members: 1 internal audit team, 1 incident handling team, 1 asset and risk management team, and 1 implementation and document management team .

### ( II ) Information and communications security policy

"Implement information security, reduce cybersecurity risks, increase customer trust, and improve operational performance."

To strengthen information security management and ensure the effective operation of management systems, thereby guaranteeing the confidentiality, integrity, and availability of our information assets, we have established specific policies and regulations to provide secure management for the continuous operation of our business, achieving sustainable business objectives and complying with

relevant regulatory requirements .


Our company has established a complete Information Security Management System (ISMS) , created a cross-unit information security organization, ensured the availability of continuous business operations, implemented an information security risk assessment mechanism, improved the effectiveness of information security management, implemented an internal information security audit system, ensured the effectiveness of information security management implementation, assisted the Group's business development and sustainable operation, and ensured that business activities comply with policy and legal requirements. Through continuous planning, execution, verification and action, we ensure the effective operation of the system, and that activities are documented or recorded in the system. All accidents or anomalies should be assessed and confirmed in accordance with procedures.

( III ) Specific management plan and resources invested in information security management.

Information security management measures implemented by our company

Type	Illustrate	Related Assignments
Access Management	Management of system accounts and permissions	Information Request Form
Access Management	Access to internal and external data, email transmission, and filtering control	Internal/external access control measures Control of data leakage channels Operation behavior trajectory record
External defense	Network security, antivirus software, outsourcing and cooperation vendors	Network security maintenance, network point installation Legal copyright, antivirus software installation Signing a confidentiality agreement Join TWCERT/CC cybersecurity alliance
System Repair	System usage status and procedures for handling connection interruptions	Maintenance notification system
Database Management	Database backup	Back up your data regularly Off-site backup

Our company's emergency response plan for information systems is as follows, and the reporting and handling of cybersecurity incidents shall be carried out in accordance with the procedures outlined herein.



( IV ) Explanation of the implementation status in 2025

1. Since the establishment of the "Information Security Committee" in September 2019, our company has held regular meetings of the Information Security Committee every quarter.
2. Joined the TWCERT/CC cybersecurity alliance in August 2022.
3. A total of 4 meetings were held in 2025 (March 6, June 10, September 3, and December 11).
4. In 2025, we carried out important cybersecurity issues and events, including equipment failure drills, social engineering drills, cybersecurity education and training, access control account verification, illegal software verification, cybersecurity risk assessment, etc.
5. In 2023, the Information Security Committee passed a resolution, and in 2024, ISO 27001:2022 was officially implemented. The certificate was obtained on March 21, 2025, and is valid until March 20, 2028. In 2025, the ISO 27001:2022 PDCA cycle was continuously implemented to ensure that the organization can effectively manage risks and maintain the confidentiality, integrity and availability of information assets within an acceptable range.
6. The status of information security implementation was reported at the 11th meeting of the 8th Board of Directors on December 19, 2025.
7. List the losses, potential impacts, and countermeasures suffered due to major cybersecurity incidents in the most recent year and up to the date of publication of the annual report. If such losses cannot be reasonably estimated, state the fact that they cannot be reasonably estimated: there is no such situation.

## 4.7 Intellectual Property Management

### Smart Property Management Plan

In order to protect the achievements of Sheng Hung Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") in the process of market development, and at the same time strengthen the competitive advantages of products, enhance corporate profits, create market value, and consolidate market position.

In response to the company's diversified business layout and future development strategy, the company has formulated an intellectual property management plan related to its operating objectives or development strategy to support the growth of new businesses, strengthen corporate governance, safeguard the rights and interests of the company, partners and customers, and ensure sustainable operation.

1. Scope of intellectual property  
Our intellectual property includes trademark rights, copyrights, and trade secrets.
2. Applicable to  
Our employees (including those on temporary and permanent contracts) and external persons involved in our related projects or collaborations.
3. Smart Property Management Policy
  - i. Strengthen the protection of the company's intellectual property and implement intellectual property risk management.
  - ii. We will improve the management of our existing intellectual property to avoid infringing on the intellectual property rights of others.
  - iii. In line with the company's operational goals, we will strengthen the analysis and layout of intellectual property.
4. Smart asset management goals
  - i. Conduct at least one intellectual property education and training session each year.
  - ii. In response to factors such as the company's operational goals, the overall external environment, and changes in regulations, the current intellectual property management plan is reviewed annually and revised or adjusted as necessary.
  - iii. Report to the board of directors on the implementation of the intellectual property management plan at least once a year.
5. Principles of Intellectual Property Protection
  - i. Our company should apply for intellectual property protection as soon as possible for all innovative or technologically valuable achievements (systems, processes, designs, instrumentation technologies, etc.); all relevant information must be kept confidential before the application.
  - ii. Before applying for intellectual property rights, it should be confirmed that there is no infringement. When applying it to company business, in addition to the relevant legal requirements for intellectual property rights management and infringement protection such as trademark law, patent law, copyright law, and trade secret law, the commercial and technical value should also be taken into

- consideration.
- iii. If research and development is involved, our R&D personnel should properly preserve basic design and R&D records for future use in proving or resolving disputes.
  - iv. Any employee of this company who wishes to publish or introduce innovative achievements to the outside world must first obtain approval from their supervisor; if intellectual property rights can be applied for, the relevant application procedures must be completed first.
  - v. If the company's intellectual property rights are disputed or subject to litigation, the relevant personnel or entities should assist the company in providing necessary information.
  - vi. When our company has outsourced research and development or system development needs, we should require the outsourced vendors to not infringe on the rights of others through contracts; otherwise, the outsourced vendors shall be liable for compensation.
6. Principles of Intellectual Property Use
- i. Our company should value its own intellectual property rights while respecting the intellectual property rights of others.
  - ii. When introducing medical equipment, system platforms, software, instrument technologies or processes, our company must ensure that it will not infringe on the rights of others and should require the technology provider to assume relevant responsibilities in the contract.
  - iii. The company shall manage the intellectual property owned by each of its subsidiaries in accordance with their respective rights and responsibilities, based on the category or attribute of the intellectual property owned.
7. Trademark Management
- i. Our company shall use the trademarks registered in our company name on goods, documents, advertisements and websites relating to our business .
  - ii. We regularly review the number and status of trademark cases filed by the company each year, and examine the consistency between the product or service name and the trademark in terms of name and market to ensure that the company's products or services have corresponding trademark protection. In addition, we also review and assess the necessity of registering and maintaining trademarks in the company's name to avoid maintenance costs.
8. Copyright Management
- Regarding our company's network software system, the IT department grants access permissions to each employee according to their usage needs for management purposes. We also conduct regular annual checks for unauthorized software to ensure that employees' personal computers use legally authorized software.
9. Trade secret management
- i. Regularly review the contents of the "Confidentiality Agreement" and "Employment Contract" signed with employees each year, and revise them as necessary.

- ii. All network and computer access to our company is based on employee personal account passwords, and passwords are required to be changed regularly. As for the company's software systems, the IT department grants access permissions to each employee according to their usage needs for management purposes, and checks are conducted annually to ensure that personal computers have antivirus software installed.
10. Information disclosure  
The Company shall disclose its intellectual property management plan and the consolidated implementation status of intellectual property management at least once a year in its annual report, corporate social responsibility report or company website.

Smart Property Management Plan Implementation Guide				
Item	Implementation indicators	Execution content	Implementation status	whether Achieve
1	Smart asset management goals	Intellectual Property Series Education and Training	Training on handling trade secrets in the second half of 2025	V
2		Review the intellectual property management plan	In the first half of 2025, the intellectual property management plan will be reviewed and refined (as described above).	V
3		Report the implementation status to the board of directors.	on December 19, 2025 .	V
4	Trademark Management	Use of our registered trademarks in matters relating to our business.	Confirmation of the use of Sheng Hong Pharmaceutical's logo in external products, documents, advertisements, and websites.	V
5		The number and status of the company's trademark cases are reviewed annually.	Trademark inventory to be completed in the second half of 2025, and trademark validity periods to be confirmed.	V
6	Copyright Management	Regularly check for illegal software every year	Complete the illegal software check on employees' personal computers in the second half of 2025.	V
7	Trade secret management	Regularly review the contents of the "Confidentiality Agreement" and "Employment Contract".	The content review of the "Confidentiality Agreement" and "Employment Contract" will be completed in the second half of 2025.	V
8		Antivirus software installation checks are conducted annually.	Complete the installation and verification of antivirus software on employees' personal computers in the second half of 2025.	V

9	Information disclosure	Smart Property Management Plan	Disclosed on the company's official website in the Corporate Governance / Risk Management section.	V
10		Implementation status of smart property management		V

#### 4.8 Important Contracts

Contractual nature	party	Contract start and end dates		Main content	Restrictions
		rise	until		
Outsourcing Service Contract	Taiwan Semiconductor Manufacturing Company Limited Liability Company	2024/01/01	2028/12/31	Health Center Business Services	none
Medical Service Contract	Min Sheng General Hospital	2022/01/01	2031/12/31	Health checkup services	none
Medical Service Contract	Min Sheng General Hospital	2022/01/01	2031/12/31	Inspection services	none
Medical Service Contract	Longtan Minsheng Hospital	2022/01/01	2031/12/31	Inspection services	none
Medical Service Contract	Longtan Minsheng Hospital	2022/01/01	2031/12/31	Health checkup services	none
Medical Service Contract	Dayuan Min-Sheng Hospital	2022/01/01	2031/12/31	Inspection services	none
Medical Service Contract	Kung Memorial Hospital Foundation	2024/01/01	117/12/31	Health checkup services	none
Yonggeng Health Checkup Support Cooperation Agreement	Yonghe Gengxin Hospital, Catholic Medical Foundation	2023/06/15	2026/06/14	Health checkup services	none
Yonggeng High Procuratorate Center Cooperative Operation Case	Yonghe Gengxin Hospital, Catholic Medical Foundation	2023/06/15	2026/06/14	Health checkup services	none
Procurement Contract Documents and Agreements for the Medical Supplies of National Taiwan University Hospital	National Taiwan University Hospital	2023/05/01	2026/06/30	Procurement Case Number: Case No. UD11E20A Name of the tender item: Biochemical and immunological testing reagents (with instruments)	none
Equipment Procurement Contract	Ruide Medical Equipment Co., Ltd.	2025/01/23		Extracorporeal shock wave therapy system	none
Equipment Procurement Contract	Yuanyou Industrial Co., Ltd.	2025/02/05		Ultrasonic endoscope main unit	none

Contractual nature	party	Contract start and end dates		Main content	Restrictions
		rise	until		
Equipment Procurement Contract	Lianmingsheng Trading Co., Ltd.	2025/03/13		Carotid artery and transcranial ultrasound scanner	none
Equipment Procurement Contract	Huafeng Technology Co., Ltd.	2025/06/27		Digital color ultrasound scanner	none
Equipment Procurement Contract	GE Healthcare Co., Ltd.	2025/03/28		Two-way angiography system	none
Equipment Procurement Contract	Hui Dun Trading Co., Ltd.	2025/05/19		Digital imaging system	none
Equipment Procurement Contract	PerkinElmer Ltd.	2025/07/07		Inductively Coupled Plasma Mass Spectrometry System (ICP-MS)	none
Equipment Procurement Contract	Vision Optics Technology Co., Ltd.	2025/08/08		Alcon Surgical Microscope	none
Equipment Procurement Contract	Vision Optics Technology Co., Ltd.	2025/08/08		Scanning frequency light source tomography biometer	none
Equipment Procurement Contract	Jiuhe Medical Co., Ltd.	2025/09/25		Fusion optical surgical microscope	none
Equipment Procurement Contract	Yixin Industrial Co., Ltd.	2025/10/22		Multifunctional operating table	
Medical Equipment Rental Contract	Min Sheng General Hospital	2025/01/01	2026/12/31	3D rigid endoscope	none
Medical Equipment Rental Contract	Min Sheng General Hospital	2025/02/01	2028/01/31	Centrifugal pump system	none
Medical Equipment Rental Contract	Min Sheng General Hospital	2025/03/01	2028/02/29	Electronic gastrointestinal endoscope	none
Medical Equipment Rental Contract	Min Sheng General Hospital	2025/04/01	2028/03/31	Two items including hydrogen peroxide low-temperature plasma sterilizer	none
Medical Equipment Rental Contract	Precision Health Co., Ltd.	2025/05/01	2028/04/30	Color Doppler ultrasound scanner (including two probes) and breast probe	none
Medical Equipment Rental Contract	Min Sheng General Hospital	2025/06/01	2028/05/31	Portable echocardiogram scanner (including two probes)	none
Medical Equipment Rental Contract	Min Sheng General Hospital	2025/06/01	2028/05/31	Electric burner/argon plasma hemostasis device and ultrasound endoscope main unit	none

Contractual nature	party	Contract start and end dates		Main content	Restrictions
		rise	until		
Medical Equipment Rental Contract	Longtan Minsheng Hospital	2025/08/01	2027/07/31	Multifunctional single-hydraulic pusher and double-hydraulic pusher	none
Medical Equipment Rental Contract	Min Sheng General Hospital	2025/10/01	2028/09/30	Carotid artery and transcranial ultrasound scanner	none
Medical Equipment Rental Contract	Min Sheng General Hospital	2025/11/01	2028/10/31	Surgical microscope	none
Medical Equipment Rental Contract	Min Sheng General Hospital	2025/12/01	2028/11/30	Inductively Coupled Plasma Mass Spectrometry System (ICP-MS)	none

## 5. Review and Analysis of Financial Status and Financial Performance and Risk Issues

### 5.1 Financial Status

Unit: NT\$ thousand

project	year	2024	2025	difference	
				Amount	%
Current assets		3,392,392	3,132,191	(260,201)	(7.67%)
Financial assets measured at fair value through profit or loss - non-current		27,853	24,210	(3,643)	(13.08%)
Financial assets measured at fair value through other comprehensive income or loss – non-current		770,686	430,675	(340,011)	(44.12%)
Financial assets measured at fair value through other comprehensive income or loss – non-current		43,334	43,533	199	0.46%
Equity method investment		76,056	97,190	21,134	27.79%
Real estate, plant and equipment		1,490,229	1,449,014	(41,215)	(2.77%)
Right of use assets		350,060	277,089	(72,971)	(20.85%)
Investment real estate		111,884	171,089	59,205	52.92%
Intangible assets		322,120	310,072	163,275	(3.74%)
Other assets		517,103	680,378	26,582	31.57%
Total assets		7,101,717	6,615,441	(486,276)	(6.85%)
Current liabilities		1,859,999	1,563,678	(296,321)	(15.93%)
Non-current liabilities		1,260,652	1,219,489	(41,163)	(3.27%)
Total liabilities		3,120,651	2,783,167	(337,484)	(10.81%)
Rights belonging to the parent company's owners		3,556,895	3,443,761	(113,134)	(3.18%)
Share capital		1,310,861	1,376,404	65,543	5.00%
Capital Reserve		1,150,037	1,150,776	739	0.06%
Retained Earnings		1,048,993	1,059,888	10,895	1.04%
Other rights		47,004	(143,307)	(190,311)	(404.88%)
Non-controlling interests		424,171	388,513	(35,658)	(8.41%)
Total equity		3,981,066	3,832,274	(148,792)	(3.74%)
<p>Explanation of the reasons for the increase or decrease in the two periods: those with an increase or decrease of 20% or more and an amount exceeding NT\$10 million.</p> <p>1. The decrease in non-current financial assets measured at fair value through other comprehensive income or loss was primarily due to reclassification to current financial assets measured at fair value through other comprehensive income or loss and a decrease in fair value.</p>					

2. Increase in investments using the equity method: This is mainly due to increased investments in equity method investee companies during the current period.
3. The decrease in right-of-use assets was mainly due to the expiration and termination of lease contracts for buildings and transportation equipment.
4. The increase in investment properties was mainly due to the extension of lease terms for the sublease of right-of-use assets during the period.
5. Other asset increases: primarily due to increased hospital operating margin.  
The decrease in other equity was primarily due to a decrease in unrealized gains or losses on financial assets measured at fair value through their comprehensive profit or loss.

Source: Financial report audited and certified by accountants

## 5.2 Operating Results

(I) Comparative analysis of operating results:

Unit: NT\$ 1,000

project \ year	2024	2025	Increase (decrease) amount	Change percentage
Operating revenue	4,325,831	4,357,867	32,036	0.74%
Gross profit	714,404	709,013	(5,391)	(0.75%)
Operating profit and loss	178,489	170,855	(7,634)	(4.28%)
Non-operating income and expenses	(4,579)	(20,705)	(16,126)	352.17%
Net profit before tax	173,910	150,150	(23,760)	(13.66%)
Net profit of continuing operating units this period	122,398	111,897	(10,501)	(8.58%)
Losses of businesses that have ceased operations	0	0	0	0%
Net profit (loss) for this period	122,398	111,897	(10,501)	(8.58%)
Other comprehensive profit and loss for this period (Net amount after tax)	(76,034)	(194,647)	(118,613)	156.00%
Total comprehensive profit and loss for the period	46,364	(82,750)	(129,114)	(278.48%)
Earnings per share	1.45	1.03	( 0.42)	(28.97%)
Analysis of increases and decreases: Those with an increase or decrease of 20% or more and an amount exceeding NT\$10 million.				

1. The decrease in non-operating income and expenses was mainly due to a decrease in dividends distributed by investee companies of financial assets measured at fair value through other comprehensive income in 2015 compared to the same period last year.
  2. Other comprehensive gains or losses for the period: mainly due to the decrease in unrealized valuation gains arising from investee companies of financial assets measured at fair value through other comprehensive gains or losses in 2015.
- The decrease in total comprehensive profit or loss for the period was mainly due to a decrease in unrealized valuation gains arising from investee companies of financial assets measured at fair value through other comprehensive income or loss in 2015, and a decrease in dividends distributed by investee companies of financial assets measured at fair value through other comprehensive income or loss compared to the same period last year.

Source: Financial report audited and certified by accountants

- (II) Expected sales volume and its basis, possible impact on the company's future financial operations and response plans

The company's sales forecast for 2024 is estimated based on factors such as market demand and industry development trends. In addition, the company will continue to develop new markets, constantly improve service quality, satisfy customers and maintain good cooperative relationships with suppliers.

### 5.3 Cash Flow

1. Analysis and explanation of cash flow changes in recent years:

Unit: NT\$ thousand

project	2024	2025	Increase (decrease) ratio (%)
Cash flow ratio (%)	14.34	23.29	62.41%
Cash flow adequacy ratio (%)	72.80	64.23	(11.77%)
Cash reinvestment ratio (%)	3.90	5.61	43.85%
Explanation of changes in the percentage increase/decrease: to the effective management of operating expenses in 2025 , which led to an increase in cash inflow from operating activities compared to the same period last year, resulting in an increase in the cash flow ratio .			

## 2. Cash liquidity analysis for the next year:

2025/12/31 Unit: NT\$ 1,000

Beginning cash Balance	Expected net cash flow from operating activities for the whole year	Full year forecast Cash inflows/outflows	Expected cash balance (insufficient)	Expected cash shortfall Remedial measures	
				Investment Plan	Financing plan
1,338,686	71,705	-159,869	1,178,817	not applicable	not applicable
<p>(1) Analysis of cash flow changes in the coming year:</p> <p>① Operating activities: Profitability is expected to remain stable and grow in fiscal year 2026 , with net cash inflow .</p> <p>② Investing activities: The Company will have capital expenditures such as purchasing equipment and buying securities to support business development, resulting in cash outflows .</p> <p>③ Financing activities: The Company will generate cash outflows this year due to the repayment of some long-term and short-term borrowings .</p> <p>(2) Remedial measures and cash flow analysis for anticipated cash shortages: Not applicable.</p>					

## 5.4 Impact of major capital expenditures on financial operations in the most recent year : None

## 5.5 Recent investment policies, major reasons for profit or loss, improvement plans, and investment plans for the coming year

- Investment Policy: To meet business and operational needs, we are committed to building an ecosystem for digital transformation and healthcare in the medical industry, providing integrated medical logistics services, and carefully evaluating various investment plans in line with the company's long-term development strategy .

2.Main reasons for profit or loss and improvement plan:

2025.12.31; Unit: NT\$ thousand

Reinvestment Company	Shareholding ratio	Recognize the investee company's profit and loss for the most recent year	Profit or loss main reason	improve plan
Mincheng Health Technology Co. , Ltd.	61.46	(10,203)	Demand mask materials declines for filter	We will undertake a strategic transformation, leveraging the group's brand and distribution resources to actively seek strategic partners.
Shenghong Pharmaceutical ( Hong Kong ) Company	100	(5,646)	Adjustment of sales and management costs	Diversified income sources
Zhongyuan Medical Management ( Stock ) Company	100	291	Cost structure optimization	Continuously expand business
Precision Health (stock) company	38.19	(9,057)	Repositioning of organization and business direction	Adjust business strategy and continuously develop new customers.
Shengshi Digital Health (stock) Co., Ltd.	100	(64)	Adjustment of sales and management costs	Optimize cost structure
Medical Electronics Digital Transformation Co., Ltd.	6 0	2 50	Cost structure optimization	Continuously expand business
Fangding Information Technology Co., Ltd.	5 1	3 98	Cost structure optimization	Continuously expand business

Note 1 : The investment returns for the most recent year only represent the investment gains and losses of the Company as a whole.

Note 2: Investment plans for the next year: None .

## 5.6 Risks

### 1. Risk factors:

1. The impact of interest rate, exchange rate changes, and inflation on the company's profits and losses and future response measures:

- (1) The impact of interest rate changes on the company's profit and loss and future response measures

The Company's interest expenses for 2025 and 2024 were NT\$47,811,000 and NT\$58,342,000 respectively, accounting for 1.10% and 1.35% of the revenue for the respective years. These expenses were mainly interest expenses incurred from loans from various financial institutions. Since the proportion of interest expenses to operating revenue was very small, changes in interest rates had no significant impact on the Company.

The Company will keep an eye on interest rate changes and strive for more favorable interest rates with its banks to reduce interest costs.

- (2) The impact of exchange rate changes on the company's revenue and profits:

Our company's business model is mainly domestic sales-oriented, and most of our purchases and sales are conducted in New Taiwan dollars, so exchange rate changes have no significant impact on the company's profits and losses.

- (3) Impact of inflation:

The Company's products are not basic consumer goods and are not immediately sensitive to inflation. However, the Company will continue to pay close attention to economic developments and respond appropriately.

2. Policies regarding high-risk, high-leverage investments, lending funds to others, guarantees, and derivatives trading; the main reasons for profits or losses; and future countermeasures:

Adhering to the principle of prudent operation, the Company focuses on its core business. In the most recent year and up to the date of publication of this prospectus, the Company has not engaged in high-risk, high-leverage investments, lending of funds to others, or derivative transactions.

The Company has established procedures for "acquiring or disposing of assets", "loan of funds to others", and "endorsement and guarantee procedures", which have been approved by the shareholders' meeting. The Company's endorsements and guarantees have been processed in accordance with the prescribed procedures, and as of the date of publication of the prospectus, the amount of endorsements and guarantees is NT\$ 231,029,000.

3. Future R&D plans and estimated R&D expenses:

Our company is engaged in medical logistics services, with its main focus on business and channel expansion. We are not a research and development-

oriented company. Our company focuses on cultivating professional talents and innovating operating models, and invests in related expenses.

4. The impact of major domestic and international policy and legal changes on the company's financial business and the corresponding measures:

The Company's operating policies are all handled in accordance with laws and regulations, and the Company pays close attention to important domestic and international policy and legal changes at any time. When necessary, it consults relevant experts and takes appropriate response measures. As of the date of publication of the prospectus, the Company has not been affected by any major domestic and international policy and legal changes that have had a significant impact on its financial operations.

5. Impact of technological and industrial changes on the company's financial business and corresponding measures:

As of the date of publication of the Prospectus, the Company has not experienced any material impact on its financial operations due to technological and industrial changes in the most recent year.

6. The impact of corporate image changes on corporate crisis management and response measures:

The company continues to provide integrated medical logistics management and other services and has a good corporate image and corporate reputation. Since its establishment, the company has been committed to maintaining its corporate image and complying with laws and regulations. So far, no incidents have occurred that would affect its corporate image. If there are any events that affect the corporate image in the future, the crisis management team composed of the company's first-level managers will hold meetings at any time to respond to sudden crises.

7. Expected benefits, potential risks, and countermeasures of the merger and acquisition: In response to the group's organizational restructuring, the Company and Smart Medical City Company underwent a simplified merger in January 2025. The investee companies formerly held by Smart Medical City Company were directly held by the Company .

8. Expected benefits, possible risks and countermeasures of factory expansion: The Company currently has no plans to expand its factory.

9. Risks and countermeasures faced by concentrated purchase or sales:

- (1) Description of purchase status:

In order to prevent the risk of concentrated purchases, the company maintains stable and market-adaptive supply agreements with several suppliers at the same time. In addition to ensuring the quality and quantity of the supply sources, it can also enhance the integrity and competitiveness of the supply chain.

- (2) Sales status description:

In order to avoid the risk of sales concentration on major customers, the

Company will continue to develop customer base and expand sales channels in the future with high-quality products in addition to the existing stable basic customers with whom it has close cooperation, so as to maintain a stable sales target.

10. Impact, risks and response measures of large-scale transfer or replacement of shares by directors, supervisors or major shareholders holding more than 10% of the shares on the company: There is no such situation.
11. Impact of the change of management rights on the company, risks and countermeasures: The management of the Company is focused on the operation of the company, with the assistance and support of directors and supervisors. There is no risk that the change of management rights may cause to the company.
12. Other important risks and countermeasures: None

## 2. Litigation or non-litigation events:

1. The company shall disclose the facts in dispute, the subject amount, the commencement date of the litigation, the main parties involved in the litigation, and the current status of the litigation, non-litigation, or administrative disputes that have been decided or are currently under investigation in the most recent two years and as of the date of publication of the prospectus, if the results of which may have a significant impact on shareholders' equity or securities prices: none.
  2. The company's directors, supervisors, general manager, de facto responsible persons, major shareholders with a shareholding ratio of more than 10%, and affiliated companies, any litigation, non-litigation, or administrative disputes that have been decided or are currently in the process of being decided in the past two years and as of the date of publication of the prospectus, the results of which may have a significant impact on the company's shareholder rights or securities prices: None .
  3. The company's directors, supervisors, managers and major shareholders holding more than 10% of the shares have any of the following circumstances specified in Article 157 of the Securities and Exchange Act in the past two years and up to the date of publication of the prospectus, and the company's current handling of the situation: None
- (3) If the company's directors, supervisors, managers, and major shareholders holding more than 10% of the shares have experienced financial difficulties or lost credit in the most recent two years and up to the date of publication of the prospectus, the impact on the company's financial status shall be listed: None.

(IV) Other important matters: None.


## **5.7 Other important matters : None .**

## 6. Special matters to be recorded

### 6.1 Relevant information of related enterprises in the most recent year:

#### (I) Merger business report of related enterprises

##### 1. Organizational Chart of Related Companies :



##### 2. Basic information of related companies

2025.12.31

Company Name	Date of establishment	address	Paid-in capital	Main business or production projects
Zhongyuan Medical Management Co., Ltd.	2005.07.12	19th Floor, No. 168, Jingguo Rd., Taoyuan District, Taoyuan City	10 million	Management Consulting
Mincheng Health Technology Co., Ltd.	1990.08.06	19th Floor, No. 107, Minsheng Road, Wuling Village, Taoyuan District, Taoyuan City	365.36 million	Nonwoven fabric manufacturing and processing and sales of medical and sanitary supplies
Shenghong Pharmaceutical (Hong Kong) Co., Ltd.	2012.10.25	Room 511, Tower 5, New Harbour Centre, 30 Canton Road, Tsim Sha Tsui, Kowloon	44.83 million	Investment management industry
Minsheng Asia Pacific (Beijing) Enterprise Management Co., Ltd.	2014.09.17	Room 506, 5th Floor, Building 7, No. 1 Courtyard, Jinfang Road, Chaoyang District, Beijing	5.12 million	Hospital management consulting services

Company Name	Date of establishment	address	Paid-in capital	Main business or production projects
Precision Health Co., Ltd.	2017.12.26	19th Floor, No. 168, Jingguo Rd., Taoyuan District, Taoyuan City	329.92 million	Health management services
Shengshi Digital Health Co., Ltd. (formerly known as Shengshi Technology Co., Ltd.)	2019.07.02	9F-5, No. 294, Section 1, Dunhua South Road, Da'an District, Taipei City	1 million	Management Consulting
Medical Electronics Digital Transformation Co., Ltd.	2020.05.20	6F-1, No. 103, Section 2, Nanchang Road, Zhongzheng District, Taipei City	10 million	Information software services
Fangding Information Technology Co., Ltd.	1994.09.17	7th Floor, No. 53, Minquan Rd., Yonghe District, New Taipei City	12 million	Medical information software services
Mincheng Co., Ltd.	2021.11.05	No. 545, Section 2, Hezhen North Road, Neiding Village, Zhongli District, Taoyuan City	60 million	Nonwoven fabric manufacturing and processing and sales of medical and sanitary supplies
Leap Lion Health Co., Ltd.	2015.02.05	2nd Floor, No. 31, Lane 17, Ziqiang North Road, Guishan District, Taoyuan City	60.35 million	Pharmaceutical wholesale and retail and pharmacy management consulting
Minsheng (Tianjin) Investment Management Co., Ltd.	2013.03.05	No. 12, west side of Jingjin Highway, Hexiwu Town, Wuqing District, Tianjin	11.88 million	Investment management industry
Shengyun Pharmaceutical Co., Ltd.	1991.06.10	3rd Floor, 18th Floor, No. 303, Zhongming South Road, West District, Taichung City	64.6 million	Wholesale and sale of pharmaceuticals

3. Information on shareholders who are presumed to have a controlling and subordinate relationship: Not applicable.

4. The industries covered by the overall business of the related enterprises: pharmaceutical procurement, equipment leasing, non-woven fabric manufacturing and processing, management consulting, Health management and information software services , etc.

5. Information on directors, supervisors and general managers of related companies:

2025.12.31

Company Name	job title	Name or representative	Shareholding	
			Number of shares (shares)	Shareholding ratio
Zhongyuan Medical Management Co., Ltd.	director	Shenghong Pharmaceutical Co., Ltd Representative: Liu Qingwen	1,000,000	100.00%
		Shenghong Pharmaceutical Co., Ltd Representative:Wu Mingxun	1,000,000	100.00%
		Shenghong Pharmaceutical Co., Ltd Representative:Huang Yamei	1,000,000	100.00%
	Supervisor	Shenghong Pharmaceutical Co., Ltd Representative: Cai Yufang	1,000,000	100.00%
Mincheng Health Technology Co., Ltd.	director	Shenghong Pharmaceutical Co., Ltd Representative: Yang Hongren	22,453,719	61.46%
		Shenghong Pharmaceutical Co., Ltd Representative: Liu Qingwen	22,453,719	61.46%
		Shenghong Pharmaceutical Co., Ltd Representative: Xie Jiannan	22,453,719	61.46%
		Shenghong Pharmaceutical Co., Ltd Representative:: Yang Kunzhang	22,453,719	61.46%
		Yangzheng Investment Co., Ltd Representative: Zhang Changrong	177,814	0.49%
		Yangzheng Investment Co., Ltd Representative: Yang Wenren	177,814	0.49%
	Independent Directors	Yu Qizhang	0	0.00%
		Zhang Hengyu	0	0.00%
		Wu Mengchu	0	0.00%
Shenghong Pharmaceutical (Hong Kong) Co., Ltd.	director	Shenghong Pharmaceutical Co., Ltd Representative: Yang Hongren	1,500,000	100.00%
Minsheng Asia Pacific (Beijing) Enterprise Management Co., Ltd.	none	none	N/A	N/A
Precision Health Co., Ltd.	director	Shenghong Pharmaceutical Co., Ltd Representative: Yang Hongren	12,600,632	38.19%
		Deficit	0	0%
		Fubon Health Management Consulting Co., Ltd Representative:Wang Hongjun	7,796,875	23.63%
		Fubon Health Management Consulting Co., Ltd Representative:Zheng Da	7,796,875	23.63%
		China Development Biomedical Venture Capital Limited Partnership	8,880,445	26.92%
	Supervisor	Ye Jingwen	50,000	0.15%
		Zhang Changrong	0	0.00%
Shengshi Digital Health Co., Ltd.	director	Xu Shiming	0	0.00%
		Yang Hongren	0	0.00%

Company Name	job title	Name or representative	Shareholding		
			Number of shares (shares)	Shareholding ratio	
(formerly known as Shengshi Technology Co., Ltd.)		Yang Shunjun	0	0.00%	
		He Weiguang	0	0.00%	
		Hong Taixiong	0	0.00%	
	Supervisor	Wu Xinyi	0	0.00%	
Medical Electronics Digital Transformation Co., Ltd.	director	Yang Hongren	100,000	10.00%	
		Shenghong Pharmaceutical Co., Ltd.	600,000	60.00%	
		Leap Lion Health Co., Ltd.	200,000	20.00%	
		He Weiguang	100,000	10.00%	
	Supervisor	Lin Hongwen	0	0.00%	
Fangding Information Technology Co., Ltd.	director	Shenghong Pharmaceutical Co., Ltd. Representative: He Weiguang	612	51.00%	
		Shenghong Pharmaceutical Co., Ltd. Representative: Liu Qingwen	612	51.00%	
		Shenghong Pharmaceutical Co., Ltd. Representative: Yang Hongren	612	51.00%	
		Shenghong Pharmaceutical Co., Ltd. Representative: Chen Pengxuan	612	51.00%	
		Chen Liuchang	147	12.25%	
		Tao Zhenrong	232	19.33%	
	Yang Hongcheng	209	17.42%		
Supervisor	Chen Zhuwen	0	0.00%		
Mincheng Co., Ltd.	director	Mincheng Health Technology Co., Ltd Representative: Yang Kunzhang	6,000,000	100.00%	
		Mincheng Health Technology Co., Ltd Representative: Yang Wenren	6,000,000	100.00%	
		Mincheng Health Technology Co., Ltd Representative: Lu Meizhen	6,000,000	100.00%	
Leap Lion Health Co., Ltd.	director	Mincheng Health Technology Co., Ltd Representative: Yang Hongren	6,034,951	100.00%	
		Mincheng Health Technology Co., Ltd Representative: Chen Pengxuan	6,034,951	100.00%	
		Mincheng Health Technology Co., Ltd Representative: He Weiguang	6,034,951	100.00%	
		Mincheng Health Technology Co., Ltd Representative: Wang Bosen	6,034,951	100.00%	
		Mincheng Health Technology Co., Ltd Representative: Yang Kunzhang	6,034,951	100.00%	
	Supervisor	Mincheng Health Technology Co., Ltd Representative: Liu Qingwen	6,034,951	100.00%	
Minsheng Investment Co., Ltd.	(Tianjin) Management	none	none	N/A	N/A

Company Name	job title	Name or representative	Shareholding	
			Number of shares (shares)	Shareholding ratio
Shengyun Pharmaceutical Co., Ltd.	director	Precision Health Co., Ltd. Representative: Yang Hongren	6,460,000	100.00%
		Precision Health Co., Ltd. Representative: Li Hongyi	6,460,000	100.00%
		Precision Health Co., Ltd. Representative: Cai Aiwen	6,460,000	100.00%
		Precision Health Co., Ltd. Representative: Chen Pengxuan	6,460,000	100.00%
		Precision Health Co., Ltd. Representative: Shen Jiaying	6,460,000	100.00%
	Supervisor	Precision Health Co., Ltd. Representative: Ye Jingwen	6,460,000	100.00%

## 6. Overview of related business operations

### (1) Financial status and operating results of each affiliated enterprise:

December 31, 2025 Unit: NT\$ 1,000

Company Name	Capital	assets Total Value	Liabilities lump sum	net worth	Business income	Business Benefit	Profit and loss for the period (After tax)	Earnings per share (NTD) (after tax)
Zhongyuan Medical Management Co., Ltd.	10,000	11,979	20	11,959	0	(68)	292	0.29
Mincheng Health Technology Co., Ltd.	365,356	594,425	9,512	584,913	0	(14,446)	(16,600)	(0.45)
Shenghong Pharmaceutical (Hong Kong) Co., Ltd.	44,831	14,432	0	14,432	0	(3,530)	(5,646)	-
Minsheng Asia Pacific (Beijing) Enterprise Management Co., Ltd.	5,124	5,377	234	5,143	0	(1,109)	(1,261)	-
Precision Health Co., Ltd.	329,919	641,808	445,232	196,576	63,445	6,390	(23,702)	(0.72)
Shengshi Digital Health Co., Ltd. (formerly known as Shengshi Technology Co., Ltd.)	1,000	631	7	624	0	(69)	(65)	(0.65)
Medical Electronics Digital Transformation Co., Ltd.	10,000	4,663	389	4,274	4,653	420	417	0.42
Fangding Information Technology Co., Ltd.	12,000	48,336	26,609	21,727	71,961	3,554	6,546	0.55
Mincheng Co., Ltd.	60,000	148,355	83,288	65,067	179,473	1,790	5,067	0.84
Leap Lion Health Co., Ltd.	60,350	656,967	497,655	159,312	1,765,377	(12,602)	4,559	0.76

Company Name	Capital	assets Total Value	Liabilitie s lump sum	net worth	Business income	Busines s Benefit	Profit and loss for the period (After tax)	Earnings per share (NTD) (after tax)
Minsheng (Tianjin) Investment Management Co., Ltd.	11,885	3	0	3	0	(2,040)	(2,046)	-
Shengyun Pharmaceutical Co., Ltd.	64,600	203,855	133,774	70,081	165,934	947	5,052	0.78

Note 1 : Affiliated companies are foreign companies and the relevant figures are expressed in New Taiwan dollars as of the date of this table.

Note 2 : Fangding Information Co., Ltd. has a par value of 10,000 yuan per share and has issued 1,200 common shares .

(2) Consolidated financial statements of related companies and CPA review reports: see the Public Information Observatory website

[https://mops.twse.com.tw/mops/#/web/t57sb01\\_q1](https://mops.twse.com.tw/mops/#/web/t57sb01_q1)

(3) Relationship report: None.

## **6.2 Status of private placement of securities in the most recent year and up to the publication date of the annual report: None.**

## **6.3 Other necessary supplementary explanations:**

(I) Continuously track commitments made for listing on the over-the-counter market

The Company undertakes that any adjustments to the pricing and cooperation models for drug sales and health check-up services with Min Sheng Group hospitals must be approved by the Company's Board of Directors, the independent directors must attend and express their opinions, and a letter must be sent to the Taiwan Stock Exchange for record -keeping and material information must be entered into the Public Information Observation Station.

(II) Implementation status of commitments made at the counter

The above commitments were lifted by the OTC Exchange on 2025/4/24 ( Letter No. 1140002422 ) .

**7. Article 36, Paragraph 3 , Item 2 of the Securities Exchange Act have occurred in the most recent year and up to the date of publication of the annual report : None**

**Sharehope Medicine CO. LTD**



**Chairman: Hung-Jen Yang**



# ShareHope

SHAREHOPE MEDICINE CO., LTD.

Stock Code: 8403

# 114

annual  
report

SHAREHOPE MEDICINE CO., LTD.



Missioncare / Since 1975

## Missioncare Healthcare

Asia's Leading Healthcare Ecosystem



50+

Years of Heritage



18

Cities & Counties  
Served



1,233

Service Locations  
Nationwide



Missioncare Website

<https://www.missioncareasia.com/>